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Abstract 
Background: 
Recent studies have shown that the two major forms of multiple sclerosis are different in the 
degree of demyelination and atrophy, degree of inflammation, and extent of axonal loss. 
However, the majority of the previous studies that compared primary progressive and 
secondary progressive multiple sclerosis were carried out at the brain level. 
Material and methods: 
Human post-mortem spinal cords were used to compare the two progressive subtypes. In 
this project, the 5 major pathological changes associated with MS were studied in the spinal 
cords of primary progressive and secondary progressive multiple sclerosis. These changes 
include degree of demyelination, atrophy of the tissue, oligodendrocytes pathology, axonal 
loss, and neuronal pathology. 
Results: 
There was significant atrophy in the spinal cords of MS compared to healthy controls, which 
affects mainly the upper cord levels. There is a greater degree of demyelination and atrophy 
affecting secondary progressive compared to primary progressive especially in the upper 
cord levels. Oligodendrocytes numbers are dramatically reduced in the chronic lesions of 
WM and GM lesions. But there was high numbers of oligodendrocytes in the normally 
appearing GM of secondary progressive multiple sclerosis. There was greater reduction in 
axonal density in the secondary progressive sample especially in the normally appearing 
WM. Neurons were reduced in the demyelinated grey matter regions with no difference 
between the two disease forms in this respect. 
Conclusions: 
SPMS seem to have greater degree of tissue destruction in the form of demyelination, 
atrophy, and axonal loss in the normally appearing WM. However, SPMS showed greater 
numbers of oligodendrocytes in the demyelinated areas of the WM and the GM. Although 
the disability scale in the two examined groups was found to be similar, the tissue damage 
appeared to be variable. 
xii 
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Chapter 1: Introduction 
Multiple sclerosis (MS) is an inflammatory autoimmune demyelinating disease of the central 
nervous system (CNS) [1]. The disease results in multiple lesions that are characterised by 
loss of myelin substance as well as oligodendrocytes (OLs), which are vital elements for the 
proper function of the CNS. Therefore, MS can lead to wide range of symptoms. 
1.1 History of Multiple Sclerosis 
In the book entitled "Multiple Sclerosis: The History of a Disease" the author, Dr T J Murray, 
described symptoms of many patients during the 18th century who had features similar to 
MS [2]. The earliest described case is thought to be Saint Lidwina. Saint Lidwina was born in 
Schiedam of Holland on 18th April 1380. She fell on ice at the age of 15 years and broke her 
rib [3]. Following this, she developed weakness in both lower limbs and severe tooth pain, 
which are believed to have been the paraplegia and the trigeminal neuralgia of MS 
respectively. She also suffered from unilateral blindness and became paralysed and 
confined to bed. Severe bed sores complicated her condition and affected her entire body. 
People at that time believed that she was under the influence of an evil spirit [3]. She died in 
April 1433 at the age of 53 years [4]. In 1947 her remains were exhumed for analysis, and 
they demonstrated marks of spastic paraplegia [5]. 
Augustus d'Este (1794-1848) remains the most famous historic case of what is believed to 
have been MS. He kept detailed records of all his symptoms in his diary. Briefly, he suffered 
from blurred vision in 1822, which resolved spontaneously. Then he began to develop visual 
loss and was unable to read. He described in detail all the types of treatment he received. 
His condition progressed to paraplegia until he died in 1848 [5]. 
The German pathologist Friedrich Theodor von Frerichs (1819-95) established the first 
diagnosis of myelitis in 1849, which is believed to be MS. Eduard Rindfleisch (1836-1908), 
Pathology of the spinal cord in progressive multiple sclerosis (primary progressive vs secondary progressive) 
was the first person to describe the perivascular cellular infiltration and neuroglial 
involvement as part of the disease process [4, 6]. 
MS as a distinct new disease was described for the first time in 1868 by the French 
neurologist Jean-Martin Charcot (29 November 1825-16 August 1893). Charcot and his 
colleague Edme Vulpian were studying a specific type of tremor in young patients, and were 
trying to differentiate it from paralysis agitans caused by Parkinson's disease. Charcot and 
his assistant noticed that this type of tremor frequently affected young adults and was 
associated with paralysis. They then noticed patchy greyish plaques in the autopsy of these 
patients, which were scattered throughout the spinal cord and the brain. In 1866 Charcot 
presented three cases and differentiated MS tremor from paralysis agitans. Later, Charcot 
described a number of MS features, and he named it sclerose en plaque disseminee [5, 7]. 
Charcot also contributed largely to developing criteria for the diagnosis of MS [8]. The criteria 
are known as the Charcot's triad, which includes diplopia, ataxia and dysarthria. He 
observed these three symptoms in his housekeeper, who was affected by MS. Furthermore, 
Charcot was the first neurologist to provide a detailed description of MS histopathology, 
including loss of myelin [6, 9]. 
After Charcot's work there was little progress in MS and most of the research was focused 
on finding the disease aetiology. In 1933 the first model of MS was produced in monkeys, 
which was called disseminated encephalomyelitis. Then MS model was produced in mice 
and was called experimental allergic encephalomyelitis (EAE) [2, 4]. Until 1935 there were 
about 150 proposed treatment strategies for MS [4]. 
The world 'sclerosis', meaning hardening, was used to describe the scarring that follows the 
damage of the nervous system by the disease process. The disease causes demyelination 
2 
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of the axons in different areas of the white matter (WM). Therefore the word 'multiple' was 
used to describe the disseminating characteristic of the lesions, which are disseminated in 
time and place. These lesions were called plaques, which are well-defined areas of 
demyelination and neuro-axonal degeneration. The word sclerosis had previously been used 
in the USA to describe another neurological disease (amyotrophic lateral sclerosis). In 
Britain the disease was called disseminated sclerosis. Then the name was changed to MS 
because of the establishment of the MS Society in the USA [10]. 
1.2 Epidemiology 
By reviewing European hospital records and comparing them to the present MS features, 
Dr T J Murray was able to conclude that MS had been prevalent in the European population 
for many centuries, and that its prevalence did not change with time [4]. 
Estimates of incidence and prevalence of a disease such as MS differ between various 
studies. Each study investigates a different sample size and age range, and different 
ethnicity. Various studies may apply different criteria for the diagnosis, and thus results may 
vary. 
Increase in the prevalence of MS is partly due to increased diagnosis, as many cases went 
unrecognized [11], but the latest epidemiologic studies state that the prevalence of the 
disease is, in fact, increasing with time [12-16]. 
The disease predominantly affects individuals between the ages of 20 and 40 years [16]. MS 
is the most common neurological disease that affects young western adults [17], and the 
second most common cause of neurological admissions in young adults after trauma [11]. In 
2002 it was estimated that 2.5 million people are affected with MS worldwide [11]. In the UK 
3 
Pathology of the spinal cord in progressive multiple sclerosis (primary progressive vs secondary progressive) 
approximately 100,000 individuals suffer from MS, according to the MS Society in 2005, 
while the number reaches 350,000 patients in the USA [16]. 
The prevalence of MS is geographically variable according to latitude, where it reaches 60-
200/100,000 in Northern Europe and North America compared to 6-20/100,000 in lower risk 
areas, such as Asia [16]. 
MS disease does not cause significant life shortening, but has a high morbidity rate and a 
strong impact on the social and economic status of the affected individual and the whole 
country. In 1995, the cost of the disease in the UK was estimated to be around £1.2 billion 
[18]. In a cross-sectional study, the average cost of MS was calculated in various countries 
for one patient for a period of three months [19]. The study revealed that the cost was 
variable according to the country and the stage of the disease. In the UK, according to 
Expanded Disability Status Scale (EDSS), a patient in stage III costs $14,622 every three 
months [19]. 
1.3 Risk factors 
The cause of MS is believed to be multifactorial. The role of environmental factors in 
developing MS has been shown in a number of studies [15, 20], but the extent of this role is 
not yet certain. As genetic studies have shown genetic contribution, it is thought that MS 
develops in genetically susceptible individuals after exposure to triggering factors, which 
could be infectious factors. 
1.3.1 Genetic factors 
It is important to mention that geographic variation of MS epidemiology is not only dependent 
on environmental factors, but also depends on ethnic or genetic factors where each ethnicity 
usually inhabits a certain geographic area [15]. 
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First degree relatives of MS patients have 20-50 fold higher risk of developing the disease. 
The most relevant gene was found on the area of the major histocompatability complex, 
which accounts for 10-60% of the genetic risk of MS [21]. The concordance rate in 
monozygotic twins is 20-30% [16, 21, 22]. Moreover, the concordance among monozygotic 
twins has been also affected with latitude and with the time of the diagnosis, ie the 
concordance of MS in northern monozygotic twins was greater than southern monozygotic 
twins by two times [23]. The risk of MS in the co-twin is increased by two times when the 
affected twin had early disease, that is before the median age which is 29.3 years [23]. 
These data suggest additional risk factors, including infection, latitude and amount of sun 
exposure during childhood [22], and there may be hormonal factors [24]. 
1.3.2 Latitude and sun exposure 
The prevalence of MS is more in the northern areas of the northern hemisphere, while the 
prevalence is more in the southern areas of the southern hemisphere [15]. These changes in 
MS prevalence with latitude have been attributed to the amount of sun exposure. In a 
relatively recent study which investigated twins with MS in North America between 1980 to 
1992 [22], the sun exposure during childhood was studied. The study controlled to some 
degree the genetic factors, as part of the sample contained monozygotic twins, thus 
investigators were able to assess the effect of sun exposure independently. The study 
reported that degree of sun exposure in childhood reduces significantly the risk of MS. The 
risk of developing MS was reduced by 25% for each unit increase in the sun exposure index 
[22]. 
The UV light has an effect on the immunoregulatory cells [16] and has also an effect on the 
levels of vitamin 0, because most of our body's vitamin 0 is synthesized in the skin and then 
activated in the kidneys [25), The other proportion of vitamin 0 is obtained from food, 
especially seafood. Therefore, vitamin 0 deficiency can be seen due to less sun exposure, in 
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people with dark skin colour who absorb less UV light, and due to malabsorbtion [25], 
Vitamin D has anti-inflammatory effects and down-regulates inflammatory markers [25]. This 
has been confirmed by treatment of EAE mice with an active form of vitamin D, which 
resulted in complete inhibition of the progression of the disease [26]. Surprisingly, Vitamin D 
levels were found to be higher in the north European countries. This may be partly explained 
by the fair skin colour in northern Europeans, whose skin absorbs more UV light [25]. 
1.3.3 Hormonal factors 
Hormonal factors may play a role in MS pathology, because females are affected more than 
males, and the concordance in monozygotic twins is more when the twins are female (23). 
Additionally, MS has a reduced relapse rate during pregnancy and an increase in relapses 
occurs after delivery [24]. A recent study investigated the effect of environmental factors on 
the sex ratio of MS (ratio of F: M) and was conducted on Canadian immigrants. The study 
reported increase in sex ratio among immigrants which is also affected by the origin of the 
immigrants [27]. The study concluded that environmental factors have greater effects on 
females than males. 
1.3.4 Viral infections 
Another proposed contributory factor in the aetiology of MS is believed to be viral infection. 
Animal studies demonstrated a model of virally-induced eNS demyelination [28]. It is 
proposed that a viral infection acts as a triggering factor in initiating the cascade of 
inflammatory reactions in MS subjects. Triggering the immune response in MS and other 
autoimmune diseases is probably due to molecular mimicry with one of the virus 
components, which is believed to be a peptide [11]. 
The relation between viral infection and MS has been appearing in literature for a long time 
[29]. A number of viruses has been suggested as playing a role in MS aetiology, including 
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poliomyelitis [30], measles [31, 32], herpes simplex virus [33], Epstein-Barr virus (EBV) [34], 
parainfluenza 1 virus [35], HHV6 and multiple-sclerosis-associated retrovirus [36]. 
Among the suggested viruses, EBV may play an important role in causing MS. For recent 
reviews refer to Pohl 2009 [37] and Salvetti et al 2009 [38]. EBV is a DNA virus that affects 
90% of the population worldwide. It causes infectious mononucleosis and may result in 
encephalitis [37]. There is serological evidence that previous EBV infection may increase 
risk of MS in children and adults [38]. Several epidemiological studies have shown a relation 
between EBV infection and development of MS [28]. 
1.3.5 Other environmental factors 
MS geographic distribution generally corresponds to the distribution of developed countries 
and the economic status of the country [16]. For example, the disease is highest in Japan, 
which is located in a relatively low risk area (Asia). Two studies reported increase in 
prevalence in the Middle East; a study reported that the disease prevalence is increasing in 
Kuwait. This increase was mainly among Kuwaiti females [13]. Similar results were obtained 
from Jordan, where the prevalence of the disease has increased in the last three decades 
[14]. Increase in MS prevalence rates in these areas has been related to many factors such 
as pollution, exposure to solvents, dietary factors, smoking, and change in the amount of sun 
exposure [16]. 
1.4 Clinical presentation and disease course 
Relapsing remitting Multiple sclerosis 
MS follows a relapsing remitting course in 80% of cases and is called relapsing remitting MS 
(RRMS). Patients with RRMS experience relapses in the form of neurological symptoms that 
develop over several hours to few days and continue for several days to few weeks. A 
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patient with RRMS is most often a female in her early 30s, who presents with rapidly 
progressing symptoms. The ratio of female to male is approximately 2: 1 [7]. 
In 15% of patients, the first symptom is optic neuritis [7]. Patients usually complain of 
unilateral blurring of vision and gradual onset of pain in the affected eye with no redness. 
Examination of the affected eye may reveal optic disc inflammation. These distinct features 
of optic neuritis in MS help in supporting the diagnosis, especially when there is evidence of 
demyelination in visual evoked potentials (VEPs). 
Lower limb weakness in the form of spasticity and hyperreflexia affects 40-60% of cases [7], 
Fatigue can affect up to 40%, which can be secondary to lower limb weakness and/or 
depression [39]. Vertigo can affect 20% of cases [40). Other problems may involve the brain 
stem, cerebellum, bladder control, sexual function and neuropsychological function. 
In most cases symptoms improve with time, and patients may completely recover within a 
few weeks. It is assumed that these attacks, and the consequent temporary functional 
failure, are mainly due to acute inflammation and oedema. Remission of these attacks by 
use of immunosuppressive agents that inhibit inflammation and remove oedema supports 
this assumption. 
Progressive multiple sclerosis 
Ten years from onset of RRMS, 40% of cases enter a stage of disease progression [41]. 
This percentage increases to 80% after 20 years [42]. In this stage, patients accumulate 
neurological deficits and disability without experiencing remissions. This progressive form of 
the disease is called secondary progressive MS (SPMS) and is associated with significantly 
less acute lesions and reduced response to immunosuppressant. The reduced response to 
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treatment in SPMS may indicate a different mechanism underlying progressive neurological 
deficits [43]. 
The other less common form of progressive MS is primary progressive MS (PPMS). This 
usually affects patients in an older age group. However, patients with RRMS develop 
progression and the disease transforms to SPMS at an older age than that of those who 
present with PPMS [44]. PPMS is progressive from onset, and the affected patients 
accumulate neurological dysfunction over time. Patients with PPMS may have intermittent 
plateaus, but no clear relapses or remissions [45]. In addition, a considerable number of 
patients with PPMS experience an episode of MS many years before the onset of the 
disease [46] or after the disease onset [47]. 
PPMS has similar incidence in males and females and is characterized by 
unresponsiveness to immunosuppressant treatment from the beginning. It is believed that 
the cause of disability in PPMS is mainly irreversible degeneration ofaxons, in particular 
small diameter axons [17, 43]. 
1.5 Diagnosis 
Diagnosis of MS is based on clinical features, which are characterised by dissociation in time 
and space. There is no single test for the diagnosis of MS. Therefore, different diagnostic 
criteria were established. In 1965, Schumacher established the first criteria for MS. The 
recent advances in MRI techniques and electrophysiological studies allow scientists to 
recognise other abnormalities in MS. Therefore, Poser criteria incorporated paraclinical tests 
such as cerebrospinal fluid analysis (CSF) and evoked potentials (EPs) [48-51]. 
The recently established McDonald's criteria have replaced both Schumacher and Poser's 
criteria [52] (Table 1.1). The criteria establish diagnosis of MS earlier than the previous two 
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criteria. The criteria have been revised in 2005 by Polman et al who explained the definition 
of the attacks, dissemination and other finding [53). 
Table 11' McDonald's Criteria ..
Clinical Presentation Additional Data Needed 
2 or more attacks (relapses) None; clinical evidence will suffice (additional evidence desirable but must be consistent 
2 or more objective clinical with MS) lesions 
Dissemination in space, demonstrated by: 
2 or more attacks MRI 
1 objective clinical lesion or a positive CSF and 2 or more MRI lesions consistent with MS 
or further clinical attack involving different site 
1 attack Dissemination in time, demonstrated by 
2 objective clinical MRI or more or second clinical attack lesions 
Dissemination in space demonstrated by: 
MRI 
1 attack or positive CSF and 2 or more MRI lesions consistent with MS 
1 objective clinical lesion and 
(monosymptomatic presentation) Dissemination in time demonstrated by: 
MRI 
or second clinical attack 
Insidious neurological One year of disease progression (retrospectively or prospectively determined) and progression suggestive of MS Two of the following: a. Positive brain MRI (nine T2 lesions or four or more T2 lesions (primary progressive MS) 
with positive VEP) b. Positive spinal cord MRI (two focal T2 lesions) c. Positive CSF 
The review by Polman recommended that a clinical relapse or a T2 lesion occurring within 
one month, instead of 3 months as in the origincal McDonald's criteria, can be usefull in 
confirming dissemination in time. In addition, spinal cord lesion can be considered to confirm 
dissemination in space instead of infratentorial brain lesion but not periventricular or 
juxtacorticallesion. Pol man revised the criteria again in 2010, published in 2011. The review 
recommendations allow for a more rapid and more sensitive diagnosis. It has been agreed 
that a follow up scan to confirm dissemination in time is not needed if the baseline MRI 
demonstrated both gadolinium-enhancing and nonenhancing lesions. This simplifies the 
diagnosis of MS without affecting accuracy and also reduces the MRI examination 
requirements [54]. 
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1.5.1 Radiological abnormalities (MRI) 
MRI techniques are highly sensitive in detecting MS lesions and considered as the major 
paraclinical test in MS [55-57]. MRI is superior to all other measures in detecting subclinical 
lesions, 'silent lesions' [55, 56]. Acute plaques appear hypertense in T2 weighted images 
and proton density weighted images as they reflect a large amount of water, while chronic 
plaques are hypotense in T1 weighted images, 'black hole'. The black holes are more 
pathologically specific for MS [55]. 
Nevertheless, these changes identified by MRI are not disease-specific. Several diseases 
cause WM lesions that are similar to those of MS, such as ischaemic vascular diseases, 
normal aging process, acute disseminated encephalomyelitis, lacunar infarcts and 
leukodystrophy. Therefore, the initial important step in radiological diagnosis of MS is to rule 
out other similar diseases [49,50,58]. 
Lesions of vascular disease usually do not affect the corpus callosum and tend to be more 
peripheral (unlike MS). Those hyperintensities on T2-weighted images of the ageing process 
are smaller, tend to be symmetrically distributed, and are not usually visible in T1-weighted 
images. Acute disseminated encephalomyelitis lesions are all of similar age, whilst MS 
leSions are of different ages [56]. 
1.5.2 Neurophysiological abnormalities 
The general principle for neurophysiological studies is the use of electrodes to record the 
amplitude and the duration of neuronal impulses. This will detect delay or failure of 
transmission of an impulse in a certain tract. In MS disease, the most important finding is 
change in latency rather than amplitude, since latency prolongation is more consistent with a 
demyelinating process [59, 60]. 
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To record abnormal neurophysiological response, there should be sufficient damage in the 
examined tract. In addition, not all the tracts can be explored by these studies. Therefore, 
the correlation between neurophysiological study results and the degree of impairment is 
quite poor [60]. 
The most commonly used methods in MS are the stimulus-related EPs. The currently used 
stimulus-related EPs in the diagnosis of MS include visual EPs, auditory EPs, brain stem 
auditory EPs, and somatosensory EPs. 
The highest sensitivity is obtained from visual EPs, where a delay in latency is demonstrated 
in most cases with optic neuritis [51, 59). The diagnosis of delay in latency of the optic nerve 
is established by considering the difference between the two eyes and not by measuring the 
absolute values [59, 60]. A difference of more than 10 milliseconds in latency is abnormal 
even if both readings are within the normal range [5]. 
The sensitivity of auditory EPs in evaluating the auditory system, when complemented with 
brain stem auditory EPs, can reach 83%. For motor EPs, the sensitivity to detect central 
corticospinal spinal tract (CST) damage is low. This is due to the wide range of normal 
values [59). 
1.5.3 Cerebro-spinal fluid analysis 
A CSF sample is frequently obtained during the diagnostic process in MS. The aim of 
analysiS is to look for intrathecal markers that are most peculiar to MS. Oligoclonal bands 
are the most speCific CSF changes for MS, followed by intrathecal IgG synthesis [61, 62]. 
Both indicate increase intrathecal synthesis of immunoglobulins. However, these changes 
can be detected in other types of chronic CNS inflammation, such as neurosarcoidosis, 
subacute sclerosing panencephalitis, and primary CNS lymphoma [61]. 
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1.6 Pathophysiology of multiple sclerosis 
The principal lesions of MS are the plaques. The WM plaques tend to be round or ovoid in 
shape. In the brain, they are commonly peri-venular. MS can result in demyelination in the 
cerebral cortex and in the deep grey matter (GM) nuclei of the brain and the spinal cord. 
Initially MS causes swelling of the nervous tissue but, with progression of the disease, older 
lesions possibly shrink, and CNS atrophy is a prominent feature. It has been suggested that 
in acute MS the mechanism of injury is mainly inflammatory, while with chronic MS, 
neurodegeneration is the main mechanism [63]. In summary, stages of the plaque 
development include inflammatory loss of OLs and myelin, partial recovery, post-
inflammatory gliosis, and neurodegeneration [11]. 
1.6.1 Inflammatory loss of oligodendrocytes and myelin 
The inflammatory aspect in the pathology of MS disease was first described long ago. In 
fact, peri-vascular inflammatory cells were demonstrated when the disease was described 
for the first time by Charcot [43]. Inflammatory reaction in MS was then suggested to be 
autoimmune in nature in 1933 by demonstration of demyelination in EAE [64]. 
A great advance in the understanding of MS immunology comes from EAE [65-67]. It is the 
most commonly used animal model for MS [65, 66]. 8y examining EAE scientists were able 
to identify important disease markers, such as oligoclonal bands [5], which is used for 
supporting the diagnosis of MS [5, 65]. 
One of the earlier steps in the MS inflammatory process is thought to be migration of T cells 
from the systemic circulation to the CNS through the blood brain barrier (888). These T 
lymphocytes (CD4) are activated, possibly by antigen [17]. 
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In the CNS side, there is up-regulation of a number of molecules, such as inter-cellular 
adhesion molecule 1 (ICAM 1) and vascular adhesion molecule 1 (VCAM 1), and proteases. 
These molecules assist in adhesion and migration of T cells into the CNS [17]. This up-
regulation of adhesion molecules, and other molecules, is possibly caused by signal from the 
activated T cells themselves, via secretion of interferon Gamma (IFN-y) and tumour necrosis 
factor Beta (TNF-I3) [17, 63]. 
The abnormally active T lymphocytes (CD4) affect the permeability of the BBB. 
Consequently, these cells can penetrate the BBB to the CNS [5, 43, 65]. This may explain 
the observation that the disease plaques are found mainly around small veins, 'peri-venular'. 
T lymphocytes or CD4 cells are divided into T helper cells 1 (Th1), T helper cells 2 (Th2), T 
regulatory cells and the more recently identified T helper 17 (Th17) [68]. In the CNS, CD4 
Th1 cells secrete IFN-y, interleukin 2 (ll2), TNF-I3, and other cytokines [7, 65, 66], while 
Th17 cells secrete tissue destructive cytokine known as interleukin (ll17) [68]. These 
cytokines initiate a cascade of inflammatory reactions, which involve fluid accumulation, 
'swelling', and direct damage to myelin sheaths, Ols, and axons. 
In this acute phase of the lesion, there is evidence of active myelin destruction as seen by 
the electron microscope (macrophages filled with myelin breakdown products) [5, 65, 67]. 
There is also evidence of axonal loss in the plaque and the normal-appearing areas [69], 
which can be primary axonal loss or secondary to loss of myelin and Ols. However, 
researchers commonly describe axons as relatively preserved in MS compared to loss of 
Ols and myelin. MagnetiC resonance spectroscopiC (MRS) changes in N-acetylaspartate, a 
marker of the neuronal function, have been noted in the plaques of MS, which may indicate 
that there is also loss of function of surviving axons. Furthermore, EPs reveal a delay in 
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latency in the affected tract [59, 60]. Consequently, these acute lesions are believed to be 
responsible for neurological dysfunction (clinical relapses). 
1.6.2 Recovery and remyelination 
In RRMS the immune response will be inhibited, in most cases, after a few weeks. T 
regulatory cells and CD4 Th2 cells are possibly responsible for this inhibition. T regulatory 
cells secrete interleukin 10 (ll10) and transforming growth factor beta ( T G F - ~ ) , , which are 
major cytokines suppressing the immune reaction. CD4 Th2 cells down regulate the immune 
response by secreting different cytokines such as interleukin 4 (IL4), interleukin 5 (IL5), 
interleukin 13 (IL 13), and possibly T G F - ~ ~ [65, 66]. 
As time passes, signs and symptoms of the disease start to improve and the patient enters a 
stage of recovery. During this period, examination of some plaques shows reformation of 
thin myelin sheaths, which does not fully explain the degree of recovery [5, 66]. The number 
of Ols in lesions correlates with the degree of remyelination. Presence of remyelination and 
the clearance of the accumulated fluid and neurotoxins may allow the axons to retain part of 
their conduction capacity [43, 66]. This period of recovery refers to the remission of the 
relapse which is observed clinically in RRMS. In comparison, PPMS and SPMS do not show 
complete remission and, therefore, the mechanism of tissue injury and/or the mechanism of 
tissue repair in these forms may be different or defective. Nevertheless, with progression of 
the plaque, this repair is limited by the action of astrocytes by producing gliosis (scarring) 
[11, 43, 66]. 
1.6.3 Post-inflammatory gliosis 
Following demyelination and tissue injury, astrocytes become activated. Astrocytes are 
activated by signals released in the site of the eNS injury [70). The reactivated astrocytes 
migrate to the lesion. These activated astrocytes are responsible for the formation of the glial 
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scar, by mediating inflammatory reaction and remodelling of the lesion. This is characterised 
by hypertrophy of astrocytes, increased expression of glial fibrillary acidic protein (GFAP), 
and cellular proliferation. Many believe that the astroglial scar inhibits axonal growth and 
regeneration. However, a subset of astrocytes may act as progenitor cells, and thus may 
have neuroprotective functions [70, 71]. 
1.6.4 Neurodegeneration and axonal loss 
The long-term effects of scarring may include neurodegeneration. There is a reduction in the 
number of surviving axons in the areas surrounding lesions, which indicates that there is a 
significant number of severed axons [72]. This may result in degeneration ofaxons 
segments in areas far from the primary lesion via the effect of neuronal degeneration, which 
may continue for months or years after injury [11]. Furthermore, neuronal degeneration may 
occur due to environmental changes around the axons or the neurons, such as loss of the 
myelinating Ols. 
1.7 Nervous tissue injury 
This section discusses the normal eNS response to injury and types of consequent neuronal 
degeneration. This will provide a better understanding of the possible mechanisms of axonal 
and neuronal degeneration in MS, especially in the spinal cord. This is because the spinal 
cord contains both ascending and descending tracts, which have connections with the brain. 
1.7.1 Neuronal injury 
Apart from specifiC areas in the brain, such as the hippocampus and the olfactory bulb, 
neuronal precursors do not divide, and thus no new neurons are spontaneously produced 
following injury [73]. Neurons in the eNS are frequently exposedvulnerable to different types 
of traumas including neurotoxin exposure, infection, mechanical and neurodegenerative 
trauma. Such trauma can be tolerated by neurons with the help of microglia. Microglia have 
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an intimate relationship with neurons and have both neuroprotective and, at times, 
neurodegenerative roles. In minor neuronal insult, microglial cells protect injured neurons by 
supplying them with neurotrophic factors, such as neuronal growth factor and TGF-J3 [74, 
75). 
Initially, microglia do not express any phagocytic or cytotoxic activity against injured neurons, 
but rather respond to injury by proliferation and secretion of more neurotrophic factors, in an 
attempt to protect the injured neuron. Microglial cells can also cause de-afferentation of the 
injured neurons, which protects neurons from further damage by the excitatory synapses, 
such as glutamate [76, 77]. De-afferentation facilitates exchange of neurotrophic factors 
between neurons and microglia, by increasing the exposed surface area of the neuron. 
However, prolonged de-afferentation may result in degeneration [75, 76]. 
Neuronal phagocytosis occurs when the neurological insult is beyond the ability of the 
neuronal tissue to protect itself. At this stage, microglia express phagocytic activity against 
neurons. Response of microglial cells depends largely on signals from the injured neurons 
themselves. Microglia will then phagocytose debris of terminally damaged neurons [78]. 
1.7.2 Axonal injury 
At the axonal level damage can be induced by different types of insult, including ischaemia, 
low or high temperature, direct pressure or cutting, neurotoxins, and infection. (For review 
refer to Fitch and Silver 2008 [74]). Some of these insults are noticed in MS such as the 
effect of temperature on the function ofaxons. MS patients commonly experience worsening 
of symptoms after a hot bath such as blurring of vision and fatigue (Uhthoff's sign). There is 
also probable effect of pressure caused by the oedema on the axonal functions [79]. 
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Generally the peripheral nervous system (PNS) axons have better ability to regenerate than 
the eNS axons, due to presence of trophic factors that promote regeneration in the PNS. 
Injured eNS axons grow slowly and do not cross the site of injury forming the so called 
retraction bulbs. In the PNS, Schwann cells promote regeneration and guide axons to their 
targets, while the equivalent myelinating cells of the eNS (Ols) appear to inhibit axonal 
regeneration. Evidence of the critical role of peripheral glial cells in enhancing regeneration 
was shown by David in 1981, who demonstrated that eNS axons can regenerate when a 
peripheral nerve is grafted around them (80). 
In the PNS, myelin substance is rapidly cleared by macrophages allowing better healing, 
while myelin in the eNS is slowly cleared, due to late appearance of macrophages in the site 
of injury [81, 82). This fact indicates that the myelin substance may inhibit axonal growth, 
and that there is a critical role of the BBB in preventing recruitment of macrophages to clear 
the inhibitory myelin from the site of injury (82). One of the earliest applications of this fact is 
the use of anti-eNS myelin monoclonal antibody (IN-1). which stimulated axonal growth in 
experimental animals and improved neurological recovery [81]. later on. the antigen of this 
antibody was found to be Nogo-A. which will be discussed later in this thesis [83]. 
1.8 Neuronal degeneration 
Anterograde (Waller/an) degeneration 
For a normally functioning neuron. continuity between the neural cell body and the axon 
should not be disrupted. The axon depends largely on the cell body for survival. Therefore. 
in the eNS and the PNS. the distal segment of the severed axon degenerates. This 
phenomenon was observed by Augustus Waller in 1850 [84]. and thus named Wallerian 
degeneration. The process of Wallerian degeneration is considered a normal response of 
the body to damaged or unnecessary axons. and it is vital in normal development of the 
eNS and for regeneration of the severed axons in the PNS [85]. 
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Axons do not synthesize their own nutrients, but rather depend on special transport 
mechanism of proteins from the cell body along the nerve fibres [85]. However, starvation of 
the axons, by not being connected to the cell body, cannot be the direct cause of Wallerian 
degeneration since axonal degradation happens within a few days of axonal transection. 
Previous studies showed that Ca+ is the main factor in inducing Wallerian degeneration. 
Wallerian degeneration did not happen in the nervous tissue grown in low Ca+ media. 
Moreover, calcium channel blockers, such as cobalt and manganese, prevented Wallerian 
degradation in tissue culture [85]. Within days, presynaptic terminals of the severed axons 
retract from the postsynaptic neuron and from the presynaptic neuron. Following retraction of 
the presynaptic terminal, the distal segment degenerates by Wallerian degeneration [82, 86]. 
Stages of Wallerian degeneration are divided into four periods; the lag period, period of entry 
of Ca+, period of activation of Ca+-dependent proteases, and period of degradation of the 
axon. The lag period is variable among different species. It lasts for 24-48 hours in rats and 
up to 7 days in humans [85]. 
The first observation in Wallerian degeneration is granular disintegration, which is thought to 
be a Ca+-induced phenomenon via activating tissue proteases. This early stage happens in 
both the CNS and the PNS with the same timing, but later stages are much slower in the 
CNS [82]. Once the axon is damaged, Ca+ enters the axon and activates tissue proteases, 
which are enzymes that accelerate degeneration [85]. 
In the CNS all features of Wallerian degeneration, including axonal degradation, 
macrophage activation and myelin phagocytosis, continue for up to 90 days post injury. In 
the PNS, degeneration maximally takes 30 days to complete (animal study) [82]. A study by 
Rachel George in 1994 investigated Wallerian degeneration in rats, by transecting primary 
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sensory neurons at L4, LS, and L6 levels. The level of cut was just proximal to the dorsal 
root ganglia, which allows for studying Wallerian degeneration of the same axons in both the 
eNS and the PNS. The study revealed that the varaition between the eNS and the PNS in 
degeneration is due to the different environment. It demonstrated that the part of the axon 
that runs in the eNS shows the same characteristics of Wallerian degeneration as the purely 
eNS axons, and the part of the same axon that runs in the PNS degenerates similarly to 
peripheral axons. The author suggested that this may be due to delayed recruitment of 
macrophages as a result of the BBB [82]. This has been also supported by another study, 
which demonstrated enhancement of regeneration in the optic nerve by covering it with 
macrophages [87]. It is important to note that in the eNS and the PNS, the ability to 
regenerate axons declines with age [88]. 
Retrograde degeneration 
The proximal part of the axon, which remains connected to the neuronal cell body, usually 
does not degenerate initially and neurons may survive for years, especially when the site of 
injury is far from the cell body [89]. However, some changes in the cell body have been 
noticed following cutting the axon, therefore, retrograde degeneration affects the neurons 
and the axons. 
In fact, retrograde degeneration involves redistribution of intracellular organelles, rather than 
actual degeneration. Retrograde degeneration includes swelling of the neuronal cell body, 
redistribution of Nissl bodies on the periphery, increase in ribosomes and protein synthesis, 
and the nucleus acquires an eccentric position. These changes reflect increase in metabolic 
activity and indicate that the cell is ready to re-innervate during this period [90]. These 
changes are sometimes called chromatolytic changes and were reported after axotomy by 
24-48 hours [91]. They are not specific for neurons with severed axons, but can also occur 
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after other forms of neuronal injury: for example, they have been reported in alcoholic 
encephalitis [92] and in Werdnig-Hoffmann disease [93]. 
If time passes and the axon fails to regenerate and re-innervate, the cell body will probably 
die. In MS, different studies have suggested the potential role of retrograde degeneration in 
neuronal loss in areas far from the primary lesion [94, 95]. In both directions (anterograde 
and retrograde), degeneration may continue to the nearby synapses and neurons in a 
process called transynaptic degeneration [96). 
Transynaptic degeneration 
In long pathways, where there is more than one order neuron, degeneration may involve the 
entire pathway in a process called transynaptic degeneration. Degeneration of the pathway 
continues in both directions (anterograde vs retrograde). For example, transynaptic 
anterograde degeneration may occur when the retina is damaged, degeneration affects the 
pathway up to the visual cortex including the lateral geniculate nucleus. This has been 
suggested in a study on the lateral geniculate nucleus in patients with MS, when there was 
reduction in the number of neurons in the nucleus. While transynaptic retrograde 
degeneration occurs when the visual cortex is damaged for example, degeneration may 
continue through the lateral geniculate nucleus up to the retinal neurons [95, 97). 
1.9 The spinal cord in progressive multiple sclerosis 
In this project we have examined the spinal cord pathology in progressive MS. The 
progressive forms of MS are frequently associated with irreversible disability. The two major 
forms, PPMS and SPMS, have different clinical, radiological, and pathological features. 
PPMS commonly presents with spinal cord lesions and has been suggested to be a different 
disease entity [98-100]. PPMS is associated with poorer prognosis compared to SPMS; on 
average it takes 6 years for PPMS patients to develop severe disability, compared to 11 
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years in patients with RRMS [101]. Howeve, when RRMS patients enter the phase of 
progression, the rate of clinical deterioration was found to be similar in PPMS and SPMS 
[41]. Therefore, the subtype of the disease at presentation (PPMS vs RRMS) is considered 
the most important factor affecting disease prognosis. Radiologically, there are more brain 
lesions affecting RRMS and SPMS compared to PPMS [102], and pathologically, there is a 
greater amount of inflammation (103). However, most of the previous studies have been 
conducted at the level of the brain and few studies have been carried out on the spinal cord 
GM [104-108). Recognition of the importance of spinal cord pathology in studying MS 
disease has increased recently. Based on the recent McDonald criteria, incorporating spinal 
cord MRI with brain MRI in the diagnosis of MS increases the sensitivity of diagnosis up to 
100% [53, 109, 110). Atrophy of the spinal cord in progressive MS has been confirmed 
previously [105,111,112). This atrophy correlates significantly with disability [113-116). MRI 
measurement of spinal cord atrophy was also used as an indicator to follow the disease 
response to treatment [117-119). 
Furthermore, lesions of the spinal cord commonly involve the WM and the GM which gives 
the examiner the ability to compare pathology in the GM and the WM within the same lesion, 
same subject and same level [105, 120, 121]. Similarly, ascending tracts and descending 
tracts can be found in the same lesion and thus their pathology can be compared [122). 
More interest has arisen during the last decade in studying the mechanism and extent of 
spinal cord pathology [2,4). The new interest is evidenced by the number of publications that 
can be found in Pub Med under these keywords; multiple sclerosis; brain, gray matter or 
grey matter, and spinal cord (Pub Med was accessed through the search feature of endnote 
programme on 12111/2010). The number of articles that has multiple sclerosis in the title was 
26270 papers. If the keyword "brain" is added, the number is 889, while the number reduces 
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significantly when the keyword "spinal cord" is added instead of the keyword "brain" (230 
papers). 
The number of studies that have the keywords "multiple sclerosis" and "brain" and "gray 
matter" is 16 studies. On the other hand, only 3 studies were found, when you replace the 
keyword "brain" with "spinal cord", which were all carried out in our lab [104, 106-108]. 
Figure 1.1 demonstrates the number of published studies over the last 15 years that has the 
word multiple sclerosis and gray matter or grey matter in their title. This certainly does not 
include all the studies that investigated pathology of the GM in MS disease, but it gives a 
rough comparison between the number of studies in the last two decades. 
The data above indicates that there is a significant lack of research in the histopathology of 
the spinal cord in MS. In addition, there are few studies that investigated the differences in 
the pathology between disease subtypes at the level of the spinal cord. 
1.10 Thesis outline 
Using quantitative measures, this thesis examines the histopathology of MS at the level of 
the spinal cord. Quantification includes the five major eNS changes involved in MS, which 
are atrophy of tissue, degree of demyelination, OLs loss, axonal loss and neuronal loss. The 
project investigates the variation in these measures between MS and controls and between 
PPMS and SPMS. The analysis involves multiple spinal cord segments and is not restricted 
to the upper cervical levels. This can address the effects of topographic variation on atrophy, 
demyelination degree, OLs loss, axonal loss, and neuronal loss. 
This research has been carried out by studying human autopsy material of both controls and 
MS patients. For the next chapter, the degree of atrophy and demyelination of the spinal 
cord was investigated in PPMS and SPMS using the MBP antibody. 
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In Chapter 3, optimisation of a reliable quantification process of OLs was established. For 
Chapter 4, the unbiased quantification process of OLs was applied to assess numbers of 
OLs in the ventral hom (VH) and the dorsal hom (DH) of the spinal cord, while for Chapter 5 
we quantified OLs in the spinal cord WM. 
Quantification ofaxons was carried out for Chapter 6 using immunohistochemistry with 
NE14 marker. The quantification process ofaxons was similar to the protocol applied on 
quantification of OLs in the WM, ie quantification ofaxons and OLs was carried out in 
topographically the same fields. Chapter 7 investigates numbers of neurons in the VH. 
Chapter 8 summarises the thesis and includes suggestions for future work. 
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o 
Year 
Figure 1.1: The number of studies that have multiple sclerosis and grey (or gray) matter as the key words. Pub Med was 
accessed on 12110/2010. 
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Chapter 2: Demyelination and atrophy of the spinal cords of 
progressive MS 
2.1 Introduction 
The extent of demyelination and the degree of atrophy of the CNS are essential 
features to examine in PPMS and SPMS. It has been estimated that 75% of MS 
patients have spinal cord lesions at presentation [123]. These lesions are associated 
with loss of myelin, axons and Ols. loss of these elements may lead to CNS 
atrophy. It is also believed that this atrophy is an early process. Axonal loss and 
atrophy have been found to be significant in patients with disease duration less than 
5 years [111]. 
The exact mechanism of spinal cord atrophy in MS is still unknown. The relation 
between amount of demyelination and atrophy is not clear. Different mechanisms 
and theories have been suggested to explain nature of atrophy. An earlier 
histopathology study showed that local effects of lesions on atrophy are probably 
limited [112]. Conversely, in an MRI study, degree of atrophy was found to be 
significantly affected by degree of spinal cord lesions [115]. A histopathology study 
has also reported significant positive correlation between atrophy and demyelination 
[124]. Histopathological studies are well known as being more accurate than MRI 
studies in assessing the cord cross sectional area (CSA) and degree of 
demyelination [125]. 
2.2 Volume of the GM in multiple sclerosis 
Few studies have investigated the degree of atrophy and degree of demyelination in 
the GM of the spinal cord. While GM atrophy of the brain has been confirmed 
previously, GM atrophy of the spinal cord has not yet been confirmed. There is also 
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some evidence that spinal cord pathology is independent of brain pathology because 
neither atrophy nor occurrence of lesions correlates [126]. 
Two previous histopathology studies examined potential atrophy of the spinal cord 
GM and they showed opposite results. The first study was carried out in 2000, and 
reported that spinal cord atrophy was due to WM and GM atrophy to the same 
degree, and that the GM:WM ratio of MS subjects was similar to controls even with 
the presence of significant atrophy [127]. Later, in 2005, Gilmore et al reported in a 
histopathology study that atrophy is purely due to loss of the WM volume and that 
GM volume is well preserved in spinal cords of subjects with MS [105]. The later 
study in 2005 was well controlled and utilised a larger sample size (55 MS and 33 
controls compared to 5 MS and 6 controls). 
Gilmore and his colleagues attributed the preservation of the spinal cord GM in MS to 
the discrepancies in connectivity of the examined GM regions. Regions of the GM 
that have extensive connections with various structures of the eNS, such as the 
thalamus, are more vulnerable to atrophy than other regions. This fact has been also 
stated in other studies [105, 128, 129]. 
The effect of distant lesions via transynaptic retrograde or anterograde degeneration 
is one of the presumed mechanisms in atrophy of the GM areas with extensive 
connections [130, 131]. The reported WM atrophy and preservation of the GM in the 
spinal cord is further supported by the finding that spinal cord atrophy is minimal in 
the lower cord where the WM content is small. Therefore, understanding the 
discrepancy in nature of atrophy between the brain and the spinal cord may be very 
useful in explaining mechanisms of atrophy. 
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While the clinical significance of spinal cord GM pathology has not been confirmed 
yet, a number of studies has demonstrated the clinical significance of GM atrophy in 
the brain [132-134]. For example, GM atrophy of the brain seems to be more related 
to progression of the disease than WM atrophy [134] and GM disease dominates the 
pathological process of MS in the progressive phase of the disease [132]. Correlation 
of brain GM atrophy with disease disability has also been reported previously [132, 
134] and even reported to reflect disability better than WM atrophy or WM lesions 
[134]. In a study executed on PPMS, degree of cerebral GM pathology was found to 
be a significant predictor of disability over 5 years of follow up [135]. In SPMS, a 
cross-sectional study showed that decline in the brain volume has a significant effect 
on patient disability [136]. 
2.3 Variation between primary progressive and secondary progressive 
multiple sclerosis 
Although the two major forms of progressive MS (PPMS and SPMS) share a similar 
degree of neuropsychological disability [137], they are different in other aspects, 
such as disease course, extent of demyelination and inflammation [103, 138], total 
number of lesions, rate of occurrence of new lesions [138, 139], and degree of 
atrophy [102]. 
2.3.1 Variation in degree of demyelination and Inflammation 
A study by Foong in 2000 analysed 12 patients with SPMS and 13 patients with 
PPMS. The study demonstrated more lesions in the brains of SPMS compared to 
PPMS, but the neuropsychological deficits did not show significant difference [137]. 
Comi et al (1995) studied 14 patients with PPMS and 17 patients with SPMS for 
variation in brain MRI and relation to cognitive functions. Lesions were significantly 
more extensive in the brains of SPMS compared to PPMS, especially in the frontal 
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and occipital lobes. In addition, SPMS patients showed more neuropsychological 
abnormalities than PPMS [140]. 
The significantly higher frequency of enhancement with gadolinium in new lesions of 
SPMS compared to PPMS is a good evidence that degree of inflammation may vary 
among the two forms [139]. Revesz et al (1994) conducted a human pathological 
study on 9 cases of MS (4 PPMS and 5 SPMS). The study reported a significant 
difference in the degree of demyelination and inflammation in PPMS and SPMS. 
Degree of demyelination and inflammation was much higher in the brains of SPMS 
than PPMS, but there was no difference at the spinal cord level [103]. 
Longitudinal studies have also reported differences between the two disease 
subtypes. In an MRI study that followed up progressive MS patients over one year, 
imaging of the brain and the cord showed that 85% of new lesions occurred in the 
brains of SPMS patients, with much fewer new lesions affecting the PPMS patients. 
New spinal cord lesions formed only 5% of the total number of new lesions, with no 
difference between PPMS and SPMS [138]. It was also found that PPMS is 
associated with diffuse abnormality, but SPMS causes more focal lesions of the cord 
[102]. 
Another MRI study by Thompson et al (1991) showed that rate of occurrence of new 
lesions is 18.2 lesions per patient per year in SPMS, compared to 3.3 lesions per 
patient per year in PPMS. However, the clinical deterioration over the follow up 
period did not show significant differences between PPMS and SPMS [139]. 
There is little information about the differences between PPMS and SPMS at the 
level of the spinal cord, and the pathology study by Revesz investigated a small 
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sample size (4 PPMS and 5 SPMS). MS lesions of the spinal cord may have better 
correlation with disability than brain lesions, because higher numbers of new lesions 
in the brains of SPMS subjects were not associated with significant difference in the 
clinical deterioration between PPMS and SPMS [139]. This may indicate that the 
clinical deterioration over time correlates with new spinal cord lesions rather than 
brain lesions. Nonetheless, the better correlation of the spinal cord pathology with 
signs and symptoms of MS has been suggested previously [110, 141]. 
2.3.2 Variation in atrophy 
Degree of spinal cord atrophy is apparently not similar in PPMS and RRMS. Nijeholt 
et al (1998) used various MRI parameters of the brain and the spinal cord to 
differentiate between MS subtypes. They found that SPMS had more spinal cord 
atrophy than RRMS and PPMS [102]. 
A recent longitudinal MRI study conducted by Fisher et al (2008) followed 17 healthy 
control subjects, 36 RRMS, and 27 SPMS patients for 4 years. Both GM and WM 
atrophy were measured on a number of occasions. Fisher and colleagues reported 
that brain WM atrophy affects the three groups to the same degree, but GM atrophy 
rate varies among the groups and was most prominent in SPMS. The study also 
revealed significant correlation between tissue damage and GM atrophy in RRMS. In 
SPMS, there were no predictors of GM atrophy, which indicates that atrophy in the 
progressive form of the disease continues regardless of age and gender and, most 
importantly, regardless of lesion load. However, rate of brain GM atrophy correlated 
Significantly with development of disability over the period of follow up [132]. Although 
the study did not include PPMS subjects, it gives an idea about the pattern of atrophy 
in RRMS and SPMS. Therefore, it is important to investigate if there is any difference 
in degrees of atrophy and demyelination of the spinal cord between PPMS and 
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SPMS. In this study. post-mortem analysis of a large sample of spinal cords from 
both PPMS and SPMS was carried out. 
2.4 Aims and hypothesis 
Spinal cord atrophy correlates with disability in MS patients and can be used to follow 
up treatment strategy [116]. In spite of MRI development in estimating spinal-cord 
atrophy. the small size of the lower cord restricts accurate estimation of atrophy and 
demyelination in the lower cord levels due to MRI resolution limitation. In order to 
precisely assess the dynamics of spinal cord lesions and atrophy, accurate 
measurement of these parameters in multiple cord levels is essential. 
In addition, pathological studies have demonstrated greater accuracy in assessing 
degree of spinal cord demyelination. Gilmore et al 2009 reported less accuracy in 
identifying demyelination by in vitro MRI compared to histopathology. This was more 
obvious in the GM [108]. Such findings may direct future MRI techniques toward 
improving GM imaging. Therefore, post-mortem pathological studies are helpful in 
validating MRI results and help in improving accuracy of future MRI techniques. 
Accurate assessment of atrophy in vivo may enable clinicians to predict disability and 
response to treatment accurately. MRI studies showed differences in the nature and 
degree of atrophy between PPMS and RRMS. mainly at the level of the brain. There 
is little information about differences in the degree of atrophy and demyelination 
between PPMS and SPMS at the spinal-cord level. 
In this study, MS and healthy human autopsy material will be analysed by measuring 
the eSA of the spinal cord section. Results will be compared between MS and 
controls and between PPMS and SPMS. Same analysis will be applied on the GM 
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and the WM sectional areas separately, to assess the contribution of GM and WM in 
the atrophy. The effects of independent factors such as age, gender, disease 
duration, disease subtype and cord level on the cord CSA will be assessed. The 
demyelinated regions will be measured. Absolute lesion size (the cross-sectional 
areas of the lesion) and proportion of lesion area to the CSA of the WM and the GM 
will be calculated. 
2.5 Material and methods 
Human spinal cords autopsy material was available from three sources: the MS 
Society Tissue Bank (Imperial College, London) (PPMS = 12, SPMS = 15, Controls = 
5), Netherlands Brain Bank (Netherlands Institute for Neuroscience, Amsterdam) 
(PPMS = 7, SPMS = 23, Controls = 5), and Oxford Radcliffe NHS Trust (Controls = 
6). 
Considering the whole sample of tissue: the age range of PPMS subjects (n = 19; 6 
males and 13 females) is between 45 and 92 years (mean ± SO = 67.8 ± 13.4 years) 
and the disease duration between 5 and 54 years (mean = 25.6 ± 14.5 years); for 
SPMS subjects (n = 38; 11 males and 27 females) the age is between 34 and 85 
years (mean = 58.4 ± 13.6 years) and the disease duration between 4 and 54 years 
(mean = 26.0 ± 14.3 years); for Control (n = 16; 6 males and 10 females), the age 
range is between 33 and 93 years (mean = 67.3 ± 3.2 years). 
The spinal cords were dissected after a post-mortem delay of 8 to 33 hours for 
Controls (mean = 18.1 ± 8.4 hours), 5 to 21 hours for PPMS (mean = 10.4 ± 5.3 
hours) and 4 to 28 hours for SPMS (mean = 10.4 ± 6.0 hours). For several cases, the 
post-mortem delay was not available (Tables 2.1, 2.2, and 2.3). Consent to obtain 
tissue for research purposes and to access medical records was taken from the 
Chapter 2: Demyelination and atrophy of the spinal cords of progressive MS 
donor or the next of kin. Detailed clinical information is available for most cases. 
Diagnosis of MS has been pathologically confirmed for all cases. The clinical 
disability preceding death for the two groups (PPMS and SPMS) was found to be 
similar in a previous study, where EDSS was found to be greater than 8 for majority 
of cases [142]. The study was approved by the Local Research Ethics Committee. 
Table 2.1: The controls sample 
Source oftissue Subject 10 Gender Age Post-mortem Available spinal cord segment 
number (Years) delay (Hours) 
272 female 54 Cervical, lumbar 
414 female 66 Cervical, lumbar 
Oxford controls 458 female 68 Cervical, Lumbar 3269 male 77 Cervical, lumbar 
3313 male 50 Cervical. lumbar 
4254 male 33 Cervical (not included in analysis). lumbar 
11 male 77 26 Lumbar 
14 female 64 18 Cervical. lumbar 
Tissue bank 22 female 69 33 cervical 
controls 32 male 88 22 Lumbar 
080 female 93 9 Thoracic Lumbar 
45 female 41 14 cervical 
142 male 73 25 cervical 
Dutch tissue 250 female 68 cervical 
controls 270 female 72 cervical 
400 female 83 8 Cervical 
2.5.1 Initial preparation of tissue 
MS society tissue bank sample 
MS Society tissue bank sample includes frozen blocks from various levels of the 
cord. From 15 cases of MS subjects and 2 cases of controls we have two blocks, 
while from the other cases we have only one block from each subject. Therefore, 49 
blocks (7 controls and 42 MS) from the MS Society tissue bank were analysed. After 
dissection, all spinal cord blocks were fixed immediately in 4% paraformaldehyde for 
2 weeks, then cryoprotected with 30% sucrose for one week. This was followed by 
immersion in isopentane on a bed of dry ice. From that time, all blocks have been 
stored at -75 degrees. Blocks were then defrosted at our laboratory and formalin-
fixed paraffin-embedded blocks were produced. The formalin-fixed paraffin-
embedded sections were cut at a thickness of 5 J.1m, mounted on Superfast slides, 
and dried overnight at 37°C. 
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Netherlands brain bank 
A collection of 35 sections of tissue from Netherlands brain bank had been fixed in 
10% formalin for 30 days. Tissue material was taken from the cervical cord. Similarly, 
5 J.1m thick sections were cut from the formalin-fixed paraffin-embedded blocks, 
mounted on Superfast slides, and dried overnight at 37°C. 
Oxford Radcliffe Hospital Brain Bank 
Six controls were selected randomly from archival material that had been obtained 
originally from the neuropathology department of Oxford Radcliffe NHS trust. From 
each control subject, two blocks were selected for analysis; one is cervical and the 
other is lumbar. Similarly, the formalin-fixed paraffin-embedded sections were cut at 
5 J.1m, mounted on Superfast slides, and dried overnight at 37°C. However, one 
cervical section was not used because of partial tissue loss during sectioning. 
Therefore, 11 sections from the 6 controls were included in the analysis. 
2.5.2 Immunohistochemistry 
The sections were deparaffinised using xylene and rehydrated in reducing 
concentrations of ethanol (100%, 96%, 70% and water). Endogenous peroxidase 
was blocked using 0.3% H202 in methanol. For antigen retrieval sections were 
heated in Tris/EDTA (pH 9). The immunohistochemistry staining used primary 
antibody against myelin (MBP, dilution 1 :200, DAKO). The sABC method for 
immunohistochemistry was performed as previously described in Geurts et al 2005 
[143]. 
2.5.3 Image analysis 
The MBP-stained slides were numbered so that the primary observer is blinded to 
the disease type. All slides were scanned by the Nanozomer Digital Pathology (NDP, 
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Hamamatsu, Japan). The NDP machine converts the slides into digital slides by 
scanning the slides at specified magnification. All our slides were scanned at 
magnification of 40X. These digital slides can be viewed by the computer by special 
software called NDP.view software. The software enables the examiner to view the 
scanned slides and to magnify them up to 40 times with the same resolution as a real 
microscope. It also enables the investigator to take accurate calculations of 
distances, surface areas and boundaries. The software can be used for drawing 
around various structures, such as the GM and the WM, and export any field of 
interest as a digital image in the JPEG format [144]. 
2.5.4 Demarcation of surface areas 
The WM and GM boundaries were demarcated in all electronic sections. The GM 
boundary that we applied in this study ends at the cap of the DH, which is called the 
posterior marginal nucleus or zona spongiosa. To increase the accuracy of drawing, 
boundaries of the GM, WM area and demyelination areas were drawn using a digital 
pen on a graphic tablet (graphic tablet MD 85637 from Medion). The NDP.view 
software automatically calculates the surface area within the drawn border. Surface 
areas were measured in mm2• 
The frequency of demyelination of important structures of the spinal cord was 
estimated, such as the posterior column pathway (PCP), the area of the corticospinal 
tract (CST), the DH, and the VH. Initially, the PCP was identified in all sections and 
the area occupied by the lateral CST was identified based on the description 
mentioned previously [122]. For more objective description, it is the area of the lateral 
funiculus that is dorsal to a horizontal line passing through the posterior border of GM 
commissure. Various DH structures were identified based on Rexed description [145, 
146]. The aim is to look for involvement of the nucleus proprius. The DH was 
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considered affected when the nucleus proprius was demyelinated because the 
substantia gelatinosa is normally unmyelinated area. The nucleus proprius is a 
heavily myelinated area that forms the bulk of the DH. In all sections, the area of the 
substantia gelatinosa was initially delineated. The post marginal zone was also 
demarcated, which is the thin myelinated area dorsal to the substantia gelatinosa and 
called the cap. Ventral to the substantia gelatinosa, the nucleus proprius was 
localized. 
Table 2.2: The multiple sclerosis sample (MS society tissue bank) 
Duration 
Subject 10 Gender Type of the Age of the Post-mortem Available level disease (years) disease delay (hours) 
(years) 
8 male PPMS 77 28 5 Cervical, lumbar 
40 female PPMS 58 21 6 Cervical, lumbar 
44 female PPMS 45 20 17 Thoracic lumbar 
57 female PPMS 77 31 9 cervical 
70 female PPMS 77 22 21 Cervical lumbar 
81 male SPMS 72 47 23 lumbar 
83 male PPMS 54 16 12 Cervical, lumbar 
102 male PPMS 73 52 20 lumbar 
105 male SPMS 73 46 8 Thoracic, lumbar 
111 male PPMS 92 54 9 Cervical, lumbar 
114 female SPMS 52 15 12 Cervical lumbar 
127 male SPMS 51 10 21 thoracic 
128 female SPMS 78 50 22 cervical 
136 male SPMS 40 9 10 Cervical, lumbar 
143 female SPMS 62 19 Cervical, lumbar 
147 female SPMS 60 21 27 Cervical 
157 female SPMS 39 22 12 cervical 
162 female SPMS 58 22 14 cervical 
187 female SPMS 57 17 13 Cervical lumbar 
191 female SPMS 48 32 28 thoracic 
216 female PPMS 53 5 9 Thoracic, lumbar 
218 female SPMS 56 26 7 thoracic 
231 female PPMS 59 27 Thoracic, lumbar 
263 female PPMS 73 37 Cervical lumbar 
266 female PPMS 75 8 Cervical, lumbar 
298 male SPMS 72 43 11 cervical 
300 female SPMS 56 34 13 thoracic 
Lesions sizes were calculated and classified as pure WM lesions, pure GM lesions 
and mixed lesions. Then demyelinated areas of the WM were calculated separately 
from the demyelinated areas of the GM. 
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2.5.5 Classification of the sections according to the cord level 
The main cord level was already known for all sections (cervical, thoracic, or lumbar). 
The classification process included identifying the cord segment and whether the 
section was taken from the upper or the lower segment of the main cord level. This 
has been identified based on morphology of the spinal cross section, which mainly 
depends on GM morphology [147]. Sections were categorised into five groups; 
upper cervical (C2-C4), lower cervical (C5-C8), thoracic (T1-T12), upper lumbar (L 1-
L3) and lower lumbar (L4-L5). 
2.5.6 Statistical analysis 
All statistics were calculated using SPSS 14. The means of the two disease subtypes 
were compared using student t-test. Interobserver reproducibility was tested by 
calculating the coefficient of variation or Pearson correlation (r). Chi-squared test (X2 
test) was used to find out the relation between the frequency of demyelination of the 
spinal cord structures and progressive MS subtypes. For correlation of atrophy and 
demyelination with disease duration, partial correlation was used controlling for age, 
gender, disease duration, segment level and disease subtype. Linear regression was 
used to study the effects of gender, disease duration, and disease type, and level of 
the cord on the cord CSA and degree of demyelination. 
2.5.7 Reliability and reproducibility 
Interobserver reproducibility for identification of the cord level depending on 
morphology of cross section was tested (r = 0.9, p < 0.0001 ).The coefficient of 
variation was used for testing interobserver reproducibility of surface areas 
measurements. The results of coefficients of variation were 1.7% for the whole CSA, 
2% for the WM area, and 6% for the GM area. The two measurements of the 
demyelinated areas of the WM and the GM had interobserver coefficients of variation 
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of 4.4% and 9.3% respectively. To study the contribution of different shrinkage 
factors between London MS tissue and Netherland MS tissue, the CSA of the exact 
cord level was compared between the two sources (r = 0.877, P = 0.010). Results are 
shown in Table 2.4. 
Table 2.3: Multiple sclerosis sample (Netherlands brain bank) 
Subject 10 Gender Type of the Age Duration of the Post-mortem Available level disease (years) disease (years) delay (hours) 
21 female SPMS 70 27 6 cervical 
24 female SPMS 62 29 7 cervical 
59 female SPMS 34 10 7 cervical 
73 male SPMS 77 41 7 cervical 
115 female PPMS 57 19 6 cervical 
116 female SPMS 36 11 6 cervical 
121 female SPMS 45 14 11 cervical 
125 female SPMS 58 20 8 cervical 
132 female PPMS 79 44 8 cervical 
155 female SPMS 85 54 4 cervical 
161 female SPMS 41 7 4 cervical 
177 female SPMS 71 31 10 cervical 
189 female PPMS 82 15 4 cervical 
192 female SPMS 63 32 7 cervical 
202 male SPMS 50 7 6 cervical 
228 male SPMS 70 21 6 cervical 
232 female SPMS 40 4 7 cervical 
234 female SPMS 81 49 4 cervical 
248 female PPMS 57 7 8 cervical 
264 male SPMS 51 29 8 cervical 
276 male SPMS 56 13 5 cervical 
282 female SPMS 76 53 14 cervical 
307 male SPMS 72 42 5 cervical 
309 female SPMS 60 22 9 cervical 
323 female PPMS 70 36 9 cervical 
338 male PPMS 48 19 cervical 
352 female SPMS 53 19 7 cervical 
385 female SPMS 40 18 7 cervical 
404 female SPMS 54 11 7 cervical 
3070 male PPMS 83 37 7 cervical 
Table 2.4: Surface area of the cervical segments of MS tissues obtained from the MS society tissue bank and from 
Netherlands brain bank. Tissue from Netherlands contains only cervical cord tissue. 
CSA of the cord (Tissue bank CSA of the cord (Netherlands tissue sample) Level sample) 
Mean in mm 2 Meaninmm 2 
C2 31.10 28.25 
C3 34.53 39.30 
C4 30.35 28.20 
C5 42.20 41.55 
C6 42.00 49.90 
C7 50.95 56.74 
C8 63.10 54.46 
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2.6 Results 
2.6.1 General observations 
We examined 95 MBP-stained sections taken from 73 subjects (29 sections from 
PPMS, 43 sections from SPMS, and 23 sections from healthy subjects). It was 
possible to clearly identify the GM from the WM at low magnification for most of the 
sections. However, when there was extensive demyelination, high magnification was 
required for delineation of the GM from the WM. Spinal cord areas such as the VH, 
DH, PCP, and the area of the CST were identified in all sections. 
The MBP stain showed the unmyelinated areas clearly. The normally unmyelinated 
areas in the spinal cords of healthy controls include the part of the intermediate GM 
around the central canal, the substantia gelatinosa and the outermost area of the 
lateral horns. These areas were considered when MS slides were examined for 
abnormality. 
In MS, both spinal cord GM and WM were affected by demyelination. Lesions 
commonly involved the GM and the WM without respecting the boundary. However, 
lesions seem to extend from the WM to the GM but not the opposite direction, ie 
lesions frequently acquires the shape of the VH (Figure 2.1). 
In the PCP 14 separate lesions were detected. These were midline, bilateral and 
frequently symmetrical lesions (Figure 2.2). These lesions were seen in both disease 
subtypes and there was no association between size of lesion and disease duration. 
2.6.2 General statistics and distribution of demyelination 
Number of sections that showed abnormality was 48, which constitutes 67% of MS 
sections. About 70% of the cervical sections showed abnormality, compared to 62% 
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and 58% in the thoracic and lumbar sections respectively. Out of the 43 sections with 
SPMS, 35 sections (81%) showed abnormal appearance, while 13 sections (45%) 
from the 29 PPMS blocks showed abnormality. 
The CST and the PCP were commonly seen to be affected by complete 
demyelination. The PCP was affected in 53% of all sections and in 72% of the 
abnormal-appearing sections, while the CST was affected in 57% of all sections and 
in 69% of the abnormal-appearing sections. 
About 63% of all SPMS sections showed PCP involvement, while in PPMS 37% of 
sections showed PCP lesions (Pearson chi square = 5.067, p = 0.024). The SPMS 
also showed more frequency of CST involvement than PPMS: 74% of SPMS 
sections have CST lesions compared to 30% of PPMS sections that have CST 
lesions (Pearson chi square = 14.253, P < 0.001). 
With respect to the DH involvement, 52% of SPMS showed demyelination of DH 
compared to 27% involvement in PPMS (Pearson chi square = 4.846, P = 0.028). 
The VH was affected in 38 sections, which forms 50% of all sections. The VH was 
also involved more in SPMS, in which 63 % of SPMS sections showed VH lesions, 
compared to 30% of PPMS sections ( Pearson chi square = 7.930, P = 0.005). Ten 
sections showed extensive demyelination that occupied more than 50% of the cord 
CSA and all these sections were cervical (9 of them are SPMS and only one PPMS). 
2.6.3 The spinal cord cross sectional area 
The cross sectional areas of liS spinal cords was less than controls 
The mean CSA of spinal cords in MS subjects was lower than normal controls in all 
levels except the thoracic level. In the cervical region, there was significant 31% 
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reduction in the CSA compared to controls. This decline was more prominent in the 
upper cervical (46% atrophy, p = 0.001) compared to lower cervical (26% atrophy, p 
= 0.009). In the thoracic cord, our data showed that the CSA in MS was higher than 
controls. Since we have only one thoracic block as a control, the comparison 
between MS and controls cannot be reliable at this cord level. 
The lumbar regions of MS showed less atrophy than the cervical levels. Compared 
to controls, the sectional areas of the upper lumbar and lower lumbar regions were 
reduced by 20% (p = 0.086) and 29% (p = 0.099) respectively (Table 2.5). 
Atrophy of the spinal cords of MS affects the GM and the WM 
The amount of WM was reduced by 45% in the upper cervical segment (p < 0.001) 
and 28% in the lower cervical segment (p = 0.008). Similar results were obtained 
from the GM measurements, where the cervical GM atrophy was significant in the 
upper cervical (48% atrophy, p = 0.004) and the lower cervical GM (22% atrophy, p = 
0.045). 
Results from the lower levels of the cord showed markedly less decline in the CSA 
of the WM and the GM, which was statistically insignificant except in the GM of the 
upper lumbar segment (p = 0.049) (Table 2.6). 
Table 2.5: The CSA in the 5 examin • segments 0 t e spina co in ed fh' I rd MS and controls 
Segment Controls and MS PPMS and SPMS 
Category CSA (mm2) so (mm2) Sig C S A ( m m ~ ) ) SO ( m m ~ ) ) Sig 
Control n=4 58.82 6.03 PPMS 35.76 5.77 
Upper Cervical 
MS n = 15 31.89 6.31 
.001 
SPMS 28.50 4.80 .022 
Control n = 8 69.69 14,34 PPMS 55.36 14.23 
Lower Cervical 
MS n = 32 51.62 13.90 
.009 
SPMS 50.38 13.86 .388 
Control n = 1 20.60 .... 
.154 
PPMS 31.43 5.42 
Thoracic 
MS n= 8 28.40 4.86 SPMS 27.30 4.32 
.275 
Control n=5 42.92 11.69 PPMS 35.65 3.59 Upper Lumbar 
MS n = 11 32.5 7.34 
.086 
SPMS 32.38 10.55 .491 
Lower Lumbar 
Control n=5 49.92 1.41 PPMS 40.54 13.6 
MS n=6 37.60 17.26 .099 SPMS .115 10.60 ..... 
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2.6.4 Spinal cords of SPMS have greater degree of atrophy than PPMS in the 
upper cord levels 
When comparison of the eSA was performed between PPMS and SPMS, the mean 
eSA in SPMS was lower than eSA of PPMS in all segments; however, this 
difference was statistically significant only in the upper cervical segment. The upper 
cervical segment eSA of SPMS subjects was 28.5 mm2, while the corresponding 
segment in PPMS showed a eSA of 35.8 mm2 (p = 0.022) (Figure 2.3, Table 2.5). 
SPMS has less GM and WM surface area compared to PPMS. Nevertheless, there 
was no statistical significant difference in the GM and WM surface areas between 
PPMS and SPMS. The only exception was the WM surface area of the upper cervical 
segments, which demonstrated Significant difference between PPMS and SPMS (p = 
0.030) (Table 2.6). 
Effects of independent factors on the cross sectional area of the cord 
In controls, the eSA of the cord was Significantly reduced with age controlling for 
gender and cord level. Partial correlation between age and cord eSA showed a 
correlation coefficient of - 0.569 and a p value of 0.007. In MS, controlling for gender, 
cord level and type of the disease, there was no significant effect of disease duration 
(p = 0.446) or type of the disease (p = 0.294) on the cord eSA. 
2.6.5 Lesions numbers and sizes 
Number of lesions that have been identified was 76; average = 2 lesions/section. 
There were 40 WM lesions, 26 mixed lesions and 10 GM lesions. Average lesions 
number per section was = 2 lesions/section in the cervical, = 2 lesions/section in the 
thoracic, and = 1 lesion/section in the lumbar area. The mean lesion size was 7.18 ± 
SO = 8.8 mm2 in the cervical, 1.70 ± 1.5 mm2 in the thoracic and 2.59 ± 3.3 mm2 in 
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the lumbar. According to lesions type, the mean lesion size was 0.8 ± 0.66 mm2 in 
the GM, 2.3 ± 2.5 mm2 in the WM, and 13.4 ± 9.6 mm2 in mixed lesions. 
When the two disease subtypes were compared, the mixed lesions sizes had a mean 
of 14.7 mm2 in SPMS and 11.1 mm2 in PPMS (p = 0.390), the pure WM lesions have 
a mean of 2.7 mm2 in SPMS and 1.1 mm2 in PPMS (p = 0.009), and pure GM lesions 
have a mean of 0.6 mm2 in SPMS and 1.0 mm2 in PPMS (p = 0.450). 
Linear regression, controlling for age, gender, disease duration, disease type, lesion 
type, and cord level showed that the main predictor for lesion size was the lesion 
type, by being larger in mixed lesions (p < 0.001). When lesion type was dropped, the 
main predictor was the cord level by being larger in upper cord levels (p = 0.013). 
Table 2.6: The CSA in the GM and the WM separately 
GM WM GM WM 
Type of Type of the level sample CSA (mm2) 
CSA disease CSA CSA p (mm2) p (mm2) p (mm2) p 
Control 7.63 51.20 PPMS 4.43 31.32 .030 Upper 
.000 .197 Cervical MS 4.00 
.004 27.89 SPMS 3.62 24.88 
Control 13.03 56.65 PPMS 11.19 44.17 
Lower 
.045 .008 .269 .437 Cervical MS 10.14 41.48 SPMS 9.80 40.58 
Control 2.64 17.96 PPMS 4.39 27.04 
Thoracic 
.336 .186 .060 .433 
MS 3.64 25.21 SPMS 3.18 24.12 
Control 12.91 30.01 PPMS 6.26 29.39 Upper 
.049 .389 .693 .108 Lumbar MS 6.73 27.43 SPMS 7.30 25.08 
Control 17.66 32.26 PPMS 16.23 24.31 
Lower 
.275 .056 .126 .113 Lumbar MS 14.46 21.09 SPMS 5.65 4.95 
2.6.6 Proportion of demyelination 
Proportion of demyelination Is higher In the upper spinal cord segments 
Demyelination affected mainly the cervical regions of the spinal cord (24%) 
compared to the thoracic (6.5%) and the lumbar regions (4.7%). Proportion of 
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demyelination was highest in the lower cervical region, where 26.8% of the cord was 
demyelinated, while the upper cervical cord showed 18.4% demyelination. In 
contrast, the upper lumbar showed 6.95% demyelination and the lower lumbar region 
showed only 0.58% of demyelination. Demyelination of the GM and the WM were 
observed to be greater in the higher cord levels (Tables 2.7 and 2.8). 
Proportion of demyelination in SPMS and PPMS spinal cords 
Regardless of cord level, overall demyelination was 8% in PPMS and 24% in SPMS 
(p = 0.002). In the upper cervical segment of PPMS degree of demyelination was 
6%, compared to 29% in the corresponding area of SPMS (p = 0.053). In the lower 
cervical region the mean proportion of demyelination was 30.2% in SPMS and 16.6% 
in PPMS (p = 0.247). Similarly, results from the rest of the spinal cord segments also 
did not show significant differences between PPMS and SPMS in the degree of 
demyelination (Table 2.8, Figure 2.3). 
Table 2.7: Proportion of demyelination in the main cord levels and in the main 5 seaments cateQories. 
Corddem % Segment Corddem % Type of the Corddem% P Block 
level Mean Range Category Mean SO disease Mean Range value (median) (median) 
Upper 18.35 23.66 PPMS 5.93 00-28 (0.00) .053 cervical SPMS 29.22 00-78 (28) 
Cervical 24.12 00-91(19) Lower PPMS 16.65 00-75 (0.6) 
cervical 26.83 28.34 SPMS 30.22 00-9f(29) .247 
thoracic 00-39 (0.9) Thoracic 6.53 13.40 PPMS 2.09 00-6(0.00) .511 6.53 SPMS 9.20 00-39 (2) 
Upper 6.95 11.88 PPMS 7.50 00-26-(00) .878 lumbar SPMS 6.29 00-30 (00) 
lumbar 4.70 00-30 (0.00) Lower PPMS 0.70 00-2 (00) 
lumbar 0.58 0.90 SPMS 0.00 00-00 (00) .542 
Proportion of demyelination of the GM and the WAf 
By further categoriSing results by the area involved, the GM of upper cervical 
segment of PPMS was affected by 20% demyelination compared to 50% in the 
corresponding segment of SPMS (p = 0.142). The lower cervical cord GM was 
affected by 24% GM demyelination in PPMS and 34% GM demyelination in SPMS (p 
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= 0.476). Similarly, results from the rest of the cord segments did not reveal 
difference between the two forms. 
Similar results were obtained from the WM demyelination, in which SPMS did not 
show difference from the PPMS. The only exception was the WM of the upper cord, 
which revealed significant difference between PPMS and SPMS (p = 0.043) (Table 
2.8). 
Proportion of GM demyelination Is higher than proportion of WAf 
Proportion of GM demyelination was significantly higher than WM demyelination in all 
levels except lower lumbar cord (Table 2.8). Although the proportion of demyelination 
in the whole section and in the GM area was higher in SPMS, the ratio of GM 
demyelination to WM demyelination was higher in PPMS. 
2.6.7 Effect of independent factors and correlation with disease duration 
Studying effects of age, gender, disease duration, type of the disease, and cord level 
on proportion of demyelination showed that age of the patient (p = 0.001) and the 
COrd level are significant predictors of proportion of demyelination. However, when 
we dropped age from the controlling factors, type of the diseasee (p = 0.014) and the 
cord level (p = 0.038) were significant predictors of demyelination. Disease duration 
showed a trend toward significance (p = 0.059). This points to the complicated 
relation between age of the patient and the disease duration. 
Similar results were obtained when the previous regression model was applied on 
the WM demyelination. It showed that there is Significant effect of disease type (p = 
0.009) and cord level (p = 0.046). When the same regression model was applied on 
the GM exclusively, only the cord level showed significant effect on GM 
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demyelination (p = 0.049) with no effects of disease subtype on GM demyelination (p 
= 0.155). 
2.6.8 Effect of demyelination on atrophy 
Using Pearson coefficient, the correlation between degree of atrophy and 
demyelination was evaluated in the cervical cord. Bivariate correlation for the whole 
sample was -0.229 and p value was 0.122. However, considering the two subtypes 
of the disease and controlling for age, gender, disease duration, and post-mortem 
delay, there was significant correlation between proportion of demyelination and the 
cervical eSA in SPMS (correlation = -0.605, P = 0.001), but not in PPMS (correlation 
= -0.557, P = 0.152). 
Table 2.8: Proportion of demyelination in the 5 segments in the GM and the WM WIth the variation between PPMS 
and SPMS 
GMdem% WM dem% GMdem% WMdem% 
Disease Sig Sig Mean subtype Media Median Mean Median Mean Median Mean n 
PPMS 20.00 0.0 3.71 7.01 
cervical 37.29 20.8 15.47 5.2 .142 0.043 
SPMS 52.41 67.2 25.77 24.99 
Lower PPMS 23.57 0.9 15.10 24.61 
cervical 31.25 17.85 25.98 20.1 .476 0.212 SPMS 33.81 28.7 29.61 28.80 
PPMS 5.64 0.0 1.61 2.79 Thoracic 9.00 0.00 6.23 1.0 .638 0.496 
SPMS 11.02 0.0 9.00 17.00 
Upper PPMS 22.26 0.0 4.87 7.75 
lumbar 17.36 0.00 4.95 0.0 0.57 0.977 SPMS 11.48 0.0 5.00 11.28 
Lower PPMS 0.96 0.0 0.51 0.75 
lumbar 0.80 0.00 0.43 0.0 0.57 0.568 SPMS 0.00 0.0 0.00 ... 
2.6.9 Summary of results 
In conclusion, decline in the eSA in MS cords compared to eSA of controls was 
statistically significant only in the upper and lower cervical segments. SPMS 
appeared to have a greater degree of cord atrophy than PPMS, but the difference 
was statistically significant only in the upper cervical cord. Reduction in the WM and 
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GM surface areas in MS compared to controls was significant in upper cervical and 
lower cervical segments. 
Proportion of demyelination is higher in upper spinal cord levels and this applies to 
WM and GM demyelination. It seems that there is greater degree of demyelination in 
SPMS spinal cords, especially in the higher cord levels. The higher proportion of 
demyelination in SPMS affects mainly the WM of the upper cord levels. In addition, 
the mean size of pure WM lesions was greater in SPMS compared to PPMS. 
GM demyelination was greater than WM demyelination in both disease forms, but the 
ratio of GM demyelination to WM demyelination was higher in PPMS than SPMS. In 
the present sample, neither atrophy nor demyelination correlated with disease 
duration in the whole sample, but the two parameters correlated with each other in 
SPMS subjects. 
2.7 Discussion 
The present study compared the cord atrophy and demyelination between PPMS and 
SPMS in multiple cord levels. It included a relatively large sample size, compared to 
previous MS histopathology studies [103, 105, 122]. Although there was a difference 
in the mean age of subjects between the two examined MS subtypes (PPMS 67 
years and SPMS 58 years), the sample was controlled for the duration of the disease 
(approximately 25 years), scale of clinical disability [124), and for post-mortem delay 
(10 hours). 
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2.7.1 Comments on the possible effect of tissue shrinkage on interpretation 
of results 
Since we have two sources of MS tissue, shrinkage factor may vary and may affect 
interpretation of results. However, tissue shrinkage is expected to affect the absolute 
values of the CSA and not the proportion of demyelination. A possible concern, which 
may lead the shrinkage to affect proportion of demyelination, is that the normally 
appearing areas may have different shrinkage factor from that of the chronically 
scarred tissue. This issue remains a possibility and needs to be investigated further. 
To test the variability in the CSA, the CSA was calculated for the two sources of MS 
tissue and were compared together. Comparison included the exact segment level 
and not the segment category. The Pearson correlation coefficient was 0.877 and the 
p value was 0.010. Having strong and Significant correlation in the surface areas of 
the exact cord level between two different sources of MS tissue supports our 
assumption that the expected atrophy from MS is presumably greater than effect of 
shrinkage (Table 2.4). In addition, the two sources of tissue have been differentiated 
in the graph in Figure 2.4. The graph shows that the two sources of MS tissue are 
located near each other compared to the location of controls form the same sources. 
Therefore, we were convinced that variation in shrinkage factor was significantly less 
than degree of atrophy and thus did not have considerable effects on interpretation of 
results. 
2.7.2 Identifying the cord level 
Classification of spinal cord segments into 5 categories is based on the normal 
enlargements of the spinal cord. A controlled morphologic study of human spinal 
cord was carried out by Kameyama in 2005 [147]. The human spinal cord has 
normally two enlargements, which are the cervical and lumbar enlargements. The 
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cervical enlargement occurs from C5 to C8 which is larger than upper cervical 
segment (C2 to C4) in the CSA and GM surface area. Similarly the lumbar cord has 
been classified into upper and lower segments where the lumbar enlargement mainly 
occurs at L4-L5. Therefore, L 1, L2 and L3 were considered one segment and L4-5 as 
another segment (Figure 2.5). 
Considering changes in morphology of the thoracic cord, there are no reliable 
morphological changes to differentiate between various thoracic segments [147]. In 
addition, there are no significant changes in the eSA between various thoracic 
segments (Figure 2.5). Therefore, the thoracic sections were classified as one 
segment. Other studies categorised the cord segments differently; for example, 
Gilmore et al (2005) and Evangelou et al (2005) performed pathological studies on 
MS atrophy and divided the thoracic cord into upper and lower thoracic segments. 
Due to the long thoracic segments, pathologies of the upper and the lower thoracic 
segments may vary [105, 112]. Although classification of the thoracic cord into upper 
and lower thoracic can be more useful, identification of the thoracic level depending 
on morphology is not as reliable as for the cervical and the lumbar cords. 
2.7.3 Distribution of lesions 
In this study, proportion of abnormal section within the cervical segment was 70%. 
MRI study of the spinal cord in MS showed that possibility of MS lesions in the spinal 
cord is 75% [123], which is more than our histopathology study. Our pathology study 
should presumably show more than 75% because histopathology studies are more 
accurate than MRI in detecting abnormalities [108]. This is probably because our 
sample does not include serial sections like MRI, and there is a chance that 
abnormal areas in higher or lower levels are missed. 
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Spinal cord lesions were commonly seen in the postero-Iateral compartment [120). 
The common postero-Iateral lesions in MS may affect vital spinal cord structures 
such as the CST, PCP, and the DH. Symptoms related to lesions of these tracts are 
common in MS. For example, CST abnormalities in the brain were found to be 
associated with weakness in MS [148, 149). Fatigue, which can affect up to 78% of 
MS patients [150], can be related to CST pathology, in that walking induces 
functional changes in the CST (measured by the motor evoked potentials) leading to 
central fatigue [151]. 
The significantly higher frequency of CST involvement in SPMS than PPMS may 
explain the suggestion that SPMS spinal cord pathology correlates better with 
disability [152]. The calculated higher proportion of demyelination and larger lesion 
sizes in SPMS in this study may be responsible for the higher frequency of lesions in 
the VH, DH, CST, and PCP in SPMS compared to PPMS. 
The observation that some GM lesions are limited by the GMIWM boundary and take 
the shape of the VH may be due to physical limitation caused by two different 
environments at the WM/GM border or may imply that the GM pathology is different 
from the WM. The isolated midline lesion of the PC was frequent in our sample and 
has been reported previously [120]. Such lesions can be due to mechanical pressure 
or secondary to axons' degeneration in the midline within fasciculus gracillis. These 
midline axons come from the lower limbs and have a long course in the CNS, and 
are thus more liable to lesions. 
2.7.4 Predilection for the cervical cord 
Demyelination and atrophy appeared to have predilection for the cervical spinal cord 
in the two disease forms. There is obvious preservation of the lower cord levels. In 
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addition, we found that SPMS has a higher degree of demyelination compared to 
PPMS, which was more obvious in the upper cord. There was a trend toward 
significance between the two disease forms in the upper cervical cord when the 
proportion of demyelination of the whole cord was examined (p = 0.053). Similarly, 
SPMS demonstrated more atrophy than PPMS, which was only significant in the 
upper cervical segment. 
Significant atrophy in the higher cord levels, with less atrophy of the lumbar regions, 
has been mentioned in other studies [105, 127]. Although the calculated higher CSA 
in the thoracic cord of MS subjects may not be reliable in the present study, because 
we have only one thoracic block as a control, upper thoracic segment distension in 
MS has been observed previously with much bigger control sample size [112]. 
Gilmore et al suggested that preservation of the lower cord CSA is due to lesser 
amounts of WM compared to GM. The assumption was based on observation that 
GM is well preserved in the cord. In this study and another two previous studies, GM 
atrophy of the spinal cord was observed [124, 127]. 
Rarity of lesions in the lower cord may play a role in preservation of the lower spinal 
cord from atrophy. In progressive MS spinal cord lesions detected by MRI constitute 
only 5% of newly-detected lesions [138]. We calculated that the average lesion per 
section was 2 lesions/section in the cervical level and 1 lesion/section in the lumbar 
level. The mean lesion size was 7 mm2 in the cervical cord and 2 mm2 in the lumbar 
cord (p = 0.003). However, the relationship between demyelination and atrophy is not 
well understood. From the data above, it seems that there is agreement between 
atrophy and demyelination of the cord in that both of them have predilection to affect 
the cervical cord. Previous studies that have examined for correlation between 
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demyelination and atrophy in the spinal cord reported different results. An MRI study 
showed that atrophy of the cord correlates with degree of demyelination [115]. In the 
present study, there was significant correlation between lesion load and atrophy in 
SPMS only. Evangelou and his colleagues studied local effects of spinal cord lesions 
on the degree of atrophy in 55 MS subjects and 33 controls. There was no correlation 
between demyelination and atrophy. They attributed this finding to atrophy of the 
normal-appearing areas. This does not conflict with the results of this study, because 
there was no correlation between atrophy and demyelination in the whole sample. 
The correlation was found only in SPMS. 
However, it is not clear why the lower cord is a rare site for MS lesions. On 
presentation, site preference has been detected in PPMS and SPMS. Early in the 
disease course spinal cord lesions are more related to PPMS, with a few small 
lesions in the brain [153], while SPMS is more associated with brain lesions. It is 
possible that both forms have predilection to affect higher levels of the CNS in the 
early stages. Early in the disease process there is significant demyelination and 
atrophy of the spinal cord in patients with less than 5 years' disease duration [111]. In 
fact, the spatial progression of CNS atrophy in the rostro-caudal direction over time 
has been reported in the brain. The fact that atrophy of MS is confined to 
supratentorial structures in the early disease course and then progresses to infra-
tentorial structure later on may partly explain the relative sparing of the caudal levels 
of eNS (152). 
2.7.5 Variation between PPMS and SPMS 
Several studies have compared degree of demyelination between PPMS and SPMS 
in the brain and the spinal cord, including cross sectional and longitudinal studies. 
Most of those studies showed a higher degree of demyelination in the SPMS spinal 
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cords, but not all of them reported significant difference. It was found that lesions 
affecting PPMS patients appear to be fewer and smaller [153]. PPMS has been 
found to be associated with an MRI picture of diffuse abnormalities in the brain and 
the spinal cord, rather than focal lesions. There was a higher degree of 
demyelination in the brains of SPMS, with no difference at the spinal cord level [102]. 
Kidd and colleagues demonstrated a greater degree of demyelination in SPMS spinal 
cords, which did not reach statistical significance [138]. A study by Thompson 
showed that the difference in the proportion of demyelination between PPMS and 
SPMS does not include the spinal cord region but is restricted to the brain [139]. 
Alternatively, in 1999, Stevenson conducted MRI study of the brain and the spinal 
cord, and showed that degree of demyelination was higher in the brains and spinal 
cords of SPMS [154]. 
Variation among studies seems to occur between cross sectional studies [102, 103, 
153, 155, 156], while longitudinal studies conSistently show more frequency of new 
lesions in SPMS [138, 139, 157]. This can be due to difference in the baseline 
disease duration among studies. Rate of atrophy and occurrence of lesions are not 
constant throughout the disease course. The preceding relapsing phase of SPMS is 
associated with larger lesions and with profound atrophy of the brain and the spinal 
cord compared to PPMS [102]. Rate of atrophy in the first 10 years (3.5% per year) 
was greater than rate of atrophy during the entire course of MS (0.75% per year) 
[112]. But with progression, frequency of new spinal cord lesions is quite rare in the 
two disease forms and PPMS was associated with an even higher rate of spinal cord 
atrophy compared to SPMS [157]. 
Therefore it is possible that causes of atrophy in early MS are different from causes 
of atrophy in late MS; subsequent slow atrophy in progressive MS may be due to 
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degenerative process rather than direct effect of the disease, especially in PPMS. 
For example, spinal cord atrophy in progressive MS was found to be significant over 
one year of follow up without detecting new lesions [138, 158]. Over 5 years of follow 
up a correlation was found between atrophy and clinical deterioration, but not 
between atrophy and lesions [159]. 
While effects of disease duration on the eSA of the cord has been demonstrated to 
be significant previously [105, 112, 114, 152], there was no significant correlation 
between duration of disease and eSA of the cord in the present study. We further 
examined the relationship between the cervical-segment eSA and the disease 
duration. The graph shows that MS patients who died within the first 10 years of 
having the disease have the highest rate of decline in the cervical eSA. This raises 
the importance of tissue atrophy in morbidity and mortality in MS patients. Although 
this is not a longitudinal study, the graph in Figure 2.6 may indicate that rate of 
atrophy is high in the first 10 years of the disease. Although there is a normal decline 
in the volume of the spinal cord with age, MS subjects showed reduced volume of the 
spinal cord compared to the age matched healthy controls. 
2.8 Conclusion 
The spinal cord is affected by demyelination and atrophy in progressive MS. This is 
more obvious in the cervical cord. There seems to be a greater degree of 
demyelination and atrophy in the cervical cord of SPMS subjects compared to PPMS 
subjects. The size of WM lesions appears to be greater in SPMS, but PPMS shows a 
higher tendency to affect the GM. 
Atrophy of the spinal cord is significant in MS and does not appear to follow a steady 
rate over time. Atrophy seems to be caused by multiple factors. Effects of these 
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factors on atrophy are not steady through the disease course, resulting in a variation 
in the rate of atrophy over time. Initially, in the first 5 years of age, there is high rate 
of atrophy as shown by previous studies. With more progression of the disease 
duration, rate of atrophy becomes slower and may reach a plateau. This can be 
concluded from the graph in Figure 2.6. The slow rate of atrophy after a few years of 
the disease is possibly caused by degeneration of small axons and other elements, 
and not by demyelination. This is because frequency of new spinal cord lesions is 
very low. 
We believe that SPMS causes more spinal cord demyelination and atrophy because 
it causes more frequent lesions and more inflammation, which possibly causes more 
tissue scarring. This may explain the significant correlation between atrophy and 
demyelination in SPMS and not in PPMS. 
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Figure 2.1 : MBP stain of spinal cord section showing lesions affecting the right side of the cord in A (left side of 
observer). Note that the lesion involves the WM and the GM but also respect the boundary of the VHs in both sides 
and did not pass to the adjacent WM. Demyelination extends from the right side to affect the left side through the 
intermediate GM without passing to the nearby WM (in A and B). These two observations were commonly seen. (The 
scale bar = 3 mm). The arrow in B points to a commonly lesion of the PCP. The lesion is frequently symmetrical and 
bilateral (The scale bar = 4 mm). 
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Figure 2.2: Six examples of the common PCP lesion. The lesion is usually midline, symmetrical and bilateral. Size of 
the lesions varies greatly. It is frequently associated with bilateral lesions of the lateral funiculus. 
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Figure 2.3: Bar charts showing the variation in the eSA and proportion of demyelination in various spinal cord levels 
in controls, PPMS, and SPMS. Note the highest proportion of demyelination is found in the GM, which may be due to 
its small size. The data represent the mean eSA ± SEM and the mean proportion of demyelination ± SEM. The 
significant difference between PPMS and SPMS is indicated by an asterisk, while the significant difference between 
MS and controls is indicated by the number sign # . The p values < 0.05 are indicated by one sign, while the p values 
< 0.01 are indicated by two signs. 
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Figure 2.4: The graph demonstrates the eSA of the upper and lower cervical cord in MS and controls in the two 
sources of tissue. Only the cervical cord included because for the rest of the cord, we have one source of MS tissue. 
Note source of tissue and the consequent variation in shrinkage between the two sources of tissue appear to have 
little effect on the eSA compared to atrophy caused by MS. 
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Figure 2.5: The CSA in mm2 of the spinal cord segments from C2 to 53. Note the cervical thickening and lumbar 
thickening, which provides the basis of categorizing the spinal cord into 5 segments; upper cervical, lower cervical, 
thoracic, upper lumbar, and lower lumbar [147]. 
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Figure 2.6: The CSA of the cervical cords in our study sample and their relation to the disease duration. The sharp 
decline in the CSA in the cervical cord in MS is seen in the first 10 years of disease duration. 
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the WM of the spinal cord 
3.1 Introduction 
OLs are one of the important CNS elements that are greatly affected by MS and 
therefore identifying their fate in SPMS and PPMS is an important issue. OLs are part 
of the neuroglial cells of the CNS. The first description of neuroglia dates back to 
1846, when Virchow published a description of cells that act as glue in the brain 
[160]. Although the name is still in use, the concept has been totally changed. 
Among all the neuroglial cells, OLs were the last to be discovered because of their 
high resistance to staining agents [161] and their small size (8-15 ~ m ) ) [162]. The 
term OLs was introduced for the first time in 1921 by Rio-Hortega when he used the 
metallic impregnation method to visualise the neuroglia. He initially discovered the 
astrocytes by using the gold impregnation, then he used the silver carbonate 
impregnation to visualise the OLs and microglia. Metallic impregnation stains both 
the cell body and the processes [160]. 
In addition to staining difficulties, there are other difficulties with quantification of OLs; 
OLs are sensitive and affected widely by changes in environment during culture and 
by the stains during slide preparation; OLs form extensive networks of branches in 
three dimensional space with very complex connections [163]. It has been suggested 
also that the number of OLs is not constant during stages of maturation and their 
number is reduced with age progression [164], health status [165], and by chronic 
use of alcohol or anti-psychotic drugs [166]. 
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3.1.1 Structural features and classification of oligodendrocytes 
Although the name implies that OLs have few processes, these cells form an 
extensive network of fine branches [162]. OLs have variable morphologies depending 
on their location in the eNS and the stage of maturation (Figure 3.1). According to 
distribution in the eNS, Hortega recognised three types of OLs; near axons 
(interfascicular), near cell bodies (perineuronal), and near vessels (perivascular) 
[167]. 
White matter (interfascicular) ollgodendrocytes 
According to the size and interaction with other cells, Hortega classified WM OLs into 
four subtypes. These subtypes are distributed variably within the eNS, and each type 
myelinates certain diameter and number ofaxons. Type I is found in the forebrain 
and cerebellum and myelinates up to 50 small axons (15-20 ~ m ) , , while type II is 
located in different sites of the WM and myelinates fewer and thicker axons (20-40 
~ m ) . . Type III, which myelinates only 3-4 larger axons, is more distributed in 
cerebellar peduncles, medulla oblongata, and the spinal cord. The rare type IV OLs 
have no branches and are restricted to the exit of the nerve root areas. Each type IV 
OL myelinates only one large diameter axon and greatly resembles Schwann cells 
[167]. 
The cytoplasmic density of OLs is variable under the electron microscope by being 
dark (electron dense) for the mature cells and lighter for the less mature cells (Figure 
3.1). The cytoplasmic density reflects the amount of ribosomes and degree of 
chromatin condensation. There are not many differences among OLs subtypes in 
types of organelles inside the cell apart from their densities [160, 162, 168, 169]. 
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These subtypes were recently found to be expressing different molecules. The S-
isoform of myelin associated glycoprotein (MAG) is expressed in types III and IV and 
not in types I and II [170]. There is also evidence that these subtypes have variable 
expression of MBP and proteo-lipid protein (PLP). It was found that small fibre myelin 
has more MBP content, while large diameter fibre myelin has more PLP content 
[171]. Nevertheless, OLs still share common features that differentiate them from 
other cells. 
OLs are small cells with large round or oval nucleus that is almost always 
eccentrically located leaving a large mass of cytoplasm at one pole of the cell. The 
nuclear membrane is rimmed by chromatin that extends into less dense 
nucleoplasm. The endoplasmic reticulum is well developed with large amounts of 
ribosomes. OLs appear moderately electron dense compared to astrocytes. 
According to the type of organelles inside the cells, there are two differences 
between astrocytes and OLs; OLs have neither glycogen granules nor bundles of 
specific intermediate filaments, such as GFAP which is a characteristic of astrocyte 
[160, 167, 169, 172]. 
Grey matter (per/neuronal or satellite) ollgodendrocytes 
The term perineuronal OLs was also used for the first time by Rio-Hortega in 1921 
[162, 167]. This term was used for OLs that are located in close proximity to neurons 
of the GM. The exact function of these perineuronal cells is not well known. It has 
been suggested that these cells have functions related to structural and functional 
support to neurons [160, 162, 167]. 
Ludwin described the ultrastructure of GM satellite OLs in a study in 1984. His 
description has not many differences from WM Ols. Satellite GM Ols were seen to 
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be oval with clumped chromatin. They were seen to be abutting and extending 
processes to numerous myelinated axons with the formation of the inner and outer 
lope of mesaxons [172, 173]. Cragg 1976 also classified perineuronal GM OLs with 
respect to their cytoplasmic density into light, medium, and dark OLs (Figure 3.1) 
[169] 
3.1.2 Identification of oligodendrocytes 
The optimal target for counting is to identify all OLs without extensively staining their 
processes. It is difficult to recognize OLs by light microscope using a classical stain 
such as haematoxylin and eosin. This is due to the difficulty in differentiating different 
types of glia. Although astrocytes are generally larger in size and have lighter 
cytoplasm, some light OLs may resemble astrocytes in size and cytoplasmic density 
[174]. 
During development of OLs, different proteins are either down regulated or up 
regulated according to the stage of differentiation without apparent change in 
morphology [175]. Therefore, the only way to distinguish between differentiating OLs 
is by detecting these markers [160]. It is possible to evaluate the number and density 
of OLs by means of immunohistochemistry. Immunohistochemistry utilises several 
antigens to identify OLs, such as MBP, PLP, MAG, cyclic nucleotide 
phosphodiesterase (CNPase), carbonic anhydrase II (CA II), galactosylceramide 
(GaIC) and others. Immunohistochemistry also provides information about the cell 
identity as well as the functional state of the cell. These markers have variable 
distribution within the OLs in that some of these markers are traced in the cell body 
and the processes, while others are only present in the cell body. 
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Most of these markers can be also traced by in situ hybridization of their mRNA. The 
mRNA localisation can reach as far as the Ranvier node for some proteins such as 
PLP or CNPase. This is because free ribosomes can reach as far as the site of 
myelin synthesis, due to the action of microtubules [176, 177]. In this pilot study two 
markers, which have been used to quantify OLs, will be compared; these are CA II 
[174, 178] and CNPase [165, 179). CA II has been also used to stain and trace GM 
OLs in spinal cords (animal study) [180). 
Carbonic anhydrase 1/ 
CA II mainly stains the cell body [174, 176, 180]. CA II catalyses the hydration of 
carbon dioxide to bicarbonate. In the CNS, CA II can be found in two forms; soluble 
form (55%) and membrane bound form (45%) [181]. CA is found in seven isozymes 
(from CA I to CA VII) [181], which are distributed in different types of mammalian 
tissues with variable amounts [176]. In humans there are two major iso-enzymes; CA 
I and CA II, which differ in both enzymatic activity and in antigenic properties 
(antibody that recognises CA II does not recognise CA I) [176]. 
The enzyme is vital for the function of erythrocytes in removal of carbon dioxide. CA 
II may also playa role in K+ homeostasis [176] and lipid metabolism [181]. Other 
functions of CA may include regulation of pH, water balance, gluconeogenesis, bone 
resorbtion, and formation of CSF. CA inhibitors are already in use as anti-glaucoma 
drugs, diuretics, and anticonvulsive drugs [182). Deficiency in CA II has been 
reported in humans and found to be associated with mental retardation, brain 
calcification, osteopetrosis, and renal tubular acidosis [183]. 
CA II expression in OLs has been identified in humans between 16 and 22 weeks of 
gestation. CA II is expressed in the cell bodies and processes during early 
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differentiation of Ols and it is found in all stages of Ols development [184], but in 
adult myelinating Ols it is restricted only to the cell body. However, expression of CA 
II is reduced with age in both Ols and choroid plexus, which might explain the 
reduction on CSF production in old age [182]. 
CA II is considered as a specific marker for both mature and less mature Ols. This 
has been demonstrated by double labelling of Ols by CA II and MBP [185]. Tracing 
CA II by means of immunohistochemistry has been stated to be a good method for 
counting Ols [174], as it stains only the cell body. It was suggested that CA II is 
found in astrocytes , choroid plexus, some neurons, espeCially GABAergic neurons 
[182, 186]. later it was possible to recognise that these are actually immature Ols, 
which are frequently mistaken for astrocytes or small neurons [185]. 
CA II enzyme has been appearing in literature since 1932 [187]. Around 4865 articles 
that have carbonic anhydrase in their title can be found on the Pub med and around 
787 articles on the subject of CA II (last accessed on 23 Aug 2010). 
Dr Ghandour, who published 19 studies that utilized the CA II in Ols, stated via 
personal communication that immunohistochemistry with CA II stains all types of Ols 
in human CNS, and that both GM and WM show good results with paraffin-
embedded tissue sections. A number of studies have described the 
immunohistochemistry protocols for CA II tracing in OLs in animals [188, 189] and in 
humans [182]. 
2'3'-cycllc nucleotide 3'·phosphodlesferase 
2'3' -cyclic nucleotide 3' -phosphodiesterase, or CNPase, is a marker of mature and 
less mature OLs [165]. It accounts for 4% of the myelin protein. It hydrolyses 2'3'-
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cyclic nucleotides [184], but the physiological role of this interaction is not well 
understood. However, patients with Down's syndrome and Alzheimer's disease have 
low levels of CNPase [164]. 
CNPase consists of two polypeptides; CNP1 and CNP2. CNPase appears early 
during Ols differentiation and is synthesized in the cell body, but deposited near the 
plasma membrane and in myelin sheaths [190]. 
CNPase antibody is capable of reacting with mature and immature Ols, and thus can 
stain most Ols. It reacts in both human and rat with high penetration of thin sections 
[165]. This enzyme is specific for Ols and not expressed in astrocytes or other cells 
[164, 165]. 
A number of studies have utilised CNPase immunoreactivity to count Ols in humans 
[165, 177, 179] and in MS specifically [179]. In 1999 Dr. Claudia lucchinetti studied 
quantitatively Ols in MS plaques. The study utilised a number of antibodies such as 
MOGs, CNPase, and MBP antibodies [179]. Claudia lucchinetti has also stated via 
personal communication that CNPase is an excellent marker for labelling Ols. 
In another study human autopsies were used to compare numbers of Ols in the 
cerebral cortex of schizophrenic patients with normal controls. CNPase antibodies 
have been used to trace and count Ols in the cerebral cortex. CNPase antibody was 
considered as a robust marker for mature and nearly mature Ols. CNPase 
monoclonal antibody detects OLs specifically and distinguishes them from astrocytes 
and other elements [165]. 
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It has been suggested that CNPase tracing does not stain all GM OLs [177]. CNPase 
labelling was used to evaluate the effects of ischaemia on human cortical OLs 
following cardio-respiratory arrest. CNPase positive OLs were clustered in layers IV, 
V, VI of the cerebral cortex, with few CNPase positive cells in the outer laminae. 71 % 
of all satellite OLs have been found positive for CNPase [177]. 
3.2 Aims and hypothesis 
OLs are important in MS disease and quantifying them efficiently is essential. Our 
main aim from this study is to develop a reliable and efficient counting method for all 
OLs lineage in both the GM and the WM. In the literature different markers were used 
to quantify OLs. CA II and CNPase have been explicitly said to be ideal for counting 
OLs [162, 165, 185]. CA II labelling can be more helpful for counting OLs, as it stains 
only the cell body [162]. CNPase was reported to be a robust marker and ideal for 
counting and tracing mature and nearly mature OLs [165]. Therefore, we compared 
CA II and CNPase and studied the abilities of both markers to identify OLs and 
showed the anatomical structures of the spinal cord such as the GM, the WM, and 
the DH laminae. 
3.3 Material and methods 
3.3.1 Autopsy sample 
Two blocks were selected randomly from the MS tissue sample. These are human 
spinal cord autopsies from the MS Society tissue bank in London. The process of 
initial fixation of the tissue from the MS Society tissue bank was mentioned in Section 
2.5.1. Briefly, the frozen blocks were defrosted and formalin-fixed paraffin-embedded 
blocks were prepared. Then 15 sections were cut from each block at 5 ~ m m thickness 
to optimise the immunohistochemistry of the two markers. 
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3.3.2 Immunohistochemistry of oligodendrocytes 
CNPase mouse monoclonal antibody and CA II rabbit polyclonal antibody were 
purchased from abcam [191, 192]. Optimisation was carried out by an expert 
technician, Neil Hand. The slides resulted from each dilution were reviewed by Prof 
Jim Lowe, Consultant Neuropathologist. The best results for CNPase were obtained 
with pre-treatment using 10 mmol sodium citrated at pH 6 with a dilution of 1 :2000. 
This was heated in a microwave oven. The CAli sections were pre-treated with 10 
mmol EDTA at pH 8. For antigen retrieval, sections were heated in microwave oven 
for 25 minutes. The primary dilution was 1 :8000 for 1 hour. This was detected using 
Rabbit/Mouse Envision (Dako K5007) for 30 minutes. All sections in both stains were 
counterstained with haematoxylin. All sections were stained automatically using Tech 
Mate 500+ immunostainer (details in appendix 8). 
3.3.3 Slides scanning 
Slides were numbered and scanned by the NDP view Hamamatsu at magnification of 
40X. The produced digital slides were then viewed by the NDP.view software and 
demarcations were performed using the manual graphic tablet MD 85637 from 
Medion. Features of the machine and the associated software can be found in 
Section 2.5.3 and Hamamatsu web site [144]. 
3.3.4 Comparing CA II and CNPase 
Gener.a/observaUons 
The appearance of the GM and the WM and the ability of the stain to show 
abnormally demyelinated areas were observed in the two stains. The GM boundary 
and DH laminae were identified and demarcated as mentioned previously (Section 
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2.5.4). The ability of the stain to show OLs as distinguishable cells from the 
surrounding neuropil was considered at high magnification. 
Sampling the GM and the WM 
We sampled the VH and the area of the lateral funiculus (lateral CST) to represent 
the GM and the WM respectively. From each section, the VH and the CST were 
sampled using a strict protocol which allows the examiner to select the same region 
from the two sections (Figure 3.2). The sampling protocols of the VH and the CST 
are mentioned in details in subsequent chapters (see Figures 4.1 and 5.1). The 
regions of interest were exported as an image of the computer screen when the 
magnification is 40X. These regions were exported as JPEG format images and were 
given codes that do not refer to the type of the stain. In total, we calculated OLs in 34 
fields from the VH (17 CNPase and 17 CA II) and 40 fields from CST (20 CNPase 
and 20 CA II). 
3.3.5 Counting process of oligodendrocytes 
OLs were counted in each field so that the observer was blinded to the type of stain 
(it is difficult to identify type of stain at high magnification in a small field; 0.047 mm1. 
The exported images were viewed by imageJ software. ImageJ is popular software 
for image processing. ImageJ is freely available image editor software that has 
multiple functions such as editing, processing and performing automatic and manual 
counting of particles. The software can also measure surface areas and pixel values. 
The freeware of ImageJ can be downloaded from the internet [193]. 
OLs were counted manually and categorised into possible OLs and definite OLs. The 
identification criteria of OLs include intensely stained cells, round to oval cell bodies 
of variable size. However, very small rounded dots were excluded from counting in 
70 
Chapter 3: Identification of oligodendrocytes in the GM and the WM of the spinal cord 
both markers because they represent myelinated axons. Cells with light staining, 
stained rim, or irregular shape were all considered possible Ols. 
Using imageJ, the field was opened and the manual counting was carried out. With 
the computer mouse cursor, all typically stained Ols were selected. The software 
automatically counts the selected points. Then the colour of selection is changed and 
the possible Ols were then selected. The software, again, counts the new particles 
and put them in a different group. Therefore, two numbers were produced from each 
counting process; one representing definite Ols and the other possible Ols. The 
ratio of possible Ols to definite Ols was calculated for both CA II and CNPase. 
Reliability of our identification criteria and reproducibility of our counting process has 
been tested by repeating Ols counting by two observers (interobserver 
reproducibility was 16%). 
3.3.6 Scoring system 
We developed a scoring system for comparing the two stains that depends mainly on 
microscopic observations and quantification measures. Factors which have been 
taken into account at low magnification include the ability of the stain to demarcate 
GM various structures and the ability to obscure demyelinated and partially 
myelinated areas. At higher magnification, the ability of the stain to show Ols clearly 
and the calculated ratio of possible Ols to definite Ols were included in the ranking 
system. 
3.3.7 Statistics 
Results were exported to SPSS 14 software. The data table contained field code, 
number of definite Ols, number of possible Ols, and ratio of possible to definite Ols. 
Student t-test was used to compare the means. 
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3.4 Results 
3.4.1 Observations at low magnification 
Both CA II and CNPase can demarcate the GM from the WM fairly well. Some CA II 
sections had less clear borders of GM making delineation with the WM harder. In 
fact, in CA II the intenSity of the GM stain is more than the WM while in CNPase the 
reverse is true. The border between the GM and the WM in CNPase is clear and 
resembles that seen in MBP stain (Figure 3.3). 
The identification of spinal cord major laminae was possible using both stains to the 
same degree. The unmyelinated substantia gelatinosa (laminae II and III) is well 
demarcated and greatly helps in differentiating the marginal zone (lamina I) dorsally 
and the nucleus proprius (laminae IV and V) ventrally. Both CNPase and CA II are 
able to distinguish the GM and different laminae of the DH to the same degree 
(Figure 3.4). 
An interesting observation is that demyelinated areas are not detectable in CA 11-
stained sections. Ability of the CA II to obscure areas of demyelination and partial 
myelination is useful in increasing the observer blinding to demyelinated areas. This 
is not the case with CNPase stain, which shows abnormally myelinated area and 
thus may reduce the examiner blinding when counting Ols, especially when manual 
counting is to be carried out. Another remarkable observation is that the GM and its 
boundary are frequently identifiable in CA II-stained sections even with the presence 
of severe demyelination (Figure 3.5). 
3.4.2 Observations at high magnification 
In CA II and CNPase, Ols appeared generally heterogeneous in size with round to 
oval shape. The Ols processes and cytoplasm could not be identified in most of the 
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sections (Figure 3.6). There were frequent counterstained cells with traces of 
CNPase or CA II stain around their border, which was more obvious in CNPase-
stained sections. 
Because of the staining of the nearby myelin with CNPase, Ols do not appear as 
clear as in CA II-stained sections, especially in the WM as it contains more 
myelinated axons [176, 194, 195]. The CA II shows less intensity in the myelin 
sheath than in Ols. Therefore, staining myelin with CA II did not interfere with Ols 
counting and showed Ols clearly. Non specific staining of counterstained cells was 
minimal in CA II. 
3.4.3 Numbers of oligodendrocytes 
The mean density of definite Ols varied between the two stains. The mean density of 
definite Ols in the GM of CNPase-stained sections was 48.98/mm2 compared to 
167.28/mm2 in the CA II-stained sections (p = 0.006). In the WM, the CA II-stained 
sections showed also significantly more density of definite Ols than CNPase stained 
sections (119/mm2 vs. 31/mm2, p < 0.001). On the other hand, the mean density of 
possible Ols in the GM of CNPase-stained sections was 27.40/mm2 and in CA 11-
stained sections was 5.78/mm2 (p = 0.05). In the WM, the calculated density of 
possible Ols in CNPase-stained sections was 33.17/mm2 and in CA II-stained 
sections was 19.66/mm2 (p value = 0.265). 
The mean ratio of possible Ols to definite Ols was 0.6 in the GM of CNPase-stained 
sections compared to 0.03 in CAli-stained sections. In the WM the ratio was 1.1 in 
the sections stained with CNPase and 0.2 in sections stained with CA II. 
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3.4.4 The scoring system 
The scoring system for this study favours the use of CA II, as it seems to be superior 
to CNPase in the identification of Ols and in obscuring areas of demyelination or 
partial myelination. But both markers identified the GM and the laminae of the DH to 
the same degree (Table 3.1). 
Table 3.1: Comparison between C C NPase and All 
Factors CAli CNPase 
Ratio of query OLs to definite OLs 1 0 
Identifying the GM 1 1 
Identifying the DH various laminae 1 1 
Obscuring the demyelinated and partially myelinated areas 1 0 
Identification of OLs in an isolated form 1 0 
5 2 
3.5 Discussion 
This study is probably a pioneer study in quantification of Ols in the spinal cord 
particularly in the GM, thus our aim is to quantify all Ols regardless of maturation 
status. There are a number of markers that can be traced in Ols during maturation. It 
is important to differentiate between two types of Ols markers; maturing Ols 
markers and Olslmyelin markers. For example, markers such as nestin, platelet 
derived growth factor a receptor (PDGF-a), ganglioside GD3, NG2 proteoglycan and 
the 04 are all markers for maturing Ols and are not myelin markers [160]. 
Nestin is a class of intermediate filaments that are found in neuroepithelial cells and 
some radial glia. Expression of nestin is downregulated in differentiated Ols [196]. 
PDGFR-a is expressed in the early stages of Ols lineage and not in mature Ols. 
Ganglioside GD3 is not very specific for Ols in vivo. Its expression disappears as the 
Ol matures. It is considered ideal for identifying Ols in culture [197]. NG2 marker is 
an integral membrane proteoglycan. These NG2 positive cells may also express 
PDGFR-a in the early stages. However, these cells continue as a distinct population 
in the adult CNS and do not express markers of mature Ols (for review of NG2 
positive cells, see Nishiyama et al (1999» [198]. The 04 monoclonal antibody marks 
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unidentified glycolipid in Ols. It labels a specific stage of Ols maturation called pre-
Ols, or sometimes called pro-Ols, and does not cover all maturation stages [199]. 
Markers of Ols and myelin include GaIC, RIB antigen, CA II, NI-3S/2S0 proteins, and 
myelin specific markers (CNPase, PlP, MBP, MOG, MAG, and other minor proteins). 
GalCs are early markers of Ols. It is located on the surface of early Ols and 
continues to be expressed on the surface of mature Ols [200). It is believed that they 
appear to express in the late stages of pro-Ols. However, labelling GalC in the early 
stages of Ols maturation is inconsistent, due to lack of specificity of the used 
antibodies [160). MOG is a glycoprotein that is expressed in latest stages of Ols 
myelination [201]. The rest of the myelin specific proteins such as MBP, PlP and 
MAG are markers of myelinating mature Ols and thus do not cover all maturation 
stages. Therefore, we compared CA II and CNPase because CA II expression covers 
all the stages of Ols maturation and continue to be expressed in mature Ols [202] 
and CNPase is the earliest marker that can be reliably labelled in Ols [203, 204]. 
The method used allows for comparison between the two markers in the GM and the 
WM in the same anatomical regions. To accomplish this, a sampling protocol was 
used to select fields from the GM and the WM. In conclusion, the results obtained 
from this pilot study favour the use of CA II stain over CNPase for counting Ols. 
The CNPase stains Ols and the nearby neuropil. Although it forms 4% of the 
isolated myelin proteins, CNPase is not present in the compact myelin. It is localised 
in the cytoplasm of non compacted myelin sheaths and the cytoplasm of OLs 
processes [20S-207]. CNPase appears early during development of OLs and 
continues to be expressed in Ols and myelin [160). It is synthesised primarily in the 
cell body and then transferred to be deposited in the myelin sheath. This explains the 
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presence of the stains in the surrounding neuropil and myelin. In comparison, CA II 
minimally stains the neuropil. The ability of the CA II to obscure demyelinated and 
partially myelinated areas in most of the cases is an important feature of this marker. 
At low or high power no demyelinated or partially myelinated areas could be 
identified with CA II (Figure 3.5). At high power, however, only the lesion border can 
be identified on CA II stain. 
Another important feature is the ability of the CA II stain to delineate the GM borders 
within the lesion. In the spinal cord MS lesions extend from the WM to the GM 
without respecting GMIWM boundary. The MS lesions usually appear homogenous 
without clearly showing the GM and the WM architecture in a number of stains, such 
as MBP, H&E, and with CNPase. But with CA II it was possible to demarcate the GM 
from the WM in sections, even when there is MS lesion. This was obvious when you 
compare the MBP and CA II stains in Figure 3.5. 
The capability of the two markers to differentiate between different laminae of the DH 
was noticed to be similar. Applying the sampling protocol on the whole DH may 
include some areas from the normally unmyelinated substantia gelatinosa, which is 
found in the middle of the laminae between the marginal zone (lamina I) and the 
nucleus proprius (lamina IV and V). Therefore, choosing the nucleus proprius to 
represent the DH was essential for number of reasons; first, the nucleus proprius is 
directly related to an important function which is the proprioception; second, the 
nucleus proprius is heavily myelinated and contains numerous Ols; and finally the 
nucleus proprius is large enough to be sampled. 
At high magnification, Ols were recognisable using the two markers. Features of 
Ols, such as oval to round cells with variable sizes, were recognisable in the two 
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stains. Although OLs were variable in sizes and they tend to be small cells, the 
misinterpretation of OLs as axons was not possible. Large myelinated axons were 
identified by having central faint, while OLs were homogenously stained. 
Nevertheless, OLs appeared clearer with CA II marker. 
In the scoring system, we included the ratio of possible OLs to definite OLs. 
Comparing the two markers by counting only the definite OLs number across the 
spinal cord can be an unreliable process, since each marker has different sensitivity 
in various areas. It was mentioned previously that both CA II and CNPase do not 
stain all OLs, because CA II is not present in certain types of OLs [175], while 
CNPase stains about 70% of GM OLs [177]. 
Counting the possible OLs that appeared in the fields and comparing them may also 
not be a reliable process, since each marker may have a different degree of non-
specific staining of other cells. We believe that possible OLs are OLs that do not 
have the same intensity of staining as other OLs. Therefore, the ratio of possible OLs 
to definite OLs was considered in the ranking system rather than the absolute 
numbers. From this study one can conclude that the ratio is more with CNPase than 
CA II. This means that CA II stains more definite Ols. The sum of possible and 
definite Ols was also greater in CA II-stained sections, which may indicate that CA II 
stains more Ols. In fact the absolute number of definite OLs was greater in CA 11-
stained sections. Most importantly, histopathologic appearance of the two stains has 
been reviewed by Prof Jim Lowe (Consultant Neuropathologist) who found that with 
CA II stain, recognising Ols was better. 
For many reasons, these results could not be generalised. Firstly, this is only a pilot 
study with a limited number of cases. Secondly, 74 fields from only two subjects were 
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analysed and this may not be representative. Thirdly, the sample includes MS cases' 
autopsies which were dissected from the cadaver at variable times after death and 
thus different proteins may denature faster than others. This means that if CNPase 
denature faster than CA II, a comparison at fixed post-mortem delay period will result 
in more Ols with CA II. Finally, apart from the first criterion, other criteria of the 
scoring system are subjective and depend on the research goals. For instance, the 
criterion of obscuring demyelinated areas may not be desirable for other types of 
study that do not require unbiased selections and therefore CNPase marker would be 
favoured over CA II in this case. Furthermore, CA II probably stains more Ols 
because it covers all stages of Ols lineage, while CNPase stains only mature and 
nearly mature Ols [202]. 
All the criteria included in the ranking system are directed toward establishing a 
reliable and reproducible quantification process for Ols, and our decision depends 
on our research objectives. Therefore, a marker such as the CNPase is still 
considered a robust marker for labelling Ols. 
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Figure 3.1 : Illustration of the three subtypes of OLs as seen under the electron microscope in rats [208]. 
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Figure 3.2: Two differently stained sections that belong to the same subject and same spinal cord level (CA 11-
stained section in A and CNPase-stained section in B). Note the extensive staining of myelin in B. The sections were 
sampled using strict protocol that allows the investigator to compare fields taken from the same anatomical area. 
Details of sampling protocols of the VH and the CST are mentioned in chapters 4 and 5. The area within the white 
border is the area occupied by the CST (scale bar 4 mm). 
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Figure 3.3: CA II and the CNPase at low magnification (scale bar 4mm). Note the sharp demarcation of the GM in 
CNPase compared to CAli at higher magnification (scale bar 1 mm). 
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Figure 3.4: In A, CA II stained spinal cord cross section. We demarcated the GM and the DH major structures such 
as the nucleus proprius within the blue border, the substantia gelatinosa within the yellow border. The rectangle is 
magnified in B. The cap of the DH is a thin layer forming Lamina I. The head of the DH is formed of the substantia 
gelatinosa Laminae (Laminae II and III) and the nucleus proprius (Laminae IV and V). The neck is continuous with 
the base and both of them form Lamina VI. 
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A 
B 
3.5: Two same su and the same level; in and 
in B with CA II. Within the plaque area, the GM is not easily identified . But in B, which is stained with CA II stain , the 
plaque does not appear while the GM boundary is prominent 
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WM 
Figure 3.6: OLs as they appeared at high magnification power in CA II (A&C) and CNPase (8&0). A & B fields 
compare the GM in between the two stains, while B & 0 fields compare the WM. Note in both the GM and the WM; 
myelin is less stained in CA II sections making OLs easily identifiable. It can be noticed also that in CNPase myelin is 
more intensely stained in the WM compared to the GM. 
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4.1 Introduction 
The spinal cord GM has myelinated axons that traverse the GM and WM boundary. 
These axons are myelinated by the widely-dispersed Ols in the WM and the GM 
[174). Ols are possibly vulnerable to injury in the GM following MS. Involvement of 
the GM in MS was reported in the literature as early as 1898 [121], while 
morphological description of the spinal cord GM lesions was described by Fog in 
1965 [209], Oppenheimer in 1987 and recently by Gilmore in 2009 [105, 120]. In the 
WM, injury to Ols usually results in demyelination ofaxons and reduction in the 
speed of the action potential. This has been demonstrated in animals [210] and in 
humans [211]. In comparison, consequences of Ols loss in the GM are uncertain. 
A number of observations support that GM Ols are different from the WM Ols. For 
example, many GM OLs acquire a perineuronal position and may react to MS 
differently. Ols in the GM may have additional functions such as providing trophic 
support to neurons. Moreover, spinal cord GM has different stages of development 
and final architecture from the WM and from the brain GM [212]. In MS specifically, 
there are number of observations that suggest that GM pathology is independent of 
WM pathology; two previous studies demonstrated that spinal cord GM 
demyelination is more extensive than WM demyelination [105, 127], which was also 
shown in the study of proportion of demyelination in chapter 2 of this thesis. Bo et al 
(2007) demonstrated that subpial cortical demyelination is independent of WM 
demyelination [213]. Degree of inflammation and recruitment of inflammatory and 
cytotoxic cells also varies between the GM and the WM of the brain; GM lesions has 
Significantly less apparent inflammation [103, 214]. Variation between GM and WM 
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pathology in MS extends to include degree of remyelination; Albert et al 2007 
conducted post-mortem study on 33 patients with chronic MS and reported that GM 
remyelination is more extensive than WM remyelination [215]. Therefore, it may be 
essential to study the fate of GM Ols in MS separately from WM Ols. 
The majority of previous studies on GM pathology in MS, both in vivo and in vitro 
studies, were carried out on the brain GM (for reviews refer to 80 2006 [121], and 
Geurts et al 2008 [216]). In spite of the increasing Significance of GM pathology, 
there is no previous study that has specifically investigated the fate of Ols in the GM. 
Due to the lack of information about the fate of GM Ols in MS, the rest of the 
introduction will discuss normal development of Ols in the CNS in general and the 
spinal cord in particular. The introduction will also review all stages of development 
until maturation of Ols and production of myelin. This will provide a preface to the 
next chapter, which studies WM Ols. The previously published work. that 
investigated pathology of Ols in WM MS lesions is reviewed in the next chapter. 
Studying normal development of Ols has enabled researchers to suggest and 
develop potential therapeutic strategies for MS. These strategies were developed 
from molecules that share functions with different Ols mitogens and have been 
proven to be effective in EAE [217-220]. For example, a new treatment strategy was 
derived from a sphingolipid, sphingosine-1-phosphate, that affects differentiation and 
migration of Ols [221]. Phase III clinical trials of fingolimod (FTY720) in MS are 
showing promising results [222]. Although fingolimod acts as immunomodulator and 
may not have effects on Ols, it was originally derived from the signalling molecule 
sphingosine-1-phosphate (most recent review by Coelho et al2009 [218]). 
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In addition, understanding Ols' development may explain and consequently resolve 
two important issues; why GM in MS demonstrated more extensive remyelination 
than the WM [215], and why remyelination fails with disease progression in both GM 
andWM. 
4.1.1 Development of spinal cord oligodendrocytes 
The spinal cord and the brain develop from the neural tube [212]. The neural tube is 
formed from ectoderm by a process called neurulation, where a closed tube is 
formed from the neural plate. When the process of neurulation starts, a single layer 
of cells can be found lining the tube. This single layer is formed of a homogenous 
population of precursors called the neuroepithelial stem cells. These non-branching 
cells are multipotent and they can give rise to both neurons and glia. The cellular 
layer of the tube starts to proliferate to a multicellular layer [212]. 
The process of development of the spinal cord GM is different from that of the 
cerebral cortex. Rostrally, the tube starts to dilate forming the brain vesicles, while 
caudally, the tube does not dilate. Therefore, neuronal cells do not migrate a very 
long distance, but stay around the tiny central canal forming the spinal cord GM. In 
the brain neurons and neuroglia migrate longer distances from the ventricular zone to 
the cerebral cortex [223). 
The last cells that are generated from the sub-ventricular zone are the Ols [224]. 
Ols' progenitors (Opes), which are positive for the PDGFR-a, proliferate in the 
ventral part of the spinal cord subventricular zone [223). Therefore, this study will 
also examine if there is variation in Ols' density between the ventral and the dorsal 
regions of the cord. 
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OPCs migrate and distribute widely in the WM and GM. The processes of 
proliferation and then migration are affected by several trophic factors and biological 
molecules [223]. One of the most important stimulating factors for migration is the 
PDGF. PDGF is considered as the major mitogen for Ols [223,225]. PDGF acts on 
the PDGFR-a found on the surface of OPCs, which is expressed on the ventral 
neuroepithelial stem cells [225]. OPCs originate in the ventral region around the 
embryonic day 14 [194, 225] and they express, in addition to PDGF-a, the NG2 
chondroitin sulphate proteoglycan [194, 226], 04, and DM-20 (the gene encoding for 
PlP subunit) [194]. At this level of development OPCs do not express markers of 
mature Ols, such as MBP or CNPase [194]. 
The significance of PDGF in stimulating Ols' proliferation, and subsequently 
remyelination, has been tested on animal studies. Allamargot at al (2001) examined 
acute demyelination of the corpus callosum in Wistar rats by injecting intrathecal 
PDGF. Allamargot and colleagues reported 49% increase in Ols and 60% reduction 
of demyelination within 2 weeks. Remyelination to demyelination ratio has also 
increased by 10 fold. Complete remyelination was noted in some animals within 3 
months with no evidence of significant gliosis [219]. Effects of PDGF also extend to 
include chronic demyelination. In 2007 Vana and colleagues examined chronic 
demyelination of the corpus callosum in mice. They reported significant effects of 
PDGF on proliferation and regeneration of new Ols [220]. 
Another important factor which induces proliferation is a chemokine known as CXCL 1 
[227]. CXCL 1 stimulates proliferation of OPCs and acts in synergism with PDGF in 
inducing migration by acting on specific receptors (CXCR2) on the surface of the 
spinal cord OPCs [227]. In MS, CXCL 1 is probably produced from activated 
astrocytes [217]. IndUCing EAE in mice that were treated to produce high amounts of 
88 
Chapter 4: Pathology of oligodendrocytes in the GM of progressive MS spinal cords 
CXCL 1 resulted in significantly less inflammation and demyelination. There was also 
a high numbers of OLs associated with extensive remyelination [217]. 
An important factor associated with OLs' lineage is insulin-like growth factor, which 
induces migration and accumulation of OPCs post-injury and thus stimulates 
remyelination [228, 229]. Expression of this protein was found to be extensive at the 
lesion border of demyelination in animals [230] and in MS [231]. However, at the 
lesion border in MS, there was also extensive expression of the insulin-like growth 
factor binding proteins. These binding proteins are believed to be potent inhibitors of 
myelination [231]. 
After this, migration of OLs is inhibited and cells start to proliferate again under the 
effect of PDGF and CXCL 1. At this point in development and around birth, immature 
OLs become multi-processed and immobile but maintain expression of PDGF and 
NG2 [194]. Most of these OLs are still immature and thus not myelinating [160, 232, 
233]. This explains the duration of extensive myelination between postnatal day 10 
and postnatal day 60 as revealed by MRI studies [234]. 
As development continues, OLs lose expression of PDGF and NG2 (except for a 
population of cells that continue to express NG2 during adult life, these cells are 
called adult OPCs) and enter a stage of intermediate pro-OLs, which is the 04+ 
stage [194]. These 04+ cells are more mature, less motile and do not migrate [227]. 
On the other hand, NG2 positive cells continue as a distinct population of cells and 
spread in the GM and WM during adult life. The fate of NG2 cells and their role in 
oligodendrogenesis is discussed later in the thesis. 
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Initially, an excess number of pro-OLs is produced from proliferation of PDGFR-a 
positive cells and distributed widely in the GM and WM. Nevertheless, the 
programmed cell-death process (apoptosis) controls the final number of OLs so that 
it matches myelination requirements [194, 223, 227]. The final stages of maturation 
include expression of mature OLs' markers, such as PLP, MBP, MOG, and CNPase. 
As these cells mature, they start myelinating axons. 
In summary, to reach the appropriate number ofaxons and the appropriate amount 
of myelination, the progenitor cells migrate, proliferate, differentiate, and then 
undergo timely programmed cell death [227]. The ultimate cytoarchitecture of OLs in 
the spinal cord involves interfascicular OLs and perineuronal OLs. Interfascicular OLs 
are heterogeneous in morphology [235] and in biochemical composition [175]. The 
process of establishing normal spinal cord cytoarchitecture depends largely on the 
correct localisation of the OLs and axons [223]. 
We have emphasized that OLs are a heterogeneous population of cells and each 
type myelinate a different number ofaxons [167, 174, 175]. However, the process by 
which these myelinating OLs acquire their distinct morphology is not clear. Early in 
development, PDGFR-a positive cells begin migration in response to other factors 
which act as guidance to these OLs [223]. These factors may include electric field 
currents, mechanical factors, or chemotactic substances, but it is not well understood 
whether these cells are programmed to a specific morphology or they acquire this 
morphology after migration and under the effects of the new environment. Studies on 
cultured neuroepithelial stem cells showed that all stem cells cultured under the 
effect of PDGF give rise to OLs [225]. This is an important issue in MS and has been 
raised in a number of MS studies to explain why Ols in chronic lesions fail to mature 
and gain the functional and morphologic characteristics of mature cells [236-239]. 
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4.1.2 Functions of oligodendrocytes 
The only proven function of Ols is myelination of the eNS axons, which is ascribed 
mainly to interfascicular Ols, while perineuronal Ols are assumed to have functions 
other than myelination, such as supporting and protecting neurons [169, 240, 241]. 
Intercellular junctions, including gap junctions and to a lesser extent tight junctions, 
are found in the wall of Ols. Freeze fracture of Ol membrane has revealed the 
presence of gap junctions connecting two Ols or Ol and astrocyte. This coupling, 
via gap junctions, between peri neuronal Ols and other cells is currently under 
investigation [162]. 
In 1979 Ludwin studied the remyelination process in mice. Peri neuronal Ols were 
seen clearly remyelinating. Ludwin assumed that these cells may participate in 
normal myelination [173]. After a few years, he investigated the possible functions of 
peri neuronal satellite Ols in the mouse; he used anti MBP and MAG and analysed 
OLs histochemically during the remyelination process. He concluded that these cells 
are functionally similar to other Ols in many respects. Ludwin stated that satellite 
OLs proliferate and produce myelin in response to injury or any demyelinating event 
[173]. 
It is believed that most of the functions that were attributed to Ols are thought to be 
functions of myelin rather than the cell itself [160, 240]. These include maintenance 
ofaxons, regulation of the axon calibre, and inhibition of axonal growth and 
regeneration [160]. 
4.2 Alms and hypothesis 
Ols' numbers and function have proven to be essential in maintaining myelin and 
remyelination. Previous work revealed that cortical GM has more extensive 
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remyelination than the WM, which has been attributed to less inflammation [215]. 
Another animal study assumed that perineuronal Ols in the GM have an essential 
role in remyelination after injury [172]. Moreover, the significant role of perineuronal 
Ols in protecting neurons from undergoing apoptosis was also illustrated in a study 
by Taniike and colleagues in 2002 [240]. There is no study that investigated 
specifically the fate of Ols in the GM of MS. 
Our aim is to study the pathology of Ols in the GM of spinal cords by comparing MS 
tissue and controls, and further comparing the two progressive subtypes of MS; 
PPMS and SPMS. Results obtained from counting Ols in the GM will be compared 
with results obtained from the WM in the following chapter. Axonal loss in NAWM has 
been confirmed previously [242] and found to correlate with the progressive form of 
the disease and with disability [127, 243], but the possible associated Ols pathology 
in normally appearing areas, especially the GM, has not yet been assessed. 
4.3 Material and methods 
Human spinal cord blocks were obtained for this study from the MS Society tissue 
bank in london (PPMS = 13, SPMS = 14, Controls = 5), Oxford Radcliffe NHS Trust 
(6 controls), and archival material from the Neuropathology Department of 
Nottingham University Hospital NHS Trust (7 controls) (Table 4.1). Details of the 
material from the MS Society were described as part of material in Chapter 2. Two 
controls from the MS Society tissue bank and 2 controls from Oxford were excluded 
because of inadequate staining (subjects 10 numbers 11, 32, 3269, and 458). 
For PPMS (4 males and 9 females) the age was between 45 and 92 years (mean = 
66.23 years ± SO = 14.16 years) and the disease duration between 5 and 54 years 
(mean = 26.69 ± 14.57 years). For SPMS (5 males and 9 females) the age was 
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between 39 and 78 years (mean = 57.23 ± 13.59 years) and disease duration was 
between 9 and 50 years (mean = 29.62 ± 13.49 years). For control (5 males and 9 
females) the age ranged between 33 and 93 years (mean = 64.15 ± 15.64 years). 
d Table 4.1: N e u r o p a t h o l o ~ y y epartment 0 Nottingham tissue 
Subject 10 Gender Age Number of Level of each sections 
number sections 
N8298 male 33 1 Cervical 
NP4 female 60 2 Cervical, thoracic 
NP47 female 72 3 Cervical, thoracic, lumbar 
NP82 I male 77 2 Cervical, thoracic 
NP89 II male 73 1 Thoracic 
NP94 female 75 2 Cervical, lumbar 
NP96 female 64 1 Thoracic 
4.3.1 Initial preparation 
Initial preparation of tissue from London and Oxford has been mentioned in Chapter 
2 (Sections 2.5.1 and 2.5.3). To increase the number of controls, archival material 
from the Neuropathology Department in Nottingham University was added to our 
sample. Tissue from Nottingham was fixed in 10% formalin and embedded in 
paraffin. The formalin-fixed and paraffin-embedded blocks were cut at 5 IJm 
thickness. Sections were processed for immunohistochemistry and stained against 
CA II. Immunohistochemistry protocol for CA II used the protocol mentioned in 
Section 3.7.2 and appendix B. Immunohistochemistry for tissue from Nottingham was 
carried out by another technician using a manual technique as opposed to the 
automatic immunostainer used for the tissue from London and Oxford. 
Since we have two blocks from a number of subjects, the total number of blocks 
outnumbers the subjects. In total, 63 blocks of tissue have been analysed. From 
each block, one section was cut at 8 IJm and the following 10 sections were cut at 5 
IJm thickness. The 8 IJm sections were stained with H&E and the 5 IJm sections were 
used for immunohistochemistry. The H&E stained sections were examined by an 
expert Neuropathologist Prof Jim Lowe and by an expert Consultant neurologist Dr 
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Evangelou Nikos. The H&E-stained slides were also compared with the CA II-stained 
slides. On the majority of slides, there was more than one section that can be 
examined. This gave us the opportunity to increase the number of the examined 
demyelinated lesions and to compare demyelinated and normally appearing spinal 
cord sections from the same subject. 
Similar to the previous scanning process (Sections 2.5.3 and 3.3.3); the CA II-stained 
slides were numbered and converted into digital slides that can be viewed at the 
computer screen. Slides were viewed and edited on the computer by using the 
NDP.view software. 
4.3.2 Sampling of the ventral horn and the dorsal horn 
Using the digital pen, borders of the GM were delineated in all CA II-stained sections. 
The CSA of the cord and the GM were measured. From each VH, 5 fields were 
selected based on the protocol described in Figure 4.1. Fields were exported as an 
image of the computer screen when the magnification is set to 40X and the screen 
resolution is 1024 x 768 pixels. With this magnification and this resolution, the 
surface area of the exported field was 0.047 mm2• However, when the VH area was 
small, especially at the upper cervical or thoracic levels, smaller fields were selected 
by exporting the image of the screen at magnification of 63X. The surface area of the 
field with 63X magnifications and with the same resolution was 0.0164 mm2• The 63X 
magnification is set automatically by the software and cannot be manually adjusted. 
The majority of fields were exported at 40X magnification (65% of all fields). 
The DH sampling protocol allowed for the field of interest to sample nucleus proprius 
(Figure 4.2). This means that the DH was represented by the laminae IV and V. This 
is because lamina I is very thin and does not fill the field of interest and it is 
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separated from the nucleus proprius (Iamiae IV and V) by the naturally unmyelinated 
substantia gelatinosa (laminae II and III). 
4.3.3 Oligodendrocyte counting 
Each exported field of interest was given a number so that the observer is blinded to 
myelin status and the disease type. Fields of interest were numbered based on the 
subject 10 number, section number, side of tract (left or right) and its location among 
the 10 sections. Therefore, each field location can be traced and located on the 
original slide. All fields were viewed by imageJ software. The field was opened using 
the software and manual counting was carried out. Using the computer mouse 
cursor, all Ols were selected. The software automatically counted the selected 
points. Reliability of our identification criteria and reproducibility of our counting 
process was tested (coefficient of variation 16%). 
4.3.4 Identification of the myelin status of fields 
To determine the myelin status of each field, the MBP-stained sections were used. 
However, the MBP and CA II sections are not adjacent. The two non adjacent 
sections were selected randomly from 10 consecutive 5 ~ m m thick sections. Thus the 
maximum distance between any two sections can reach up to the thickness of 8 
sections (40 ~ m ) . . The effect of the possible maximum 40 ~ m m distance between the 
MBP and the CA II sections on our measurements was tested by measuring the 
surface area of the spinal cord and the GM in 10 subjects and in the three stains (CA 
II, MBP, and H&E). 
The CSA and the GM surface area were calculated in the three stains; CA II, MBP, 
and H&E (Table 4.2). The correlation of GM surface area between CA II and MBP 
was 0.992 (p value < 0.001) and with H&E was 0.995 (p value < 0.001). The WM 
95 
Pathology of the spinal cord in progressive multiple sclerosis (primary progressive vs secondary progressive) 
surface area calculated from the CA II and the MBP correlated with each other 
significantly (Pearson correlation r = 0.990, P value < 0.001). The GM surface areas 
calculated from the CA II sections correlate also with MBP (Pearson correlation r = 
0.996, P value < 0.001). 
4.3.1 Classification process of CA II-stained fields according to myelin status 
Using NDP.view software, the CA II-stained image was opened and then the 
corresponding MBP-stained image was opened on the same screen. By 
synchronising the two images using the NDP software, magnification and position of 
the two opened images were set equal, ie any change in the magnification or position 
of the first image was met by the same degree of change in the magnification and 
position of the second image. 
Table 42· The GM and the WM surface areas in the three stains ..
The The WM The WM The WM surface The GM The GM The GM 
subject 10 surface area surface area area (MBP) surface area surface surface 
(CAli) (H&E) (CAli) area H&E area MBP 
E49 30.2 29.4 28.0 4.11 4.08 3.74 
E55 51.0 51.0 50.8 2.58 2.31 2.48 
E72 24.9 25.0 25.0 3.38 2.41 3.29 
E104 42.6 42.2 43.1 3.36 3.36 3.50 
E109 35.5 35.3 35.8 4.18 4.29 4.16 
E122 42.6 44.5 44.7 9.21 9.08 9.73 
E135 32.2 32.8 33.1 12.23 12.70 12.29 
E164 30.4 30.1 30.1 3.59 3.40 3.28 
E197 23.4 24.0 20.6 14.09 13.43 12.52 
E49 30.2 29.4 28.0 4.11 4.08 3.74 
The only feature that was not included in synchronisation is the orientation, which 
was adjusted before synchronising the images. This was because each slide had 
been scanned in a different orientation by the NDP.view scanning machine. 
Orientation of each slide was standardised by drawing a reference line. The 
reference line was drawn from the central canal to the dorsal border of the PCP. To 
adjust and standardise the orientation, the line was adjusted to one of the vertical 
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borders of a flat computer screen. Therefore, each time the examiner opens the two 
images, he can retain the image alignment by adjusting the line to the vertical border 
of the computer screen. Once the orientation of the two opened images (CA II and 
the MBP of the same clock) was the same, images were then synchronised. 
Synchronisation of the two images allows the examiner to compare the same region 
in two different stains (Figure 4.3). 
Because the previously exported CA II-stained fields were still outlined on the CA 11-
stained sections, the same regions could be located on the MBP when the two 
images were synchronised. Consequently, the myelination status of the fields was 
then identified (Figure 4.3). Fields were classified into normally appearing GM 
(NAGM), partially myelinated GM (PMGM), and demyelinated GM (DMGM). DMGM 
included all the completely demyelinated areas. Any abnormally appearing areas that 
were not completely demyelinated were considered PMGM. Therefore, PMGM 
included the lesion border, areas of partial remyelination or areas of partial 
demyelination. 
4.3.2 Statistics and Statistical software 
Results were exported to SPSS software that has the subject number, the field 
number, Ols number, CSA of each field, and the myelin status of each field. The 
spreadsheet also has other details about the subject's age, gender, duration of the 
disease, and type of disease. 
Reproducibility and reliability were evaluated by coefficient of variation and 
Spearman correlation. T test and Mann-Whitney U test were used to compare means 
as appropriate. Multiple linear regression was used to analyse effects of independent 
factors on Ols, such as age, gender, type of disease, cord level, duration of disease 
97 
Pathology of the spinal cord in progressive multiple sclerosis (primary progressive vs secondary progressive) 
and post-mortem delay. With the help of Dr Owen, a lecturer at Nottingham 
University, comparison of the means and regression analysis were double checked 
using STAT A statistical software. 
4.4 Results 
About 864 fields were examined (Table 4.3). Some of the general features of CA II 
stained sections were mentioned in the Chapter 3, while MBP stain features were 
mentioned in Chapter 2. GM OLs appeared variable in shape and size. In controls, 
they appeared homogeneously distributed throughout the GM. The electron 
microscopic features of OLs having heterogeneous chromatin were noted frequently 
[169]. The discrimination between light, intermediate and dark OLs was not always 
possible. However, in agreement with the electron microscopic findings, it was 
noticed that darker OLs tend to be smaller. Presence of large light OLs, which 
represent early mature cells, was often observed (Figure 4.4 A). Peri neuronal OLs 
were occasionally seen in proximity with the perikaryon of neuron, and they tended to 
be darker and smaller (Figure 4.4 B). In the lesions' centres the presence of OLs was 
not associated with myelin. 
T bl 4 3 O' t 'b r f th a e • : IsnUlono I edfie f e analySt Ids rom the VH and OH 
Type of the disease Myelin status of the field Number of fields 
Normal control Normal field from normal control 250 
Demyelinated 51 
PPMS Partially myelinated 51 
Normally appearing fields from MS 219 
Demyelinated 58 
SPMS Partially myelinated 29 
Normally appearing fields from MS 191 
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4.4.1 The spinal cord grey matter of MS shows higher density of 
oligodendrocytes than normal controls. 
The mean density of OLs in the GM of MS, regardless of disease type and myelin 
status, was 139 ± 159/mm2 and in controls was 104 ± 96/mm2 (p < 0.001) (Figure 
4.5). We further examined the mean density in each of the main cord segments (the 
three main segments; cervical, thoracic, and lumbar). In both controls and MS 
subjects, there was no significant difference in OLs' density between any of the three 
segments. In addition, regression analysis did not reveal significant effect of cord 
level on GM OLs in either MS or controls. 
4.4.2 The spinal cord grey matter of SPMS has greater density of 
oligodendrocytes compared to PPMS 
By considering the disease type, the mean density of OLs in the GM of PPMS was 
122 ± 136/mm2 and in SPMS was 158 ± 180/mm2 (p = 0.007). When each subtype is 
compared with controls, only SPMS showed significant difference (comparison 
between controls and SPMS, the p was < 0.001 and with PPMS, the p = 0.064) 
(Figure 4.6). 
The increase in OLs in SPMS GM compared to PPMS GM was observed only in the 
VH. The mean OLs density in the VH of SPMS was 164 ± 182 and in PPMS was 
123/mm2 ± 132 (p = 0.006). In the DH, the mean OLs density was 135 ± 1741 mm2 in 
SPMS and 117 ± 151/mm2 in PPMS (p = 0.548). 
4.4.3 Density of oligodendrocytes In the NAGM 
When we further sub-classified our analysis according to myelin status, we found out 
that the increase in OLs was due to increase of numbers in the NAGM. The mean 
density of OLs in the NAGM of MS was 173/mm2 ± 7.99 (compared to controls the p 
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< 0.001). Ols' density in the NAGM was found to be 1491 ± 133/mm2 in PPMS and 
201 ± 186/mm2 in SPMS (p = 0.002). This increase in Ols' density in the NAGM of 
SPMS was found to be due to increase in Ols in NAGM of the VH and not the DH. 
The Ols' density in the NAGM of the VH in SPMS was 207± 187/mm2 and in PPMS 
149 ± 128/mm2 (p = 0.001). In the NAGM of the DH, Ols' density was 178 ± 
185/mm2 in SPMS and 151± 1521mm2 in PPMS (p = 0.463). 
4.4.4 Density of oligodendrocytes in PMGM 
The mean density of Ols in PMGM was 130 ± 165/mm2, which was significantly less 
than Ols' density in the NAGM (p = 0.037) and not different from healthy GM of 
normal controls (p = 0.183). In the PMGM, PPMS showed a density of 124 ± 
154/mm2 and SPMS showed a density of 142 ± 187/mm2 (P = 0.65). Comparison 
between the DH and the VH in the PMGM was not possible because there were not 
enough PMGM fields exported from the DH. Most of the lesions that affected the 
dorsal aspect of the cord resulted in complete demyelination of the DH. 
4.4.5 Density of oligodendrocytes in DMGM 
Ols' density in the DMGM was found to be tremendously less than normal healthy 
controls (83% reduction) and less than PMGM (86% reduction) -and NAGM (90% 
reduction). The mean density of Ols in the DMGM of MS was 17 ± 39/mm2• In SPMS 
the density was 28 ± 49/mm2, which was significantly more than the DMGM in PPMS 
that showed Ols' density of 4.8 ± 15/mm2 (p = 0.001). In the whole MS sample and 
the two forms of the disease, the demyelinated areas showed significantly reduced 
density of Ols compared to healthy GM from normal controls, NAGM and PMGM. 
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4.4.6 Effects of age and disease duration on GM oligodendrocytes numbers 
In normal controls, GM Ols' number decreases significantly with age (p < 0.001, 
correlation coefficient = -0.413 contrOlling for gender and cord level). However, effect 
of age on Ols' density in MS was found to be insignificant controlling for gender, 
myelin status and cord level (Correlation coefficient = -0.013, P = 0.748). 
In MS, correlation of Ols' numbers in the GM correlated better with duration of 
disease than age. Duration of the disease seems to have weak negative correlation 
with number of GM Ols in the global sample. However, effect of duration of the 
disease on Ols was only significant in the demyelinated areas in which the 
correlation coefficient was calculated to be -0.221 and the significance was 0.026 
controlling for age, gender, and cord level (Table 4.4). 
Table 4.4 correlation of OLs density with disease duration in the three differently myelinatedrElgion 
Myelin status of the Control Variables Disease duration in field years 
Demyelinated Gender & Level of the cord & Correlation -0.221 
Age 
Significance (2-tailed) 0.026 
Partially myelinated Gender & Level of the cord & Correlation -0.121 Age 
Significance (2-tailed) 0.296 
Normally appearing Gender & Level of the cord & Correlation -0.021 
from MS Age 
Significance (2-talled) 0.680 
4.4.7 Total number of oligodendrocytes in the spinal cord GM 
To validate our results further and to overcome the possible effects of atrophy in MS 
on Ols' density, which may give misleadingly higher density of Ols per 1 unit 
surface area, the total number of Ols was calculated in the GM. This has been 
calculated by multiplying the mean density of GM Ols in each subject by the GM 
surface area of that subject. Only the VHs that do not have demyelination were 
included in assessment of Ols total number. Due to significant variability in the GM 
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volumes among various cord levels, results were categorised into 5 groups according 
to the GM volumes in each segment (Sections 2.5.5 and 2.7.2). 
The total number of Ols in the upper cervical GM of controls was 449 compared to 
746 in MS (Mann-Whitney U test = 4, P 0.643). In the lower cervical GM, which has 
great surface area, the total number was 942 in controls and 453 in MS (Mann-
Whitney U test = 5, p value = 0.194). In the thoracic area, the total number was 363 
in controls and 648 in MS (Mann-Whitney U test = 13, P = 0.295). In the upper 
lumbar GM, the total number was 338 in controls and 967 in MS (Mann-Whitney U 
test = 2, p = 0.857). The total number in the lower lumbar level was 1639 and 2260 in 
controls and MS respectively (Mann-Whitney U test = 13, P = 0.295). 
4.4.8 Comparison between the dorsal horn and the ventral horn 
We demonstrated previously that the difference between PPMS and SPMS was only 
significant in the VH. However, comparison was made between Ols' density in the 
ventral GM and the dorsal GM in both controls and MS. In healthy controls, there was 
greater density of Ols in the VH (109/mm2) compared to the DH (54/mm2) with a 
significance of < 0.001. The variation was less prominent in the global sample of MS 
where the VH and the DH demonstrated mean densities of 1421mm2 and 126/mm2 
respectively (p = .319). Table 4.5 shows the variation according to the myelin status. 
4.4.9 Effects of independent factors 
A linear regression model was applied to study the effect of the independent factors 
(disease duration, gender, level of the cord, myelin status, type of the disease, region 
of the GM (VH vs DH) and post-mortem delay) on the dependent factor Ols' density. 
There was significant effect of disease type and myelin status on Ols' density and p 
value were 0.029 and < 0.001 respectively. 
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Table 4.5: Comparison between the VH and the DH in oligodendrocytes density 
Type of sample GM OLs density I mm 2 P value· 
VH 109/mm2 
controls 
54/mm2 
<.001 
DH 
VH 175/mm2 
NAGM .603 
DH 165/mm2 
VH 128/mm2 
MS PMGM .. 
DH 171/mm2 
VH 21/mm2 
DMGM 
5/mm2 
.063 
DH 
• pa Ired t test 
•• Only 3 partially myelinated fields from the DH were found in the sample and thus comparison was not possible. As 
we have already mentioned, most of the lesions were posterolateral and affected the whole DH. 
4.4.10 Summary of results 
So far, we have calculated that the mean density of Ols in the GM of MS is more 
than controls in the whole sample and in SPMS. When the analysis is extended to 
consider the myelin status, the NAGM of MS in the whole sample and in both 
subtypes demonstrated greater density of Ols than healthy GM of controls. Increase 
in Ols was found in the NAGM or the lesion border, while in the completely 
demyelinated areas number of Ols is significantly reduced. There are more Ols in 
the NAGM, PMGM and DMGM of SPMS cords compared to PPMS. This difference 
was greatest in the NAGM of the VH. In normal controls, GM Ols' number reduces 
with age, while in MS the number of Ols reduces slowly with disease duration in the 
demyelinated areas. 
4.5 Discussion 
Exporting fields of interest from the spinal cord GM using unbiased sampling protocol 
is, to our knowledge, the first quantification study of Ols in the GM of MS. Ols are 
responsible for an important element of eNS repair, which is the remyelination. The 
eNS remyelination occurs in the WM and the GM. Effective remyelination depends 
on the presence of enough functioning Ols [217, 244,245]. We have calculated Ols' 
density in four areas; healthy controls GM, NAGM, PMGM, and chronic DMGM. All 
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lesions in our sample were chronic demyelinated lesions. Inflammation stages of 
lesions in this sample have been studied previously using CD3 and CD163 and the 
majority of lesions were found to be chronic inactive with very low inflammation score 
[124]. This is an expected result, as new lesions of the spinal cord in progressive MS 
are quite rare [138]. 
Interestingly, we found high numbers of CA II positive cells in the GM of the entire 
MS sample compared to controls. We found that the NAGM is responsible for this 
increase. When the two subtypes of the disease were compared, the density of Ols 
in the GM of SPMS was greater than that of PPMS. The highest number of Ols was 
found in the spared regions of the GM of the two disease forms. 
It is possible that GM lesions are associated with some activity in the form of 
inflammation and substantial release of inflammatory molecules or chemotactic 
signals. This may affect the Ols around the lesion. Ols may undergo proliferation in 
response to a signal from the lesion. Ols' proliferation in response to injury has been 
reported on a number of previous occasions. Animal studies have reported GM Ols' 
proliferation after nervous tissue injury [246]. Experimental spinal cord injuries in rats 
have shown that new Ols are found around the lesion border as early as 7 days post 
injury, The numbers of accumulating Ols around a spinal cord lesion was found to 
be greater than in normal controls [226]. Surprisingly, Ols' proliferation resulted in 
high numbers of Ols in the GM that outnumbers GM Ols in controls. Proliferation 
was also more prominent in the GM than the WM [226]. Our results suggest that this 
finding may also occur in the human nervous system. 
The observation that spared areas around lesions have the highest numbers of Ols 
led us to execute a quick comparison between density of Ols in the spared areas 
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near GM lesions and spared areas far from lesions. We found that NAGM has 
significantly greater density of Ols in the cervical segment (199/mm2), which is 
nearer to lesions compared to lumbar segment, where lesions are rare (158/mm 2) (p 
value = 0.04). This may support further that Ols proliferate in response to the local 
effects of demyelinating lesions. 
The role of the presumed Ols' proliferation in the GM is not certain. The increased 
numbers of Ols in the NAGM may act as a reservoir for Ols. Ols' progenitors 
possibly proliferate and migrate to injured areas. These Ols accumulate around the 
border, in an attempt to migrate inside the lesion and repair it or to prevent the lesion 
from spreading further. This may explain the finding that SPMS has more Ols in both 
the NAGM and the DMGM. 
An important issue is that comparison with animal studies may not be ideal. Animal 
studies mostly test acute response to injuries of the spinal cords compared to the 
chronic lesions of MS, which have been examined in our study. Nevertheless, a 
human study in MS showed that proliferation of cells continues in chronic lesions of 
MS [247]. 
Another important concern is the possible effect of atrophy of the spinal cord in MS 
on interpretation of results. Atrophy of tissue in MS, including the GM, may result in 
overestimation of Ols' density. In an attempt to validate our results, the total number 
of Ols within the cord was calculated, which showed that there is no significant 
difference between MS and controls. It should be noted that we included only 
normally appearing sections that do not have demyelination. This resulted in 
exclusion of sections with demyelination, and consequently exclusion of the areas 
around the lesions, which are the areas with the highest number of Ols. On the other 
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hand, including sections with demyelination in the analysis of total numbers of OLs 
may not be reliable. This is because significant areas of these sections are occupied 
with demyelination, which have very few OLs. 
There may be another possible source of error coming from controls. The control 
sample was obtained from three sources and may give variable results. Initially, we 
had two sources of tissue; London and Oxford, which have been processed in the 
same lab and by the same technician. Initial results revealed that there was an 
increase in OLs' density in the GM of MS compared to controls. To increase the 
reliability of our results, we added several controls from Nottingham. For technical 
reasons, these were processed manually by another technician and using manual 
technique rather than automatic technique (immunostainer). The manual technique 
has used the same protocol that had been done by the immunostainer. The obtained 
results did not vary considerably and controls GM continue to demonstrate less 
numbers of OLs compared to MS GM. However, both Oxford tissue and Nottingham 
tissue demonstrated greater density of OLs in the GM compared to the tissue from 
London. 
4.5.1 Variation between PPMS and SPMS 
MS tissue was obtained from one source and processed by the same technician. 
Therefore, comparison between PPMS and SPMS is not affected by source of tissue 
variation. SPMS spinal cords seem to have higher density of OLs in the NAGM in 
contrast to PPMS. If we move inside the lesion, OLs number reduces tremendously. 
But still OLs density in SPMS lesions was greater than PPMS (in SPMS was 27 
OLs/mm2 and in PPMS was 5 OLs/mm2). This may indicate that OLs in the NAGM 
migrate inside the lesion or the process of production of OLs is more efficient in 
SPMS compared to PPMS. Previous studies have reported more Ols' precursors in 
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SPMS compared to PPMS. The density was 34/mm2 in lesions from SPMS and 
9/mm2 in lesions from PPMS [239]. 
Variation in Ols pathology between MS subtypes may be part of the variation in the 
whole disease process. There are differences between the two subtypes in degrees 
of inflammation, atrophy and in demyelination. The progressive phase of SPMS 
patients can be shorter than PPMS, which may explain the findings that SPMS 
maintains more inflammation [103], more inflammatory cell recruitment, more 
demyelination and even more remyelination [179]. In SPMS, there was more 
perivascular cuffing and cellularity in the parenchyma of SPMS [103]. There were 
also more T cells and activated microglia inside and outside spinal cord lesions in 
SPMS [124]. Part of Ols' response to inflammation may include proliferation or 
migration to the site of inflammation and, as an element of this inflammation, Ols' 
recruitment may be higher in SPMS. This may indicate that SPMS by having more 
inflammation attracts more Ols to the site of inflammation. In fact, an experimental 
animal study reported that inflammation is a potent stimulator of Ols proliferation and 
remyelination [248]. Specifically in MS, lucchinetti et al reported that SPMS ability to 
recruit inflammatory cells and OLs to the site of lesion was greater than PPMS [179]. 
This is supported by a previous report that SPMS patients have greater degree of 
remyelination than PPMS [249]. 
In Chapter 2 we demonstrated that SPMS has more demyelination in the spinal cord, 
but PPMS has greater tendency to affect the GM and may therefore produce greater 
damage to Ols, which may result in reduced numbers of Ols in the GM of PPMS. 
Moreover, variation in atrophy between the two disease subtypes may affect 
interpretation of our results. We found that SPMS produces more atrophy of the cord, 
especially in the upper segments, which may give misleadingly higher density of Ols 
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and thus explain the higher density of OLs in the SPMS GM. This possibility is further 
suggested by the fact that there was no significant difference between SPMS and 
PPMS in the total number of OLs in the GM. Again, we have to emphasise that 
sections with demyelination, where OLs accumulate around lesions, have been 
excluded from the study of total number of lesions. Therefore, the main contributory 
element to the increase in OLs number is not included. 
Another explanation is that SPMS subjects, due to genetic, environmental or other 
unknown factors, may have greater resistance to OLs loss. As a result, these cells 
can be mature OLs that survived demyelination. It was observed that in some MS 
lesions OLs were relatively preserved. These OLs were found to be positive for Bcl-2. 
This protein protects against OLs apoptosis. Expression was found in demyelinated 
areas, but highest in remyelinated areas. A subset of patients with RRMS 
demonstrated high numbers of Bcl-2 positive OLs (250). It is possible that RRMS 
subjects maintain expression of this protective protein in the secondary progressive 
phase of the disease. Such assumption was further supported by Bonetti et al in 
1997, reporting that similar expression of Bcl-2 was noticed in chronic active and in 
silent MS lesions (251). Therefore, future studies may compare expression of Bcl-2 
between SPMS and PPMS, and between the GM and the WM. 
4.5.2 Potential sources of oligodendrocytes 
So far, we have suggested two possible sources of OLs; new OLs from proliferation 
of the progenitor cells or mature OLs that survived demyelination. However, it is 
strongly believed that remyelinating OLs in the human eNS are new OLs that are 
produced by differentiation and proliferation of OL progenitors [194, 252-254]. There 
are two pieces of evidence to support this hypothesis; adult OLs that survive the 
demyelinating event are mature and therefore postmitotic (mitotically inactive), and 
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new Ols were found mainly in areas populated with NG2 cells [226]. Animal studies 
have demonstrated that mature Ols that survived demyelination do not playa role in 
remyelination and that new Ols are required for remyelination [255]. In fact, the 
numbers of mature Ols that survive demyelination in MS (sometimes called 
demyelinated Ols) reduces significantly with disease progression [238]. 
Moreover, Solanky et al (2001) studied 3 groups of patients; patients with MS, other 
neurological diseases, and normal controls. The study quantified proliferating cells by 
using proliferation marker (Ki-67) that stains cells in various phases of cell cycle. 
There was more proliferation of cells in MS. Most of the proliferating cells were found 
to be Ols and were traced in acute, chronically active, and chronic lesions. The 
study demonstrated that Ols' proliferation continues even in chronic lesions [247]. 
Sources of new Ols may include, NG2 positive cells, PDGF-a positive cells, nestin 
positive cells, and perineuronal Ols (Table 5.4). 
Adults NG2 positive cells 
Adult NG2+ cells are different from embryonic NG2+ cells, in that embryonic NG2+ 
precursors differentiate early during gliogenesis and are restricted to a certain area 
around the neural tUbe. The exact function of adult NG2+ cells is not clear, but it is 
believed that these cells are part of Ols' lineage and they can differentiate into Ols 
in pathological cases such as MS [194, 226]. 
Adult NG2 positive cells are a distinct population of cells that are distributed evenly in 
the adult human eNS in the GM and the WM. NG2 positive cells can be found in 
developing brain, adult brain, and in chronic lesions of MS [237, 244, 245]. These 
cells express PDGF-a, and 04, but not MBP or CNPase. These NG2+ cells are 
capable of producing Ols in response to injury, which is a rapid and efficient process 
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for remyelination in animals [194]. It was found that these cells proliferate early in 
response to injury (within the first week), and are capable of producing new OLs 
around the lesion border as early as 3 days post injury. Newly formed OLs were 
observed in areas rich with NG2+ cells [226]. Animal studies revealed that NG2 
positive cells are the remyelinating cells and their exogenous transplant in another 
lesion promotes remyelination [245]. 
After injury, NG2+ cells of the spared areas change their morphology from stellate 
shape to a more regular shape. This regular shape is believed to be the active 
proliferating form of the cell [256]. The shape of premyelinating OLs that was found in 
chronic lesions of MS in previous studies and the present study greatly resembles 
the active form of NG2 positive cells [236]. They were oval cells and were not 
associated with myelin. NG2 cell distribution correlates positively with the distribution 
of premyelinating Ols indicating that NG2 cells give rise to premyelinating OLs [236]. 
Another study compared OLs pathology in EAE and MS [252]. It demonstrated that 
NG2 cells proliferate and become active in response to injury and a transition state 
between NG2 and mature Ols was found in MS, where double stained cells with 
NG2 and CNPase were found [252]. 
PDGF-a positive cells 
These cells are earlier than NG2 positive cells in cell lineage of Ols. Although double 
labelling with NG2 is common, these PDGF-a positive cells are different from adult 
NG2 positive cells by being bipolar or sometimes with no processes. An important 
feature of these cells is that they are migratory. During normal development, the 
bipolar PDGF-a positive cells differentiate into embryonic NG2 positive cells and then 
to premyelinating Ols or to adult NG2 positive cells. Adult NG2 cells continue as the 
distinct population of cells mentioned in the previous section, while premyelinating 
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OLs are not present normally in adult brains. Premyelinating OLs are temporary cells. 
During early development, the multiprocessed premyelinating OLs either develop into 
mature myelinating OLs or undergo apoptosis within 3 days, if they do not myelinate 
axons [194, 223, 227]. Multiple processed premyelinating OLs have been observed 
in chronic lesions of MS [236]. 
During development of the spinal cord, OLs' proliferation begins in the ventral part of 
the central canal. Two foci of PDGFR-a positive OLs are generated on both ventral 
sides of the neural tube and then OLs' proliferation is started [257]. The dorsal spinal 
cord was to found to be inhibitory for proliferation of OLs in the early stages of 
development [224]. Animal studies revealed that proliferation of OLs was more 
apparent in the VH [258]. In our sample, the observation of accumulation of OLs at 
the border of GM lesion was only noted in the VH. In addition, the variation between 
SPMS and PPMS was only noticed in the VH. 
PDGFR-a positive cells were identified in 1995 in a cultured human temporal cortex 
[259]. After that, and in 1998, Neil Scolding and his colleagues examined normal 
controls, acute, and chronic MS lesions for the presence of these cells. They 
demonstrated for the first time the presence of small numbers of PDGF-a positive 
cells in the brains of normal controls, in acute and in chronic lesions of MS [245]. This 
may represent another potential source of OLs in MS. From the data in our hand, we 
calculated that in controls there are higher numbers of OLs in the VHs compared to 
the DHs. Comparison between the ventral and the dorsal spinal cord is important, 
because of the observation that most of spinal cord lesions are located 
posterolaterally in the spinal cord. 
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Nestin positive cells 
These cells are the neuronal stem cells and they are earlier than NG2 and PDGF-a 
positive cells. They are rounded-to-oval non-branching cells that can give rise to 
neurons and glia. They are positive for nestin and localised to the sub-ventricular 
zone during development. Neuronal stem cells are not different morphologically from 
PDGFR-a positive cells, as some authors describe PDGFR- a cells as non-
processed cells. The difference is that PDGFR-a cells are committed to become Ols. 
Presence of these cells in the adult human eNS has been recently reported and 
they were localised around the central canal of the spinal cord near to ependymal 
cells [260]. These cells may be an important potential source of new Ols, especially 
because they are characterised by being multipotent and migratory [160]. 
Perineuronal oligodendrocytes 
Another possible source of new Ols in the human GM is the perineuronal Ols. It has 
been suggested that perineuronal Ols play a role in remyelination in animals. 
Perineuronal Ols proliferate, differentiate and remyelinate injured axons in animals. 
In the GM perineuronal Ols, which are not associated with myelination in normal 
circumstances, were seen clearly remyelinating axons [172, 173]. This may explain 
the presence of high numbers of Ols in the GM of MS spinal cords. 
4.5.3 Further Comments on material and methods 
There are limitations to the use of the human tissue in examining diseases such as 
MS. For example, duration of the disease varies at time of death and, therefore, age 
of lesions may vary. Although most of our sample subjects had a similar degree of 
disability before death [124], pathology of GM and thus Ols changes may be 
independent of disability. Another limitation may be related to a different post-mortem 
delay of tissue. This may affect the degree of protein and enzyme expression. 
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Myelin status was determined by the MBP-stained sections. Because the CA 11-
stained section and the MBP-stained section are not adjacent, a possible error may 
arise from identification of the myelin status of the field, such as misinterpretation of 
DMGM as NAGM or vice versa. The maximum possible distance between two 
sections is 40 ~ m . . When we calculated the surface areas, there was strong 
correlation between the two images, which indicates that they are very close to each 
other. In addition, we have considered any abnormally appearing area that is not 
completely demyelinated as PMGM. As a consequence significant surface area 
around the border was included as partially myelinated areas. Having a wide border 
included as PPMS reduces the risk of misinterpretation of demyelinated areas as 
normally appearing areas. We also calculated that the mean size of spinal cord 
lesions in the cross sectional plane was 13 mm2 and therefore the effect of 40 ~ m m in 
the longitudinal plane of the spinal cord is not expected to be significant, especially 
because most spinal cord lesions run in the longitudinal plane of the spinal cord. In 
fact, for many sections, the lesion border can be identified on CA II stain at high 
power when synchronised with the corresponding MBP-stained section. The border 
is very difficult to identify on CA II-stained images alone without synchronising the 
image with the corresponding MBP-stained image. Consequently, we were confident 
that identification of myelin status using the previous method was accurate and did 
not affect interpretation of results. 
4.6 Conclusion 
There are high numbers of Ols in the GM of MS. The Origin of these Ols is 
uncertain, but animal and human studies have suggested that these cells are new 
Ols. Four sources of new OLs are suggested; from adult NG2 positive cells, PDGF-a 
positive cells, Nestin positive cells, and from perineuronal Ols. These possible 
sources of Ols may proliferate to premyelinating Ols within the lesions or migrate 
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from the nearby areas. In the WM chronic lesions of MS, the present Ols are 
premyelinating immature cells that are positive for 04, NG2, PDGF-a and CA II, and 
negative for MBP, CNPase and PlP. Therefore, identifying level of maturity of CA 11-
positive cells in the future studies is essential. 
There is little information about the degree of spinal cord GM demyelination and its 
effects on disability. We also have little information about the degree and extent of 
remyelination in the spinal cord GM, and whether remyelination of the GM plays a 
role in improving patient's symptoms and how this may affect disease progression. 
Our study showed that in GM lesions, CA II-positive cells in GM reduces slowly but 
significantly with chronological progression of the disease. 
We also demonstrated that SPMS has more Ols in the NAGM and the DMGM. 
However, the number of cells within the lesion reduces with progression of the two 
disease forms. This has been further confirmed in this study where the duration of 
the disease significantly affects the number of Ols in the demyelinated areas. This 
may indicate that MS lesions in PPMS and SPMS lose the receptive environment for 
Ols proliferation, differentiation or migration [244]. Another explanation may be the 
physical limitation caused by the astrocytic scar or loss of signal from the 
degenerated axons due to long standing demyelination. 
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Figure 4.1 : Sampling protocol of the VH. From each side, a horizontal line was drawn from the anterior border of the 
GM commissure (line 1). A second horizontal line was drawn between the tips of the VHs (line 2). A third horizontal 
line was drawn in the middle between line 2 and 1 (line 3). The intersections of the third line with the VHs boundaries 
were marked on both sides. The midpoint between the two intersections was identified. A vertical line was drawn 
through the midpoint on each side, which divided the VH into 4 quadrants (line 4) (A, scale bar 4 mm). Fields were 
selected from 5 regions of each VH at a magnification of 40X or 63X (B, scale bar 1 mm). 
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Figure 4.2: The sampling protocol of the DH. In 1, the DH is demarcated and a transverse line is drawn through the 
neck of the DH in 2. The midpoint of this line is identified in step 3. In 4, a second line is drawn from the midpoint of 
the first line to the tip of the outer border of the substantia gelatinosa. In 5, the midpoint of the second line is 
centralised in the middle of the screen. Finally, the image magnification is changed to 40X and then the whole field 
that appear on the screen is exported. 
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Figure 4.3: Two synchronised images as they appear on the computer screen. If the examiner magnifies the pointed 
field in the upper image, same region in the lower image is automatically magnified. Note the myelin status of the 
area (arrow) seen with MBP and how the same area appears with CAli above. It can be noticed that areas of 
demyelination and partial myelination are not identifiable on CA II sections. The GM boundary is more prominent in 
CA II-stained sections in the presence of severe demyelination compared to MBP-stained section (scale bar 2 mm) 
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Figure 4.4: In A, Ols in the GM of human spinal cords stained with CA II marker. Field is 40X magnification. Black 
arrows point to three possibly dark Ols. White arrows point to light Ols, which mostly represent less mature Ols. 
The condensed chromatin at the rim of the nucleus is obvious and considered as one of the characteristic features of 
Ols. All other small particles are possibly due to myelin staining. The H&E counterstained cells (blue cells) are 
possibly other glial cells or small interneurons. (Scale bar 100 ~ m m . . In B, the black arrows point to two perineuronal 
Ols in close proximity to the cell body of a neuron in the GM. Peri neuronal Ols staining was more intense than non-
perineuronal OLs (100X magnification). 
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Figure 4.5: The image in A is the right VH of upper cervical segment from control subject. OLs are seen scattered in 
the GM and the WM. GM OLs are relatively fewer in the GM of controls compared to the WM (scale bar 1 mm). The 
image in B is right VH from MS subject. There is demyelinating lesion affecting part of the VH. Note clustering of OLs 
in the NAGM. Same lesion extends to the nearby WM with no obvious prOliferation in the WM OLs (scale bar 0.8 
mm). 
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Figure 4.6: A bar chart demonstrating the variability in OLs density in the Normal controls and MS. Results include 
the VH and the DH. The bar heights represent the mean OL density in the GM ± SEM. Significant differences are 
indicated by an asterisk for p values <0.05. 
119 
Chapter 5: Pathology of oligodendrocytes in the WM of 
progressive MS spinal cords 
5.1 Introduction 
WM Ols or interfascicular Ols seem to have a vital role in the repairing mechanism 
of the eNS. Failure of the human eNS to compensate adequately for axonal and 
myelin loss is possibly the main cause of permanent disability after eNS injury. In 
CNS injury following MS lesions, Ols may produce some remyelination in the brain, 
but there is little information in relation to the extent, timing and clinical 
consequences of Ols' proliferation and the consequent remyelination in the spinal 
cord. This study will quantify Ols in the WM of the spinal cord in healthy controls and 
in the two progressive forms of MS. In this introduction, pathology of Ols and their 
role in remyelination in acute and chronic WM lesions will be reviewed. 
5.1.1 Fate of oligodendrocytes in acute WM lesions 
During the early stages of MS lesions, Ols pathology was found to be variable [261-
267). In some patients fresh lesions show preservation of Ols, while in others there 
is significant loss of Ols [261, 267]. Complete loss of Ols in the centre of the plaque 
has also been demonstrated [267]. This has been argued to be due to heterogeneity 
of MS lesions, raising the possibility that there is variability in Ols' pathology among 
different patients. Similar degrees of inflammation, axonal loss and Ols' loss were 
seen among different lesions from the same person [179, 267]. Lucchinetti et al 
described two main patterns of Ols' loss within the centre of the plaque compared to 
the active edge of the same plaque; in 70% of cases there was variable reduction in 
Ols' numbers in remyelinated or demyelinated lesions, while in 30% there was 
extensive destruction in Ols' numbers with no associated remyelination [179]. 
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Causes of ollgodendrocytes loss In acute lesions 
Ols are amongst the most sensitive cells in the CNS, due to their high metabolic 
activity. In vitro studies show that Ols are very sensitive to immune mediated and 
cellular mediated damage [268). 
Antibodies against Ols have been detected in the sera of MS patients [269, 270]. 
These antibodies have been detected in other neurological diseases and are thus 
non disease specific [270,271). Non specificity of CSF antibodies to MS disease and 
the lack of expression of MHC II expression on Ols suggest that Ols are not directly 
part of the presumed immune destruction [272]. Therefore, the role of these 
antibodies in causing damage to Ols is questionable [273,274]. 
The immune attack of MS can cause early Ols' damage via T lymphocyte activation, 
especially via activation of CD8 cells. Ols were induced to express MHC I and II in 
vitro [275], but in vivo they express only MHC I [272, 276]. Although Ols were not 
observed to express MHC II molecule in vivo, CD4 cells can affect Ols' survival via 
different mechanisms. The cytotoxic CD4 cells can stimulate other cytotoxic cells, 
such as microglia and/or macrophages. Ols also express receptor for TNF-a, which 
can be secreted from CD4 cells (275). TNF-a causes apoptosis of Ols in vivo and in 
vitro, but this effect needs high concentration and prolonged exposure [277]. 
Nevertheless, there is debate whether TNF has undesirable effects on Ols' survival 
and remyelination or not. 
T lymphocytes also colocalised with expression of heat shock protein. Heat shock 
protein is incorporated in an immunologic reaction at the edge of lesions of MS, 
which may playa role in early Ols damage. Expression of heat shock protein-65 was 
found to be significant in Ols at the lesion's border, and colocalised with 
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gamma/delta T lymphocytes. OLs at the nearby normal areas did not show 
expression of heat shock protein [278]. 
Interaction of microglia and OLs was reported at the active border of MS lesions, but 
not in NAWM or inside the lesion. The adhesion molecule VCAM-1 is expressed by 
microglia. These microglia that are positive for VCAM-1 were distributed in the areas 
of active lesions and may target OLs, because considerable numbers of these cells 
were surrounding OLs [279]. In addition, although OLs' number correlates negatively 
with macrophage numbers [179], cytotoxicity of macrophages against OLs was found 
to be limited in MS [280]. Furthermore, there was no significant correlation with T 
cells or with axon density [179]. 
A recent mechanism was also suggested to induce apoptosis of OLs in chronic active 
lesions, which may playa role in acute lesions. OLs' expression of cyclooxygenase 2 
(COX-2) was tested in MS and in experimental model of MS. COX-2 is an enzyme 
expressed by neurons that are susceptible to apoptosis. This enzyme is also 
expressed in OLs of chronic active lesions and in lesions of experimental model. OLs 
that express COX-2 were also found to express activated caspase 3, a marker of 
apoptosis [281]. 
The other proposed mechanism is that OLs may degenerate secondary to myelin 
loss. This is supported by the fact that OLs that fail to myelinate axons during 
development usually undergo apoptosis [194). But it is not certain whether this 
mechanism of OLs' damage is responsible for acute or chronic loss. 
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5.1.2 Response of oligodendrocytes to acute WM lesions 
There is debate about the fate of OLs in acute lesions of MS. Prineas and his 
colleagues argued that OLs are initially destroyed in active lesions, but then lesions 
are repopulated rapidly with new OLs [263, 282]. In comparison, Selmaj and 
colleagues reported preservation of OLs in acute lesions but then loss in chronic 
lesions [283]. Animal studies, however, support the first hypothesis. At day 14 post 
experimental contusion injury in rats, a dramatic increase in the formation of new OLs 
can be detected at the border of the lesion. In the spared regions there was increase 
in proliferation of NG2+ cells [226]. Timing of oligogenesis in animals is in agreement 
with timing of recovery from MS clinically (the recovery in the MS patient is usually 
within a few weeks) [226]. The importance of remyelination in protecting and 
restoring the conduction in axons has been confirmed previously in a viral model of 
MS [284]. In humans, remyelination is strongly believed to contribute, with other 
factors such as removal of oedema and inflammation, to recovery of patients' 
symptoms [43,57,66,285]. 
Examination of the lesion at early stages of plaque evolution shows OLs associated 
with remyelination [263, 286]. Remyelination is characterised by thin myelin sheaths 
and short internodes [287]. About 23% of lesions were found completely 
remyelinated, forming shadow plaques [249]. Shadow plaques were described as 
early as 1906 [288]. Until the employment of the electron microscope in examining 
lesions of MS, shadow plaques were thought to be partially demyelinated plaques 
[289]. In the brains of MS patients 19% of lesions were partially remyelinated [249] 
and about 40% of lesions have some degree of remyelination that occupies more 
than 10% of the lesion area [282]. Nevertheless, in chronic lesions presence of OLs 
and remyelination fall dramatically. This decline in OLs and remyelination may be 
responsible for deterioration of symptoms. 
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5.1.3 Fate of oligodendrocytes in chronic WM lesions 
In patients with disease duration that is more than 20 years, premyelinating Ols' 
numbers decline drastically [179, 236]. Although number of Ols reduces with 
progression of the disease, there are still considerable numbers of Ols in chronic 
lesions of MS [236, 237, 239]. 
Ols precursor cells' (04 positive) density in spinal cord chronic lesions can reach up 
to 35/mm2• A number of studies have demonstrated the presence of immature Ols in 
chronic MS lesions. These have been traced using 04 antibody [237], PDGF-a [245], 
and NG2 proteoglycan [244]. There was no difference in numbers of precursor cells 
between PPMS and SPMS [239]. A summary of previous publications that quantified 
Ols in chronic lesions of MS can be reviewed in Table 5.3. 
A study carried out on lesions from the periventricular WM illustrated that chronic MS 
lesions contain significant numbers of Ols' precursors. These cells were positive for 
04 but negative for mature Ols' markers. However, these cells were assumed to be 
quiescent (premyelinating), because there were no myelinated axons around them 
[237]. Premyelinating Ols are not normally found in the adult human brain, and are 
defined as cells with multiple processes that do not contact myelin intemodes and 
are positive for 04 [236, 237]. 
5.2 Aims and hypothesis 
The effect of spinal cord GM demyelination on the disease course is not yet 
established. When compared with poliomyelitis, which causes flaccid paralysis by 
destroying the motoneurons of the GM, MS causes predominantly spastic paralysis 
of the limbs, which supports to some degree that WM axonal pathology is the main 
cause of disability. Spinal cord pathology, including axonal loss and atrophy, was 
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found to correlate with disability better than brain pathology. Therefore, attempts to 
enhance remyelination of the WM in the spinal cord may produce better outcome. 
Ols' number and function are important for myelination and remyelination [236, 245]. 
The main aim from studying Ols in MS is to prevent their loss and/or promote their 
prOliferation and differentiation to protect axons. 
Ols in the WM are different from GM Ols by being in close proximity to axons. We 
have previous data about axonal loss in the spinal cord, but little data is available 
about Ols' pathology in the WM of the spinal cord. Both axons and Ols may affect 
each other. In this study, a comparison was made between Ols' numbers in the WM 
and the GM. Similar to the method used in the previous chapter, Ols were counted 
manually in selected fields from the CST and the PCP. Numbers of Ols were 
counted in the NAWM, demyelinated WM (DMWM) and the partially myelinated WM 
(PMWM). Numbers ofaxons were counted in the same areas of the same tracts in 
the next chapter. Ols numbers obtained in the CST and the PCP will be compared 
with number ofaxons in each field. 
5.3 Material and methods 
Except for the controls that were obtained from Nottingham, we used the same 
sample that has been used in Chapter 4. For this study, the same CA II-stained 
slides were used to count Ols in the WM. We have already analysed numbers of 
Ols in the GM. For the purpose of counting Ols in the WM of the spinal cord, we 
sampled two of the major descending and ascending tracts; the CST and the PCP. In 
all the digital slides, and using the NDP view and the digital pen, the boundaries of 
both the CST and the PCP were identified. 
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5.3.1 Sampling of the corticospinal and the posterior column pathways 
Again, an unbiased sampling protocol was used to select fields of interest from the 
CST and the PCP irrespective of myelin status. The area of the CST was selected by 
referring to previous descriptions [122, 124]. For objective description; it is the area 
that is located in the lateral funiculus and dorsal to a horizontal line drawn through 
the dorsal border of the GM commissure. While the dorsal funiculus contains purely 
axons from the PCP, the lateral funiculus contains, in addition to the CST, fibres from 
other tracts such as the spinocerebellar tract. Each side of the CST was represented 
by 5 fields. Therefore, each section was represented by 10 fields. The sampling 
protocol was carried out as described in Figure 5.1. From the PCP, 5 fields were 
selected from each side of the PCP; therefore, 10 fields were exported from each 
section as shown in Figure 5.2. Similar sampling protocols of the CST [124] and the 
PCP [122] have been previously used in literature. 
Similarly to the GM, the selected fields from the WM were exported as an image of 
the computer screen at magnification of 40X and screen resolution of 1024x768 (field 
surface area was 0.047 mm2). When the WM content was very small, like in lumbar 
cords, fields were exported with smaller surface areas at magnification of 63X 
(surface area was 0.0164 mm2). The majority of sections were exported at 40X 
magnification (95%). 
5.3.2 Oligodendrocyte counting 
Identification criteria of WM OLs are not different from the previously mentioned 
criteria of GM OLs in Chapters 3 and 4. We count OLs in the WM manually using the 
same method as previously described in Section 4.3.3. 
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Like in the GM, the myelin status of WM fields was identified retrospectively after 
counting Ols. The myelin status of each field was identified using the same method 
mentioned in Section 4.3.5. Fields were classified into DMWM, PMWM, and NAWM. 
5.3.3 Statistics 
Results were exported to SPSS analysis software. Student t-test was used for 
comparison of the mean. Both Bivariate correlation and partial correlation were used 
to study effects of age and disease duration. Multiple linear regression was used to 
study effects of age, disease duration, disease type, and myelin status on WM Ols 
density. 
5.4 Results 
From MS cases, about 58 WM lesions were examined (CST and PCP). From these, 
1206 fields were exported (DMWM n = 267, PMWM n = 222, and NAWM n = 717). 
Numbers of fields and their myelin status is summarised in Table 5.1. 
Appearance of CA II-stained Ols in the WM (interfascicular Ols) does not greatly 
differ from those in the GM. Ols appeared round to oval in shape with variable sizes 
and stain intensity. As in the GM, darker Ols in the WM tended to be smaller. In 
normal controls, distribution of WM Ols was not as homogeneous as in the GM. Ols 
were seen condensed at the entrance of the dorsal root. These Ols are believed to 
be type 4 Ols. It was also noticed that there was a higher number of Ols at the outer 
border of the WM (Figure 5.3). 
Inside the WM lesions, Ols appeared isolated with no evidence of myelin around 
them. At the lesion border, Ols were observed to be intensely stained with CA " and 
were associated with scattered myelinated axons. Intensity of staining of both Ols 
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and myelin at the lesion border appeared to be greater than in the NAWM and 
normal controls (Figure 5.4). 
T bl I ed fi Id f th hit tt a e5.1:Numbero analys Ie s rom ew ema er 
Type of the disease Myelin status of the field (first time) Number of CST Number of PCP fields fields 
Normal control Normal controls 120 88 
Demyelinated 49 62 
PPMS Partially myelinated 46 44 
Normally appearing areas 213 206 
Demyelinated 72 84 
SPMS Partially myelinated 68 64 
Normally appearing areas 136 162 
5.4.1 Quantification of oligodendrocytes in the WM 
In healthy controls the average density of Ols in the WM of the two tracts was 98 ± 
100/mm2. This does not differ from Ols' density in healthy GM. In MS, regardless of 
myelin status or type of the disease, the average density of Ols in the WM was 72 ± 
114/mm2. This was lower than the calculated density in WM of normal controls (p = 
0.001). In both MS and controls the density of Ols was greater in the CST compared 
to PCP. In the CST of controls the density was 116 ± 110/mm2 and in the PCP the 
density was 73 ± 78/mm2 (p = 0.01). Similarly, in MS Ols' density in the CST (mean 
79 ± 126/mm2) was greater than the PCP (65 ± 102lmm2) (p = 0.038). 
We also examined whether there was any variation in Ols' density among different 
cord segments. We found that the lower cord showed higher density of Ols 
compared to the upper cords in both controls and MS. One way ANOVA was used to 
examine for differences in Ols' density between the three main spinal cord levels. 
There was Significant difference among groups in controls (F (2-204) = 4.47, P = 
0.03) and in MS (F (2-1203) = 30.00, P < 0.001). In the previous chapter, we did not 
find a difference between GM Ol density between various cord levels. 
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5.4.2 Oligodendrocytes' density in the NAWM 
Analysis was further specified to include myelin status. The mean density of Ols in 
the NAWM of MS, including the two tracts, was found to be 104 ± 133/mm2, which 
does not differ from the density calculated from WM of controls (98/mm2). Within the 
MS group, Ols' density in NAWM was less than Ols' density in the NAGM, which 
was found to be 173 ± 161/mm2 in the previous chapter (p < .001). 
When the two disease types are compared, the mean density of Ols in the NAWM of 
SPMS was 69 ± 84/mm2, while in the PPMS, the density was 130 ± 155/mm2 (p = 
0.002). Note that in the previous chapter the GM showed opposing results, where the 
NAGM of SPMS showed greater density in contrast to the NAGM of PPMS. 
5.4.3 Oligodendrocytes' density in the PMWM 
Density of Ols in the PMWM of the whole MS sample was 45 ± 60/mm2. This 
number was significantly less than normal healthy controls and less than NAWM of 
MS (P < 0.001 for the two comparisons). Similar to the NAWM, which has less Ols' 
density than NAGM, the density in PMWM, was also less than PMGM areas (p value 
< 0.001). By comparing the PMWM in the two disease types, Ols' density in PPMS 
was 64 ± 69/mm2 compared to 31 ± 48/mm2 in SPMS (p < .001). 
5.4.4 Oligodendrocytes density in the DMWM 
The mean density of Ols in the DMWM was 7 ± 22/mm2• In comparison. Ols' 
density in the DMGM was 17 ± 39/mm2 (p = 0.016). There was no significant 
difference between PPMS and SPMS in the density of Ols in the DMWM. The 
density was 9.4 ± 27/mm2 in SPMS subjects and 4 ± 13/mm2 in PPMS subjects (p = 
0.602) (Figure 5.5). 
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5.4.5 Effects of age and disease duration on WM oligodendrocytes 
The effect of age on the WM OLs of controls was not significant in our sample 
(correlation = - 0.037, P value = 0.594), controlling for gender and cord level. In the 
MS sample, effect of disease duration was significant on the DMWM and NAWM 
regions, but not on partially myelinated areas. However, the correlation coefficient 
was too low for all the regions (Table 5.2). Similarly, results obtained from the GM 
showed significant effect of disease duration on the completely demyelinated areas. 
Table 5.2: correlation between WM oligodendrocytes and disease duration 
Myelin status of the Control Variables Disease duration in years field 
DMWM Gender & Level of the cord & 
Correlation .138 
type of the disease & Age 
SignifICance .027 
Gender & Level of the cord & Correlation .056 
PMWM type ofthe disease & Age 
Significance .418 
NAWM Gender & Level of the cord & 
Correlation .075 
type of the disease & Age 
Significance .047 
5.4.6 Difference between CST and PCP in oligodendrocytes density 
In MS cases, comparison was made between the two tracts based on the myelin 
status of the field. In NAWM, the mean density of OLs in the CST was 114 :t 
149/mm2 and in the PCP was 94 :t 116/mm2 (p value 0.041). In the partially 
myelinated fields, the density was 38 :t 50/mm2 in the CST and 51 :t 681mm2 in the 
PCP (p = 0.116). The demyelinated areas of the CST had a density of 13 :t 31/mm2 
while the demyelinated areas of the PCP had 2 :t 8/mm2 density of Ols (p vale 
<0.001). 
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5.5 Summary of results 
The average Ols' density in the WM of MS sample was less than normal controls. 
This reduction was due to loss of Ols in the DMWM with no difference between the 
NAWM and controls. 
Regional variation in Ols' density was found between CST and the PCP and 
between different cord levels. There was significantly greater density of Ols in the 
lower cord levels in both controls and MS. 
Unlike the GM, which showed greater density of Ols in the NAGM SPMS compared 
to PPMS, the NAWM showed greater density of Ols in PPMS compared to SPMS. 
However, there was greater density in the DMWM of SPMS compared to PPMS. but 
this was not statistically significant. 
5.6 Discussion 
This study is, to our knowledge, the first study that has investigated the difference in 
Ols' pathology in PPMS and SPMS in WM lesions of the spinal cord. The study also 
compared the GM and the WM using human spinal cord cross sections. We 
concluded from the results that Ols in the WM probably behave differently compared 
to GM Ols, where density of Ols in the NAWM and DMWM was less than NAGM 
and DMGM respectively. There is also variation in Ols' density between PPMS and 
SPMS; density of Ols was found to be greater in the NAWM and PMWM of PPMS 
compared to SPMS. The study has also demonstrated the presence of CA II positive 
Ols in chronic demyelinated WM lesions. 
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5.6.1 Variation between the grey matter and the white matter 
In Chapter 4, we discussed the possible explanation of having greater density of OLs 
in the NAGM compared to control GM. In this chapter, there was no significant 
difference between the NAWM and healthy WM. In conclusion, we found that there is 
a greater number of OLs in the GM compared to the WM of MS. In the entire sample, 
the three examined areas; NAGM, PMGM, and DMGM have higher density of OLs 
compared to NAWM, PMWM, and DMWM respectively. 
It is almost certain that the GM environment is different from that of the WM, or there 
are extra sources of OLs in the GM. The GM probably has an environment that it is 
more suitable for OLs' proliferation. It is well known that OLs' precursor cells are 
sensitive cells, and their proliferation is affected greatly by the surrounding 
environment. Proliferation of OLs is vigorously induced by PDGF, basic fibroblast 
growth factor 2 [290]. and insulin-like growth factor 1 [291]. In vitro studies 
demonstrated very sensitive precursor cells; adding fibroblast growth factor and 
PDGF to OLs' precursors caused marked increase in proliferation [292. 293]. 
Studying the degree of expression of these molecules may reveal differences 
between the GM and the WM. 
The WM also has elements that inhibit OLs growth or maturation. Myelin is a potent 
inhibitor for OLs differentiation [294]. An in vitro study reported that myelin taken from 
demyelinated lesions (experimental lesions) significantly impaired remyelination by 
arresting Ols' proliferation. Consequently. limited OLs' proliferation in MS lesions 
has been attributed to depletion of macrophages which are essential in cleaning 
myelin debris [294]. 
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Another factor that has been reported to affect Ols' survival is the presence of 
axons, which are more abundant in the WM. Abnormal axons may inhibit maturation 
of Ols. There is normally vital interaction between axons and Ols. The effect of 
axons on Ols is apparent in normal controls, where number of Ols is affected by 
density and diameters of surrounding axons [162, 167]. One Ol can myelinate up to 
50 small axons, but can myelinate smaller numbers of large axons [162]. In our 
study, Ols' density in the motor CST was found to be greater than the PCP in normal 
controls, which further supports the regional variation in Ols' density in the WM 
depending on axonal diameter (note that the diameter ofaxons in the CST is less 
than the PCP [295]). 
Axonal signals are believed to be the main regulator of Ols' survival, proliferation 
and differentiation [296]. One of the signaling molecules derived from axons is 
neuregulin 1 [297]. Neuregulin is secreted from neurons and some astrocytes. 
Neuregulin expression was found to be reduced dramatically in active and chronic 
lesions of MS [298]. In an animal model of MS, neuregulin was found to be a potent 
stimulator of remyelination [299]. Since previous studies showed that the surviving 
demyelinated axons in MS are usually dystrophic [236], and that the level of 
neuregulin is reduced, differentiation of Ols may be impaired in the WM more than 
GM. 
In addition, Ols in the WM are myelin maintaining cells. In the GM many Ols acquire 
perineuronal position and survive without essentially myelinating axons [160, 162]. 
Because we do not have neuronal tracts in the GM, axonal loss in the NAWM and 
DMWM may affect survival of Ols and further reduce their numbers. This may result 
in damage to Ols that lose their myelin processes. A previous study showed that 
numbers of demyelinated Ols, which are the mature Ols that lose contact with their 
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myelin internodes, reduce with chronological progression of the disease. They were 
found to be abundant in early lesions of MS (can reach up to 700/mm2) [238]. There 
are no previous data about the correlation between axonal and Ols loss in MS. In 
the next chapter, axonal density and numbers will be quantified in the CST and the 
PCP. It is important to notice that we found greater loss of Ols in the WM of SPMS 
compared to PPMS. This may be secondary to loss ofaxons in these areas which 
has been reported to be greater in SPMS [72]. 
On the other hand, following injury there is an inhibitory effect of non-myelinating Ols 
and myelin on CNS axonal growth. For example, Nogo-A, MAG, and Ols myelin 
glycoprotein have been demonstrated as axonal growth inhibitors of the mammalian 
CNS [300]. In a study on mice, administration of antibodies, monoclonal antibody IN-
1 generated against Nogo-A, has improved significantly regeneration and plasticity of 
the CNS [83]. Thus, Ols may have negative undesirable effects on axons, and as a 
result a vicious cycle of damage occurs to both elements. Therefore, future 
immunological studies should focus further on identifying the immunogenic 
characteristics of the WM and the GM. 
Another explanation is that the GM possesses extra sources of Ols' progenitors 
compared to the WM. The human spinal cord GM is nearer to the central canal, 
which contains significant numbers of precursor cells. These are the nestin positive 
cells that has been discussed in Chapter 4 [260] Nestin is a marker of early 
neuroepithelial cells that may give rise to neurons or glia [301]. An important 
characteristic of these cells is that they are migratory [160]. It is possible that nestin 
positive cells proliferate around the central canal and then migrate to the nearby GM 
following injury. Migration of these cells probably does not reach the WM, as animal 
studies showed that Ols do not usually migrate long distances to myelinate axons 
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[302]. In MS specifically, it was observed that brain lesions proximal to the ventricular 
zone have a greater number of Ols [244]. We have also mentioned in Chapter 4 the 
possible role of peri neuronal Ols in increasing numbers of GM Ols in response to 
injury. These cells are not present in the WM and may be responsible for the 
observed high numbers of Ols in the NAGM. 
5.6.2 Nature of CA II positive oligodendrocytes 
There is no previous study that has quantified Ols in MS using CA II stain. Most of 
the previous studies attempted to stain Ols progenitors using other markers, such as 
PDGF-a, NG2, A285, and 04. These markers do not stain all Ols lineage like CA II. 
In addition, some of these markers are not 100% specific for Ols progenitors. For 
example, A2B5 can be traced in some neurons and astrocytes and NG2 can be 
traced in microglia [277], while PDGF can be traced in some neurons [303, 304]. 
As we mentioned in Chapter 4, almost all the examined lesions were found to be 
chronic [138]. The present study revealed that the mean density of CA II positive Ols 
in chronic spinal cord WM lesions is 7/mm2 (0-147/mm2). Previous studies have 
examined the identity and role of Ols in chronically demyelinated WM lesions, and 
most of them found that these Ols are non-myelinating [236-239]. One study 
previously quantified Ols in chronic demyelinated lesions of the spinal cord and 
found that these cells are premyelinating or non myelinating [239]. Number of 
premyelinating Ols can reach up to 35/mm2 in the spinal cord and 34/mm2 in the 
brain WM lesions using 04 marker (04 positive and GalC negative cells) [237,239], 
and up to 40/mm2 in brain lesions using NG2 marker [236]. The number reduces 
tremendously to 0-2/mm2 for GalC positive cells [238]. GalC is the first marker to be 
expressed in differentiating Ols. Therefore, most researchers believe that these 
cells are quiescent and mainly represent premyelinating Ols that fail to mature to 
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myelinating Ols [237, 239]. Mature Ols that survived demyelination are frequent in 
early MS lesions but rare in chronic lesions, and become more restricted to the lesion 
border [238]. MOG positive Ols were also absent in silent lesions of MS [305). 
Consequently, it is possible that most of the CA II positive cells inside lesions are 
immature Ols. 
The maximum density of Ols in the demyelinated regions was 147/mm2 in the 
present study. A recent study showed that density of Ols in the inactive lesions of 
MS can reach up to 250/mm2 [179]. The mean duration of the disease in that study 
was 3 years, compared to 24 years in our study. A study carried out in 1994 counted 
Ols and degenerating Ols in chronic WM lesions of the brain. Density was O/mm2 
for Ols and 7/mm2 for degenerating Ols [306). The CA II marker used in our study 
possibly stains surviving and degenerating Ols. Other studies are also summarised 
in Table 5.3. 
In conclusion, CA II cells inside lesions are likely to be immature or quiescent cells. 
This is supported by the observation that presence of these cells was not associated 
with WM or GM remyelination. Future studies may double label CA /I stain with MOO 
or 04 to identify these cells. For example, CA II positive and MOG negative are most 
probably newly formed immature Ols, while CA II positive and MOG positive are 
mature Ols that have survived demyelination [238). 
In the lesion border, cellular composition is variable since the border may be active 
even in the chronic lesions. A previous study calculated the density of OLs in the 
lesion border of brain WM and found it to be 19 Olslmm2 and 14 degenerating 
OLslmm2 (sum = 331mm2). The mean density in the present study was 45/mm2. The 
lesion border may contain immature Ols or Ols that survived demyelination [238]. 
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The observed variability in Ol density between studies can be attributed to the 
following reasons; each study has different criteria of selection, different mean 
disease duration, and different markers used to trace Ols. In addition, acute lesions 
that affect early MS may produce a different pathological picture from acute lesions 
that affect chronic MS [306]. Numbers of Ols after any injury can be affected by the 
number of Ols in the area before injury, age of the patient, and proximity of the 
lesion to the ventricular zone [244]. 
6.6.3 Oligodendrocytes in chronic lesions and their role in remyelination 
A number of studies have shown that remyelination occurs mainly in the acute or 
relapsing remitting phases of MS, while progressive MS is associated with a much 
lesser degree of remyelination [179, 238, 282]. Effect of disease duration on Ols' 
number was found to be variable. It is generally accepted that there is Ols loss in 
MS lesions with disease progression [239]. In another study there was no Significant 
negative correlation [179], while in a subset of patients a positive correlation was 
found between remyelination and Ols density with time [307]. The present study has 
demonstrated very weak positive correlation coefficient between Ols' density in the 
NAWM and DMWM and disease duration, contrOlling for age, gender, cord level, 
post-mortem delay, and subtype of the disease. However, when the three areas are 
included in the analysis, MS showed significant negative correlation with disease 
duration. This may imply that the total number of Ols in MS is, in fact, decreasing. 
New OLs in the lesions of MS were found to be positive to CA II [263]. However, it is 
already established that remyelination in MS is inadequate in most of the patients, 
and chronic lesions frequently demonstrate little remyelination [239]. In this study, 
remyelination within chronic WM lesions of the spinal cord was not observed. CA II 
positive cells were seen isolated without evidence of surrounding myelin. In 
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comparison, EAE frequently shows complete recovery even with chronic disease 
[172, 173, 239, 308, 309]. It is not well known why remyelination fails in human 
nervous system or why the number of premyelinating Ols in chronic lesions of MS 
reduces with disease progression [238, 239]. 
Most studies have demonstrated what is claimed to be considerable numbers of Ols 
in chronic lesions of MS (Table 5.3). However, we do not have information about the 
importance of these numbers and their adequacy to produce effective remyelination. 
In normal circumstances one Ol can myelinate up to 50 axons, but in response to 
demyelination, one Ol may remyelinate a different number. Remyelination is 
characterised by shorter internodes compared to normal myelination; therefore, 
higher numbers of Ols may be needed for remyelination ofaxons. 
Moreover, enhancement of Ols' proliferation or transplanting Ols within chronic 
demyelinated lesions may not produce remyelination [248]. A number of studies 
showed that Ols in chronic lesions of MS were not able to remyelinate axons [236-
239, 245, 306]. Some researchers attributed limited remyelination in MS to failure of 
Ols' differentiation into mature myelinating Ols [236-239], while others suggest that 
axons are damaged and thus non receptive to being remyelinated [236]. Chronic 
lesions were found to be associated mainly with dystrophic axons with multiple 
swellings. Possibly, a combination of the two factors plays a role, in that a signal from 
dystrophic axons prevents maturation of Ols. 
However, another study proposed that axons are not the cause of failure of 
remyelination. The study assumed that failure of remyelination is due to lack of 
inflammation in chronic lesions, since inflammation is believed to be a strong 
stimulator of remyelination [248]. The relation between inflammation, remyelination, 
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and Ols' pathology is probably more complex, and seems to be variable between the 
GM and the WM. A study reported that recurrent inflammation may inhibit 
remyelination, which may explain why the GM undergoes a greater degree of 
remyelination [310]. On the opposite side, another experimental animal study 
reported increase in remyelination of the WM after experimental induction of 
inflammation [248]. Although previous studies demonstrated little inflammation of the 
brain GM compared to the WM [311], the spinal cord GM may behave differently. 
It has been also proposed that there are not enough precursor cells to produce Ols 
[255, 312]. A relatively recent animal study showed that prolonged treatment with 
glucocorticoids may inhibit proliferation and differentiation of Ols [313]. Another 
study reported interaction between astrocytes and Ols in the early stages of plaque 
development. Those Ols that interact with astrocytes were found to be immature and 
premyelinating. Astrocytes were therefore assumed to be partially responsible for 
failure of remyelination by causing apoptosis of Ols [314). 
Variability between studies in evaluation of remyelination degree may be due to 
misinterpretation of other pathologies, such as Wallerian degeneration or acute 
partially demyelinated lesions as remyelinated lesions. Homogenous lesion with 
reduced density ofaxons and thin irregular myelin is the light microscopy picture of 
the remyelinated plaque. Reduced density ofaxons with normal thickness of myelin 
is the picture of Wallerian degeneration, while reduced axons with hypercellular 
lesion is the picture of acute partially demyelinated lesion [287]. 
In conclusion, it seems that both Ols and remyelination decline in progressive MS. 
Consequently, the time window for remyelination enhancement may be limited to the 
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first 15-20 years of the disease, especially in the relapsing remitting phase of SPMS, 
after which remyelination and Ols' numbers fall dramatically [236]. 
Table 5.3: Studies that have quantified oligodendrocytes in chronic lesions of MS 
Materials and Mean Target cells and Study duration of Density of OLs Conclusion of the study methods disease the used Marker 
Ratio of density in Strong correlation 
lucchinetti Brain autopsies PlP, CNPase, anti DMWM to NAWM between remyelination 3 years and OLs density 1999 [179] and biopsies MOO range between Density of OLs in lesions 8% -79% 
of earlY MS is variable 
60% of chronic In lesions of earty MS, 
Ozawa 1994 PlP mRNA, DNA lesions showed OLs are preserved, but in 
[306] Brain autopsy 1-20 fragments density of Ols lesions develop later in 
<10/mm2 
MS, Ols are extensively 
destructed. 
Chronic Brain OLs in chronic lesions fail Wilswijk 1998 lesions (around 04, GalC 4-34/mm2 to differentiate into mature [237] 
ventricles) cells 
less than Premyelinating OLs are 
Chronic Brain 20 years Ols progenitors present in chronic lesions Chang 2002 lesions (post- duration and premyelinating 25/mm 2 of MS. Cause of [236] mortem ) and more Ols. PlP, MOO, remyelination failure is than 20 NG2 unreceptive axons 
years 
Spinal cords Negative correlation Wilswijk 2002 lesions from 16 23.9 years 04 and GaIC. 351mm 2 between age of lesion and [239] subjects 04 cells. 
1-3 OLsl100 Demonstrated the 
A2B5, GalC, and nuclei (ratio of presence of OLs 
Scolding 1998 8 post-mortem PDGF-alpha PDGF-a positive progenitors in the human brains and 12 years adult brain and lesions of [245] spinal cords targeting OLs cells to the total MS (Both acute lesions progenitors number of nuclei 
and chronic lesions) in the field) 
5.7 Conclusion 
This study provided data about numbers of Ols in the spinal cords of patients with 
chronic progressive MS. A CA II positive cell may be immature OL, OL progenitor, 
mature Ol or degenerating OL. There is a difference between GM and WM lesions in 
Ols'density. Further work should focus on identifying level of expression of certain 
molecules in the GM and the WM, such as PDGFR, insulin-like growth factor, and 
fibroblast growth factor 2. The study has further confirmed the presence of Ols in 
chronic lesions of MS. There was a difference in Ols pathologies among the two 
disease subtypes in the GM and the WM. For further understanding of this difference, 
double labelling of CA II positive Ols is essential, as CA II stains both mature and 
immature Ols. 
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Morphology 
Name 
Marker 
Potential 
Presence in 
normal adult 
brains 
Presence in 
MS lesions 
Notes 
I Pre-progenitors [288], precursors 
[160] or neural stem cells 
I Nestin, PDGF-a 
I Can give rise to neurons and glia 
[260]. 
Has been recently identify around 
the adult human central canal, 
near ependymal cells [260] 
Not identified in lesions of MS 
These stem cells express Nestin 
and sometimes PDGF-a and 
maintain same morphology. But 
researchers believe that once 
they express PDGF-a, they 
become committed to OLs cell 
lineage. These cells are migratory 
and proliferative [160, 288] 
Progenitors [288] 
A2B5, PDGF, NG2 
Can give rise to OLs and 
astrocytes in culture 
Small numbers of PDGF-a positive 
cells have been identified in human 
brains, in normal healthy controls 
and in MS lesions 12451. 
Small numbers has been identified 
in acU1e and chronic lesions [245]. 
These cells are bipolar or non-
processed. They are believed to be 
the most efficient remyelinating 
cells in animal models. exogenous 
transplant of these cells resulted in 
remyelination of cultures axons 
[245]. These cells are migratory 
and proliferative [288] 
Embryonic Pre-
Oligodendrocytes [288] or pro-
Oligodendrocytes. In adults 
CNS, thev are called NG2 
04, NG2, PDGF-a 
the 
NG2 positive cells have been 
identified in MS lesions and 
normally appearing areas. But 
their number is reduced in 
chronic lesions [244] 
These cells are proliferative 
but not migratory. Can 
differentiate in to OLs in 
culture. They are PDGF- a 
positive, but they are stellate in 
shape [244]. 
Immature or 
oligodendrocytes 
04, CNPase, GalC 
premyelinating 
These cells are committed to give 
myelinaling OLs [160] 
No evidence of their presence in 
adult human CNS in normal 
circumstances 
These cells have been identified 
consistently in chronic lesions of 
MS [236-239] 
Short life cells; undergo apoptosis if 
they don't myelinate [194]. They are 
neither migratory nor proliferative 
[315]. They Have been identified in 
chronic lesions of MS in the brain 
and the spinal cord , but they fail to 
mature further and myelinate axons 
and their number reduces with 
disease oroaression 1236 
Mature myelinating 
04, CNPase, GaIC, MBP, MAG,PLP, 
MOG 
Mature myelinating cells 
Heterogeneous in shape and size and 
distributed in the GM and the WM 
Few numbers of mature myelinating OLs 
have been identified in chronic lesions. 
More numbers of mature MOG positive 
OLs have been identified in acute lesions 
of MS [261, 287]). They mostly represent 
mature cells that survived demyelination 
[238] 
Postmitotic. Many believe that they have 
no role in remyelination. 
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Figure 5.1: The sampling protocol of the CST. In A, a horizontal line is drawn through the spinal cord section. The 
line touches the dorsal boundary of the GM commissure (line 1). A second horizontal line is drawn at the midway 
between line 1 and the dorsal boundary of the PCP (line 2). The third horizontal line is drawn in the mid-distance 
between the two previous lines (l ine 3). The most medial intersection of line 1 or 2 with the CST boundary is identified 
and a perpendicular line is demarcated (line 4). The most lateral intersection of line 1 or 2 with the GM boundary is 
identified and a perpendicular line is drawn (line 5). The sixth perpendicular line is drawn in the mid-distance between 
lines 4 and 5. In B, Five fields were then selected. 
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Figure 5.2: The sampling protocol of the PCP. In A, The first line is a horizontal line through the dorsal boundary of 
the GM commissure (line 1). The second line is parallel to the first one and lies in the mid-distance between the first 
line and the dorsal boundary of the PCP (line 2). The intersection of the second line and the DHs is identified (point 
3). The intersections of the second line and the PCP boundary are identified (point 4). The midpoint between the two 
intersections 3 and 4 is identified and a perpendicular line is drawn through that midpoint (line 5). In B. 5 fields were 
exported from each side as shown. 
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Figure 5.3 shows areas WIth aCOJmulabon of OLs (scale bar 3mm). DIStribution of OLs around the entrance of the 
dorsal nerve root in A (scale bar 0.5 mm). at the outer border of the WM 10 B (scale bar 0.5 mm), and in the nucleus 
proprius of the GM in C (scale bar 0 5 mm) 
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• 
Figure 5.4: Three MS images taken from the same subject and the fourth image from normal controls. In the DMWM, 
OLs appeared isolated without evidence of myelin around them (scale bar 90 IJm). Most of the previous studies have 
found that OLs within chronic WM lesions are not associated with myelin. At the lesion border (PMWM), OLs were 
associated with sparse but intensely stained myelin which may represent newly formed myelin as CA II is expressed 
intensely in myelinating OLs (scale bar 100 IJm). In the NAWM and healthy controls , OLs are widely spread in 
between lightly-stained myelinated axons (scale bar 100 IJm). 
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Figure 5.5: A bar chart showing OL density in normal controls and in the three examined areas in MS. The bars 
represent the mean OL density ± SEM. Significant differences of p values < 0.05 are indicated by one asterisk and p 
values of < 0.01 are indicated by two asterisks. 
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Chapter 6: Axonal loss in the spinal cords of PPMS and SPMS 
6.1 Introduction 
Axonal damage in MS has been recognised for many years, and was even reported 
when Charcot recognised the disease for the first time. Axonal loss is believed to be 
the cause of irreversible disability [316, 317], and has been correlated with disability 
better than other pathological or MRI findings [127, 318]. Axonal loss appears to be 
responsible for disability from the early stages of MS [243]. Two longitudinal MRS 
studies on the brain have shown that axonal damage correlates with disability in 
RRMS [319, 320]. Another longitudinal study has also reported that cumUlative 
axonal loss is responsible for worsening of symptoms in progressive MS [321]. 
Axonal loss can be assessed in vitro by post-mortem histopathology studies or in 
vivo by estimating levels of NAA expression using MRS. Reliability of NAA in 
reflecting axonal loss has been validated by a post-mortem study, where a significant 
correlation was found between axonal loss and levels of NAA [127]. 
6.1.1 Early axonal loss 
In EAE, the animal model of MS, axonal loss took place even before myelin loss 
[322]. A histopathology study has also reported significant axonal damage in the 
NAWM of a patient who died from acute MS [69]. Using proton MRS, significant 
decline in NAA detection was reported in the NAWM of the brain of early MS [243]. 
Acute axonal loss, labelled by Amyloid precursor protein (APP), was found to be 
extensive in the first year of disease evolution and reduces with time [323]. 
It is possible that early axonal loss is due to inflammation. Early in the plaque 
formation of MS, axonal loss accompanies demyelination and inflammation [324]. 
147 
Pathology of the spinal cord in progressive multiple sclerosis (primary progressive vs secondary progressive) 
Ferguson and colleagues have confirmed transection ofaxons within acute MS 
lesions. The numbers of severed axons, labelled by APP, which is a sensitive marker 
of axonal damage, correlated significantly with inflammation [324] and with disease 
activity [325]. In acute lesions of MS, there was a significantly greater number of 
acutely damaged axons compared to chronic lesions [326]. These data support the 
role of inflammation in inducing axonal damage inside acute lesions. 
On the other hand, a few other stUdies reported that axonal loss does not correlate 
with disease activity. A longitudinal MRI study followed 43 patients with RRMS for 
two years. The study assessed levels of NAA in the NAWM of the brain stem. The 
basal NAA detection was significantly less than controls. This continues to reduce 
during the follow up period with or without evidence of relapses [327]. In addition, 
NAA detection was significantly reduced in the cerebrum of MS patients in the early 
stages of the disease with low lesion load [328]. Similarly, a histopathologic study 
also revealed insignificant correlation between lesion load and axonal density [329]. 
Acute axonal loss can be induced by molecules released in the plaque [316] or that 
may diffuse outside the plaque to affect normally-appearing regions [242], such as 
Calpain or nitric oxide [316]. Adding CSF from patients with aggressive MS induced 
neuronal and axonal injury in culture, while CSF from patients with benign MS did not 
cause damage to the culture [330). Glutamate toxicity may also cause neuronal and 
axonal damage early in MS [331]. 
6.1.2 Chronic axonal loss 
Axonal loss continues to be a feature of chronic MS lesions and the NAWM. Both in 
vivo and in vitro studies have shown Significant axonal damage in chronic lesions. 
For example, NAA levels were reduced in the normal appearing areas by 30% and 
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42% in demyelinated areas [127]. Bjartmar and colleagues calculated axonal loss in 
the spinal cords of chronic MS patients (via MRS) and reported 68% loss ofaxons 
within the plaque [69]. Another MRS study reported 32% axonal loss in the cervical 
segment of chronic MS [332]. A post-mortem study assessed axonal density in the 
cervical cord and found a 41% fall in axonal density [318]. In chronic MS, a number 
of studies have observed axonal loss in the NAWM of the corpus callosum [242], the 
CST [122,318,329], and the PCP [122]. 
It has been hypothesised that loss ofaxons in chronic and inactive lesions may be 
secondary to loss of the myelinating Ols within the plaque area [179]. However, 
degree and timing of axonal loss secondary to Ols' loss is not clear and some 
believe that Ols are lost secondary to axonal pathology. 
long term effects of neuronal degeneration may also result in loss ofaxons within 
the plaque and in normally appearing areas. This may include Wallerian, retrograde 
or anterograde transynaptic degeneration. In addition, the recently established 
mitochondrial theory suggests that mitochondrial pathology may play a role in axonal 
degeneration [333]. The mitochondrial respiratory chain complex 4 activity was 
reduced in lesions of MS [334] (for review see Su et al 2009). 
6.1.3 Variation between PPMS and SPMS In axonal density 
It was shown in Chapter 2 that SPMS spinal cords have greater atrophy compared to 
PPMS, and both disease subtypes have less atrophy in the caudal parts of the spinal 
cord. The significant contribution of axonal loss in atrophy was revealed previously 
[318], which may explain why atrophy and axonal loss are the only parameters that 
correlate with disability [127, 318]. This leads to the conclusion that atrophy may 
exert its effect on disability primarily via axonal loss or myelin loss. However, axonal 
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loss in various levels of the spinal cord has not been examined separately in PPMS 
and SPMS. 
A study by Ganter in 1999 estimated axonal density and surface area of the spinal 
cord lateral column. The sample examined post-mortem spinal cord segments from 
C3 to T2. The segments were taken from MS subjects who lacked MS plaques at 
these levels. The CST surface area and axon density were significantly reduced in 
that study [318]. Only one study has examined for segmental variation in axonal 
pathology in MS spinal cords. However, the study did not differentiate between 
PPMS and SPMS. The study was carried out in 2004 and compared axonal loss 
between motor and sensory tracts in multiple levels of the spinal cord. There was 
significant decline in the CST area and axon density in all spinal levels. In 
comparison, the PCP showed reduction of the area and axons density only in the 
upper cord segments [122]. 
There are two previous pathological studies that compared axonal loss in PPMS and 
SPMS. The study by Bitsch in 2000 used brain biopsies from patients with MS and 
studied acute axonal loss by APP staining. The study demonstrated greater loss of 
axons in acute lesions of SPMS compared to PPMS [72]. 
The second study was carried out in our lab and analysed axonal loss in the CST of 
the cervical cord. Tallantyre et al (2009) differentiated between PPMS and SPMS 
and studied the axonal density and total number ofaxons in the CST. The total 
number ofaxons in the CST was found to be significantly reduced in the two disease 
subtypes compared to controls. In the demyelinated regions of the CST and 
compared to the NAWM, PPMS demonstrated more reduction of axonal density than 
SPMS [124]. 
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For this chapter, tissue from PPMS and SPMS spinal cords taken from multiple levels 
will be analysed. The possible difference between motor and sensory neuronal tracts 
will be addressed. In this study we also compared axonal loss in three different 
areas; DMWM, PMWM, and NAWM. 
6.1.4 Anatomy of the CST and the PCP 
In this study, two tracts have been sampled, which are the CST and the PCP. These 
are the main tracts of the motor and sensory systems. They are easily demarcated 
as the PCP is localised to the dorsal funiculus and the CST is localised to the lateral 
part of the spinal cord (lateral funiculus). 
The dorsal column-medlallemnlscal pathway 
The PCP or the dorsal column-medial lemniscal pathway is the main ascending tract 
of the spinal cord. It transmits mainly fine touch, conscious proprioception and 
vibration. Recently, the tract was found to have a role in visceral nociception [335]. 
PCP transection in cats causes marked dysmetria regardless of visual guidance of 
the limb [336]. In monkeys, transection of the PCP results in failure of discrimination 
of frequency and repetition of tactile stimuli [337]. In humans, ataxia can affect up to 
80% of MS patients during the disease course, which can be due to lesions of the 
PCP or the proprioceptive mechanisms [338]. 
The first order neuron of the tract is found in the dorsal root ganglion. It receives input 
from receptors in the skin or deep stretch receptors in the muscle spindles and jOint 
capsules. The tract ascends in the posterior funiculus of the spinal cord, where fibres 
from the lower body run medially in the gracile tract and fibres from the upper body 
run laterally in the cuneate tract. At the level of medulla oblongata, the two tracts 
synapse in nucleus gracilis and nucleus cuneatus [339]. However, only 25% of the 
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PCP axons reach the dorsal column nuclei in the medulla. Most of the axons, 
especially proprioceptive axons, leave the tract continuously to synapse in Clark's 
nucleus or nucleus proprius, which in turn continues as the spinocerebellar tract to 
mediate unconscious proprioception. The spinocerebellar tract continues ipsilaterally 
to synapse in the cerebellum. The second order neurons of the PCP run from the 
medulla oblongata and decussate to form the mediallemniscal pathway. The medial 
lemniscal pathway synapses in the thalamus. The third order neurons run from the 
thalamus and terminate in the primary sensory cortex to mediate conscious 
proprioception [339]. 
The corticospinal tract 
The CST fibres originate from lamina V of the cerebral cortex and the brain stem and 
have connections with rostral and frontal parts of the cerebral cortex. Fibres of the 
CST are not completely myelinated until the age of 2 years. Axons of the CST 
synapse in interneurons of the VH or in sensory neurons of the DH. The average 
number ofaxons in the CST is 1 million in each side [340] (Figure 6.1). In adults, 
about 70% of the axons are myelinated and the diameter for the majority ofaxons 
ranges between 1 !-1m and 4 !-1m [339]. 
6.2 Aims and hypothesis 
Maintaining axonal function seems to be crucial in determining disability in MS. The 
mechanism of axonal damage is not well understood. Patients with PPMS and SPMS 
have variable clinical course, but there are not enough data to suggest a different 
pattern of axonal loss that may explain this variation in clinical course. On the other 
hand, it is important to determine if accumulative axonal loss is mainly due to 
inflammation, and thus affected by relapses, or due to other degenerative processes. 
Studying axonal loss in various regions of the eNS in both ascending and 
152 
Chapter 6: Axonal loss in the spinal cords of PPMS and SPMS 
descending tracts may help in understanding the mechanism of damage. Especially 
because segmental difference in axonal loss between ascending and descending 
tracts of the spinal cord has been reported previously [122]. Axons are relatively 
spared in MS lesions when compared with loss of other elements such as myelin and 
Ols, but there is no previous study that quantified Ols: axon ratio. 
In this study, axons will be counted in the CST and the PCP in multiple levels of the 
spinal cord. The study will differentiate the extent of axonal loss between PPMS and 
SPMS. The same sampling protocols of the CST and the PCP that have been used 
in Chapter 5 will be used in this chapter. Therefore, results of Ols numbers obtained 
in the previous chapter will be used to calculate Ols: axons ratio. 
6.3 Material and methods 
We used formalin-fixed paraffin-embedded sections from the same sample as in 
Chapter 5. Sources of tissue include the MS Society tissue bank (PPMS n = 13, 
SPMS n = 15, controls n =5) and Oxford Radcliffe NHS Trust (controls n = 6). 
Dissection and initial preparation is mentioned in Sections 2.5.1 and 2.5.3. As we 
have already mentioned, 10 sections were cut at 5 ~ m m thickness from each block. 
We have already selected one section for MBP staining to study atrophy and 
demyelination in Chapter 2 and another section for CA II staining to study Ols in the 
GM and the WM in Chapters 4 and 5. In this study, another section was selected to 
trace axons in the WM by using anti-neurofilament (NE14). This will be used to count 
axons in the CST and the PCP. (Neurofilament 200 KD, NE14, and dilution 1 :20,000, 
Chemicon). Four controls from the Oxford tissue were excluded due to inadequate 
staining (subjects 8272,8458,83269, and 83313 in Tables 2.1 and 2.2). 
153 
Pathology of the spinal cord in progressive muHiple sclerosis (primary progressive vs secondary progressive) 
The NE14-stained slides were numbered so that the observer is blinded to the 
disease subtype. Slides were then converted to digital slides using the NDP.view 
Hamamatsu and viewed on the computer screen as previously described. 
6.3.1 Sampling the CST and the PCP 
The GM and WM boundaries were demarcated on NE14-stained slides. Then areas 
of the PCP and the CST were also identified as in the previous chapter. The surface 
areas of the CST and the PCP were measured. 
We have already established a protocol to sample the CST and the PCP to quantify 
Ols. In this study we have applied the same sampling protocol on NE14 sections to 
quantify axons in the same fields. This enabled us to sample the same anatomical 
areas in two differently stained sections. 10 fields of interest were analysed from 
each side of the section (10 CST and 10 PCP). For sampling protocols of the CST 
and the PCP refer to Figures 5.1 and 5.2. Similarly, the majority of fields were 
exported as an image of the computer screen at magnification of 40X and a 
resolution of 1024x768 (each fields surface area was 0.047). 
6.3.2 Axonal counting 
All fields of interest were examined by the imageJ software. Since numbers ofaxons 
are much higher than Ols numbers, manual counting ofaxons is very time 
consuming. Therefore, an automatic counting protocol was established. With imageJ 
software, some features of the image can be adjusted to optimise and validate 
automatic counting (Figure 6.2). We validated the automatic counting protocol by 
comparing it with manual counting. Twenty fields were selected and manual counting 
was applied. Initially, intraobserver reproducibility of the manual counting in two 
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occasions was calculated and demonstrated a Pearson correlation of 0.951 and a p 
value < 0.001. 
Several attempts were carried out to adjust the image threshold to produce the 
strongest correlation between automatic counting and manual counting. The best 
significant correlation achieved compared to manual counting was; Pearson 
correlation r = 0.882, p value < 0.001. The threshold value that was associated with 
best correlation was recorded in a "plug in". The plug in is a written programme, 
which can automatically perform the previous steps as shown in Figure 6.2. 
6.3.3 Calculating total number ofaxons in the CST and PCP 
The mean density ofaxons in the 10 fields that were exported from the CST of each 
subject was multiplied by the CST areas of that subject. Similarly, the total number of 
axons in the PCP was calculated. 
6.3.4 Identifying myelin status of each field 
After counting axons, the myelin status of each field was identified using the method 
mentioned in Section 4.3.7. Then fields were categorised according to the myelin 
status into NAWM, PMWM, and DMWM and the mean density ofaxons in each 
areas was estimated. 
6.3.5 Ratio of ollgodendrocytes to axons 
We have previously applied the sampling protocol of the CST and the PCP on the CA 
II stained sections. Numbers of OLs obtained from each field were compared with 
numbers ofaxons in the corresponding field. The obtained ratio of OLs to axons was 
calculated in the three differently myelinated areas and a comparison was made 
between PPMS and SPMS. 
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6.3.6 Statistics 
The field number, myelin status and axonal count were exported to SPSS. The 
student t-test was used to compare the means. Pearson correlation was used to test 
correlations. Controlling for the independent factors, partial correlation was used to 
look for correlation between disease duration and axonal density. Linear regression 
was also used to examine the effects of independent factors such as age, gender, 
disease duration, cord level, and disease subtypes, on axons density in the three 
differently myelinated areas. 
6.4 Results 
In total, we exported 713 fields from the CST and 721 fields from the PCP. Similar to 
the CA II stain, the NE14-stained sections do not show areas of altered myelin 
composition. Therefore, areas of abnormal myelination were identified using the MBP 
stain (Figure 6.3). The numbers of analysed fields according to disease type and 
myelin status are summarised in Table 6.1. 
1 S fth Table 6. : ummary 0 e examined fields for axonal analYSis 
Number of Number of 
Type of the disease Myelin status of the field examined examined 
fields PCP fields CST 
Nonnal control Normal 99 105 
PPMS Oemyelinated 54 45 
Partially myelinated 42 41 
Nonnally appearing from MS 208 224 
SPMS Oemyelinated 84 69 
Partially myelinated 64 97 
Normally appearing from MS 170 132 
6.4.1 Quantification ofaxons in the CST and the PCP in healthy controls 
The surface area of the CST and the PCP varied between different cord levels, which 
seem to be affected by the amount ofaxons that enter or leave the tract. The CST 
surface area is largest in the lower cervical segment and smallest in the upper 
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lumbar segment. The PCP area is largest in the lower cervical region and smallest at 
the thoracic segments (Table 6.2). 
The mean density ofaxons in the CST was 3.9x104/mm2 and was higher than that in 
the PCP, which was 2.9x104/ mm2 (p value < .001, irrespective of cord level). Total 
numbers ofaxons in the CST and the PCP were highest in the lower cervical cord, 
and were 0.7 x106 and 0.4x106 respectively. Controlling for age and gender, the main 
cord level has a tendency to affect the total number ofaxons in the CST (p = 0.061) 
but not the PCP (p = 0.843). 
6.4.2 Quantification ofaxons in MS irrespective of myelin status 
The CST surface area in MS was smaller compared to normal controls in various 
levels. This reduction was significant in the upper cervical, lower cervical and lower 
lumbar (Table 6.2 and Figure 6.4). In comparison, the area occupied by the PCP did 
not differ from controls at any cord level. 
In the two examined tracts, there was significant reduction in the density ofaxons, 
compared to the corresponding area in healthy controls. The mean axons' density in 
the CST of MS was 2x104/ mm2 (compared to controls 3.9x104/mm2, p < 0.001) and 
in the PCP was 2.4x104/ mm2 (compared to controls 2.9x104/mm2, p = 0.003). From 
the data above, it appears that there is greater reduction ofaxons in the CST (Figure 
6.4). 
When different cord segments were examined, it appeared that axonal pathology in 
the CST affected all levels almost to the same degree. In comparison, axonal loss in 
the PCP demonstrated less reduction in axonal density, especially at the lower cord 
segments (Table 6.2). 
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Since we have reductions in the axonal density and the surface area, the total 
number ofaxons also demonstrated significant reduction. The average total number 
ofaxons in all spinal cord levels in the CST of controls was 0.3x106 and in MS was 
0.1x106 (p <0.001). In the PCP the mean total number was 0.2x106 in controls and 
0.2x106 in MS (p = 0.211). The total number ofaxons is best assessed when the 
segment level is considered. Compared to controls, this reduction was significant in 
the upper cervical, lower cervical, and lower lumbar segments of the CST, while the 
total number ofaxons in the PCP was not different from controls in all segments. 
Detailed results are mentioned in Table 6.2. 
Table 6.2: ompanson en an con ros C betwe MS d t I 
Density of axons Surface area Total number of 
Location Segment Sample type <mm2) axons 
ofWM category axons/m Percentage 2 P Value P value P 
m of reduction 
Upper Control n = 2 29939 15.36 455947 
cervical MS n =11 
43% .000 .005 .021 
17095 8.39 152096 
Lower Control n = 2 36721 17.45 760383 
cervical MSn=6 
57% .000 .008 <.0001 
15654 7.17 117786 
Control n = 1 23816 5.42 129081 CST thoracic 22% .303 .758 .846 MS n=9 18521 6.11 115454 
Upper Control n = 2 38205 3.40 134962 
lumbar MS n = 10 
39% .000 .527 .541 
23496 4.25 99093 
Lower Control n = 4 48950 5.47 264256 
lumbar 49% .000 .001 .015 MS n= 7 25002 2.50 64947 
Upper Control n = 2 22719 14.50 306164 
cervical 27% .038 .256 .195 MS n =11 16684 8.22 134569 
Lower Control n = 2 23728 16.40 411491 
.074 
cervical 42% .000 .254 MS n=6 13813 12.72 194884 
pCP Control n = 1 26206 5.48 143611 
thoracic 14% .381 .159 .494 
MSn=9 22436 8.77 185415 
Upper Control n = 2 39190 12% .349 7.74 .339 277042 .486 lumbar MS n = 10 34355 9.81 369080 
Lower Control n = 4 29025 00% .163 9.01 .133 251609 .706 lumbar MS n=7 34329 5.85 215588 
6.4.3 Pathology ofaxons in the DMWM 
The mean density ofaxons in the DMWM of the spinal cord of global MS sample was 
1.9X104/mm2. This was significantly less than normal controls (p < 0.001) and NAWM 
(p < 0.001). The two tracts did not show a difference in axonal density of the 
demyelinated areas. The mean axonal densities in the DMWM of the CST and the 
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PCP were 2x104/mm2 and 1.9X4/mm2 respectively (p value 0.642). Density ofaxons 
in the DMWM of the two tracts showed significant reduction compared to the 
corresponding area of controls (p < 0.001 for the two comparisons) 
By categorising results according to the disease subtype, there was no difference 
between PPMS and SPMS in the average axonal density in the DMWM of the two 
tracts (SPMS 1.8x104, PPMS 2.1x104, p = 0.234). In PPMS there was 38% reduction 
in the axonal density compared to normal controls and 22% compared to the nearby 
NAWM. In SPMS there was 47% reduction compared to normal controls and 14% 
compared to NAWM (Figures 6.5 and 5.6) 
6.4.4 Axonal density in the PMWM 
The average density ofaxons in the PMWM of the two tracts was 1.6x104 (compared 
to controls 3.4x104, p < 0.001). The PMWM has axonal density of 1.2x104 in the CST 
and 2.1x104 in the PCP (compared to controls, p value was < 0.001 for the two 
tracts). Details are mentioned in Table 6.3 and Figures 6.5 and 6.6. 
Compared to controls, there was reduction in axonal density in the PMWM of SPMS 
in the CST (p <0.001) and the PCP (p =0.001). Similarly, in PPMS, the PMWM has 
reduced axonal density compared to controls in the CST (p < 0.001) and the PCP (p 
= 0.015). 
6.4.5 Axonal density in the NAWM in MS 
The NAWM of MS showed significant reduction in axonal density compared to 
controls. Regardless of the type of the tract, the average density ofaxons in control 
spinal cords was 3.4x104 and in NAWM of MS was 2.4x104 (p < 0.001). When the 
two tracts were compared to each other, there was significant difference in axons' 
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density in the NAWM of CST (2.2x10") compared to the PCP (2.6x10") (p = 0.002). 
When the densities ofaxons in NAWM of the two tracts were compared with controls 
separately, the CST showed significant reduction compared to controls (CST axonal 
density in controls was 3.9x10", p < 0.001), while there was no difference between 
the NAWM of PCP in MS and the PCP of controls (PCP axonal density in controls 
was 2.9x104, p = 0.141). We calculated previously that axonal density in the PCP of 
MS was reduced compared to controls when the DMWM and the PMWM were 
included in the sample. This implies that reduction ofaxons in the PCP is due to 
demyelinating lesions, whereas axons of the NAWM seem to be preserved. In the 
CST reduction affected the DMWM and the NAWM (Figures 6.5 and 6.6). 
Table ~ . 3 : : Comparison between PPMS and SPMS in axonal density in the PMWM and DMWM in the cervical cord. 
Myelin status of the field Location 
Type of the Axonal density in the field P value 
ofWM disease 
PPMS 2.Ox10" 
CST SPMS 2.0x10" 
0.868 
Demyelinated 
PPMS 2.2x10" 
PCP 
1.7x10" 
0.050 
SPMS 
PPMS 1.9x10" 
CST 
O.8x10" 
0.017 
SPMS 
Partially myelinated 
PPMS 2.2x1 0" 
PCP 
2.0x10" 
0.574 
SPMS 
PPMS 2.6x19" CST 
1.6x10" 
<0.001 
SPMS 
Normally appearing from MS 
PPMS 2.7x10" PCP 
2.4x10" 
0.156 
SPMS 
Regardless of the cord level and type of the tract, the mean axonal density in the 
NAWM of SPMS was 2.1x104 and in PPMS was 2.7x10" (p < 0.001). In both disease 
subtypes, axonal density was reduced compared to controls (p < 0.001 for the two 
comparisons). When the two tracts are examined separately, the density in the 
NAWM of CST of PPMS was 2.6x104 and in SPMS was 1.6x10" (p < .001). The 
mean axonal density in the NAWM of PCP of PPMS is 2. 7x1 04 and in SPMS is 
2.5x104 (P = 0.16). It is important to note that there was no apparent axonal loss in 
the NAWM of ascending tracts compared to descending tract (Table 6.3). 
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6.4.6 Ratio of oligodendrocytes to axons in cross sections 
As we have already demonstrated, axonal loss includes the lesion centre, the lesion 
border of the two tracts and the surrounding NAWM of the CST. The OLs: axons ratio 
may give an idea of the degree of loss of each element in the lesion and around the 
lesion. 
In controls, the ratio of OLs to axons was 0.6% (in the CST was 0.72% and in the 
PCP was 0.41%). In MS, the ratio varies according to myelin status of the fields. In 
the NAWM, the ratio was 0.6% (in the CST was 0.6% and in the PCP was 0.56%). 
Results of OLs to axons ratio obtained from the NAWM of the CST and the PCP 
were similar to those from normal controls. This may indicate that in NAWM, axons 
and OLs are affected to the same degree (Table 6.4). 
However, in the PMWM and the DMWM, Ols' loss seems to be more extensive 
relative to axonal damage. In the PMWM, the ratio was 0.39% (0.48% in the CST 
and 0.29% in the PCP). In the DMWM, the ratio was 0.06% (0.1 % in the CST and 
0.02% in the PCP). By comparing the two disease subtypes, there was no significant 
difference between OLs to axons ratio in the NAWM and the PMWM. However, the 
comparison was significant in the DMWM where SPMS has considerably higher OLs: 
axons ratio (Table 6.4). 
Table 6 4' ratio of OLs to axons in SPMS and PPMS ..
Myelin status of the field Type of the disease OLs:Axons % P value 
Demyelinated PPMS .0252 
.012 SPMS .0740 
Partially myelinated PPMS .4660 
.161 SPMS .3484 
Normally appearing from PPMS .5721 
MS SPMS .6103 .660 
6.4.7 Effect of independent factors 
Effects of independent factors, such as disease duration, gender, type of disease, 
and myelin status, on axonal density was assessed by linear regression. There was 
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significant effect of gender (males were more affected, p = 0.002), type of the 
disease (p <0.001), and myelin status (p < 0.001) on axons' density. There was no 
significant effect of disease duration on the global sample, controlling for other 
factors (p = 0.166). 
However, when correlation between disease duration and axonal density was 
compared in each differently myelinated area, results varied according to the area 
examined. Partial correlation controlling for age, gender, disease subtype, type of the 
examined tract, and cord level, was used to study effects of disease duration on 
axons. Controlling for the previous factors, the correlation was only significant in the 
NAWM (correlation = -0.217, P = <.001). There was no relation between disease 
duration and axonal loss in the areas of complete demyelination (correlation = 0.002, 
P = 0.969) and areas of partial myelination (correlation = 0.72, P = 0.267). This may 
implicate that axonal injury within the lesion is an early process, while axonal loss in 
normal areas is more progressive. 
Correlation of disease duration with total number ofaxons was calculated in each 
tract controlling for age, gender, disease subtype, and cord level. Results showed 
significant negative correlation with the CST (correlation = -0.0437, P = 0.006) and 
with the PCP (correlation = -0.487, P = 0.002). 
6.5 Discussion 
The present study quantified axons in controls and progressive MS. We have noticed 
variation in the CSA of the CST and the PCP according to the level of the cord. A 
Significant number of descending axons leave the CST at the cervical cord to supply 
the upper limbs. This results in reduction of the CSA of the CST caudally. With 
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regard to the PCP, a significant number of ascending axons from the upper limbs 
enter the cervical spinal cord resulting in increase in CSA of the PCP rostrally. 
There was also significant effect of cord level on the total number ofaxons in the 
CST, but not the PCP. It is important to mention that considerable number ofaxons 
in the CST run long distance in the tract and leave at certain segments. The majority 
ofaxons of the PCP leave the tract after a few segments. Therefore, axons continue 
entering the PCP from peripheral nerves and leaving the PCP to synapse in the 
nucleus proprius or Clark's nucleus. This may explain the insignificant effect of cord 
level on the total number of PCP axons. In normal controls, density ofaxons was 
greater in the CST compared to PCP, which is probably due to smaller axons in the 
CST compared to the PCP [295]. 
In MS, initially we estimated the CSA of the tracts and the average density ofaxons 
irrespective of myelination status. There was significant reduction in the CST area 
compared to controls in more than one level of the CST. In comparison, in spite of 
significant demyelination affecting the PCP, there was no significant reduction in its 
CSA at any of the examined cord levels. A previous study has demonstrated similar 
results; Deluca et al 2004 examined 55 cases of progressive MS and 32 controls and 
found that atrophy of the CST was more extensive than PCP [122]. This may be 
explained by the greater reduction ofaxons in the CST calculated in this study. The 
significant contribution of chronic axonal loss in causing spinal cord atrophy has been 
confirmed previously in EAE [341]. Both tracts have axonal loss compared to the 
corresponding area of controls, but we found that the CST appeared to have greater 
reduction ofaxons compared to the reduction that affected the PCP. In addition, 
axonal loss in the CST was observed in all segments of the cord, which can be the 
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leading cause of atrophy that affected the CST in multiple segments. These findings 
may explain the predominance of motor symptoms over sensory symptoms in MS. 
6.5.1 Axonal loss in the demyelinated lesions 
Axonal density was reduced in the DMWM compared to controls and the NAWM in 
the two tracts. There was no difference between axonal densities in the DMWM 
between the two tracts, suggesting similar local destructive process. There was 43% 
reduction in axonal density in the DMWM compared to normal controls. It is possible 
that the main bulk of this axonal loss in DMWM of chronic lesions occurred early 
during the evolution of the plaque. This is because MRI [243] and histopathology [69, 
324] studies showed significant axonal loss in early MS and acute MS. In addition, 
the correlation between axons' density in the DMWM and disease duration was 
inSignificant in this study, suggesting that local loss ofaxons in MS lesions is 
independent of chronological progression of the disease and may depend mainly on 
acute destructive event. In the early stages of MS, local axonal damage appeared to 
correlate with inflammation. Acute axonal loss was found to be significant in early MS 
lesions by tracing APP [324, 326]. On the other hand, acute loss ofaxons within 
chronic plaques was found to be limited compared to acute plaques [324, 326). 
So far, the longstanding effect of acute axonal loss or dysfunction within MS lesions 
is unknown. A 6-year longitudinal MRI study on a single patient with RRMS showed 
significant correlation between changes in NAA expression and a major relapse that 
was followed by recovery (319). Therefore, changes in NAA reflect axonal function 
rather than axonal loss. This is because there is frequently complete clinical recovery 
after the attack, and there is also histopathological recovery of the lesion by 
remyelination, ie fate of acutely damaged axons is unclear. 
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6.5.2 Axonal density in the PMWM 
When we moved from the lesion centre, data from the lesion border showed variable 
results. A previous study also showed variable axonal densities at the MS lesion 
border [324]. We had also variable results from counting OLs in the partially 
demyelinated areas and the lesion border. It is important to acknowledge that the 
included partially myelinated areas in this study depend mainly on the MBP stained 
section viewed under light microscopy, therefore the nature of this partial 
demyelination is unknown. These areas may represent partially myelinated areas, 
partially remyelinated areas or areas of Wallerian degeneration. Although most 
lesions in our study have been confirmed previously to be chronic [124], the level of 
lesion activity at the border may vary even in chronic lesions. Therefore, variability of 
results at the lesion border and the partially myelinated areas may be due to different 
degrees of inflammation or activity. 
6.5.3 Axonal density in the NAWM 
The present study illustrated further that loss ofaxons is not only restricted to the 
injured area but extends to affect NAWM. Axonal loss continues to be an important 
feature of progressive MS in the NAWM [242]. A post-mortem human histopathology 
study also demonstrated axon loss in the NAWM of the cervical segment [342]. It is 
believed that axonal loss in the NAWM is quite an early process. Bjartmar and 
colleagues has observed axonal loss in the NAWM of a patient who died within 8 
months from disease onset (case study) [69]. They estimated 22% reduction in 
axonal density in the NAWM of the descending tract of the MS spinal cord. In 
comparison, the present study showed 42% reduction in axonal density of the NAWM 
of the descending tract in the cervical level. These data imply that axonal loss in the 
NAWM is an early and progressive process. Interestingly, we calculated significant 
correlation between axonal loss in NAWM and disease duration. This may explain 
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the rise in axonal loss from 22% (in the NAWM of a patient with disease duration of 8 
months) to 42% (in the NAWM of progressive MS with mean disease duration of 24 
years in this study). Bjartmar and his colleagues did not find reduction in axonal 
density in the ascending tract of the cervical spinal cord in that case report of acute 
MS. In this study there was 29% reduction in axonal density of the NAWM of the PCP 
at the cervical segment (there was no difference when all levels are included). 
Axonal loss of the NAWM can be due to effects of Wallerian degeneration. There are 
two pieces of evidence to suggest this hypothesis: firstly, there is greater loss of 
axons in the NAWM of descending tracts compared to ascending tracts. This has 
been reported previously in chronic MS [122] and acute MS [69]. Secondly, an 
interesting finding in Bjartmar case study of acute MS is that there were myelin 
sheaths in the NAWM with no axons inside [69], which is the histopathological picture 
of Wallerian degeneration. Likewise, the NAWM areas in the present study are areas 
with apparently normal myelin sheaths, but we do not have evidence that any axons 
are contained in these myelin sheaths. 
Another assumption is that MS is primarily an axonal disease and that demyelination 
does not have great effect on axonal survival [326]. It has previously been 
demonstrated that axonal loss in the NAWM of MS affects mainly the small diameter 
axons. Three studies suggested selective loss of small axons in MS in the CST [122, 
318, 342] and one in the PCP [122]. Studies on healthy controls reported that density 
ofaxons is normally reduced with age progression. In addition, axonal loss that 
occurs as part of the normal degenerative aging process was found also to be 
selective for small myelinated axons [343]. In the present study, comparison 
between the NAWM of MS and the normal WM from healthy subjects was controlled 
for age, gender, disease duration, and cord level. This means that the presumed 
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loss of small axons is more prominent in MS compared to the age- matched healthy 
controls. However, it is not certain if axonal loss in NAWM of MS is only acceleration 
of normal aging degenerative process or due to a mechanism that is peculiar to MS. 
Conversely, another hypothesis says that there is no selective axonal loss in MS but 
the surviving axons undergo swelling [124]. 
6.5.4 Variation between the two tracts 
The previous data suggests that demyelination results in similar local pathology 
within the lesion itself between the two tracts, but the following effects of neuronal 
degeneration in the NAWM may vary between the ascending sensory and the 
descending motor tracts. 
Loss ofaxons in the NAWM of CST affected all levels from the cervical cord to the 
lumbar cord in spite of less demyelination in the lower cord regions. In contrast, the 
ascending PCP was only affected in the upper cord area. This is in agreement with 
Deluca et al (2004) findings. It was shown that reduction of axonal density in MS 
affects the CST in all levels but affects only the upper levels of the PCP. There are 
three possible reasons that may explain these findings: 
Variation In the tracts' anatomy 
A significant number ofaxons in the CST of the lower segments run through the 
whole length of the spinal cord. Long axons within the CST are vulnerable to 
demyelinating lesions along their course. This can be supported by the fact that lower 
limbs are more affected by paraplegia than upper limbs. 
In comparison, axons of the PCP start peripherally and enter the spinal cord dorsally. 
Most axons of the PCP ascend a few segments then leave the tract to synapse in the 
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Clark's nucleus. If a demyelinating lesion affects the upper cervical segment, this will 
likely affect the upper limb sensation, which is a notable finding in MS and has been 
discussed before [122]. This is because a significant number of PCP axons that 
come from the lower limbs already gave sensory information to the Clark's nucleus. 
Variation in type and timing of neuronal degeneration between sensory and motor 
tracts 
In the introduction, I discussed the normal response of the human CNS to injury, and 
emphasised that Wallerian degeneration can be faster than retrograde degeneration. 
In addition, timing of retrograde degeneration depends on the proximity of the lesion 
to the cell body, being slow in lesions far from the neuronal cell body [344]. 
Consequently, the abundant cervical lesions will cause Wallerian degeneration of 
distal part of the CST axons in the thoracic or lumbar cord. Alternatively, similar 
lesions in the upper cervical segment in the PCP will presumably cause Wallerian 
degeneration proximally in the brain, and much slower retrograde degeneration 
distally in the lower cord. Because of the rarity of lesions in the caudal segments of 
the cord, Wallerian degeneration of the NAWM of ascending tracts will be limited. 
One can expect that, in response to a lesion in the cervical cord, pseudounipolar 
cells in the dorsal root ganglion of the cervical cord will degenerate faster than those 
in the lumbar region. Such degeneration may cause axonal loss in the nearer NAWM 
and may explain our finding that there was 29% loss ofaxons in the NAWM of the 
PCP in the cervical cord only and not in the rest of the cord. 
In order to test this assumption, I conducted a quick comparison in the NAWM 
between the cervical and the lumbar cord in each individual. Individuals with a lower 
density ofaxons in the NAWM of CST in the cervical cord tend to have lower density 
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in the lumbar cord. This was not the case in the PCP, which showed apparent 
disagreement (Figure 6.7). 
Different axonal sizes in the two tracts 
The presumed selective axonal loss in MS, by causing damage to small axons less 
than 3.3 IJm [342]. may result in variation between the two tracts. This is because the 
PCP has mainly large heavily myelinated fibres of 10 IJm and more [345. 346]. Most 
axons of the PCP are large diameter axons of the A alpha A beta fibres [347]. In 
comparison. 90% of CST axons are 1-4 IJm in diameter [295, 348] making the CST 
axons susceptible to the hypothesised selective axonal loss. 
6.5.5 Variation between the two disease subtypes 
In addition to the differences between PPMS and SPMS in degree of atrophy, 
demyelination, and OLs' pathology, there seem to be differences in the amount of 
axonal loss. SPMS demonstrated less axonal density within the NAWM and the 
PMWM, while there was no difference in the DMWM. The difference between the two 
disease forms was more prominent in the CST. A study carried out in 2000 revealed 
significant loss ofaxons in acute MS lesions in SPMS but not in PPMS. Lovas et al 
reported 60% reduction in density ofaxons in SPMS, where small axons are lost 
more than large axons [342]. 
Tallantyre et al compared axonal loss in the DMWM with the NAWM in the cervical 
cord. and found that PPMS shows greater loss ofaxons compared to SPMS. In this 
study, we found that PPMS shows greater loss ofaxons in the DMWM when 
compared with the surrounding NAWM (PPMS 22% loss, SPMS 14% loss). When 
compared with normal controls, however, SPMS shows greater loss ofaxons (PPMS 
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38% loss, SPMS 47% loss). This can be explained by the finding that SPMS has 
significantly greater loss ofaxons in the NAWM. 
It is possible that the difference between the two diseases in axonal density is due to 
difference in inflammation and disease activity. The preceding relapsing remitting 
phase of SPMS, which can extend up to 20 years, may result in greater 
inflammation-induced axonal damage. There is some evidence to support this 
assumption; acute axonal damage correlated significantly with inflammation activity, 
SPMS showed greater degree of acute axonal loss, even in active lesions [72), and 
early axonal loss was observed in the NAWM of acute MS [324]. 
The progressive forms of the disease are also different in the degree of 
demyelination in the brain, which may affect survival ofaxons. Greater demyelination 
of the brains and the spinal cords in SPMS may result in a greater degree of 
degeneration caudally. In support to this hypothesis, we found that the difference 
between the two disease forms in axon density in the NAWM was only significant in 
the descending tract and not the ascending tract, ie axons that traverse MS lesions in 
the brain or cervical segment continue to be part of NAWM in lower cord levels. 
Since we have more areas of demyelination within the brains and spinal cords in 
SPMS, the caudal regions of SPMS can be affected more extensively than same 
areas in the PPMS, in particular the NAWM. 
Patients with MS have variable clinical course according to disease subtype. 
However, the EDSS of all subjects in this sample has been identified and was found 
to be similar [142]. Although axonal loss correlated with disability, it is possible that 
greater difference in axonal density is required between the two subtypes before a 
significant difference in disability can be observed. In EAE, up to 30% ofaxons can 
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be lost before irreversible motor deficits appear [349]. NAA expression in the brains 
of MS patients was found to be significantly reduced early in the disease, and even 
before the appearance of clinical symptoms [243]. A previous study reported 64% 
reduction in axonal density of MS lesions without evidence of clinical disability [305]. 
Degree of axonal loss in any tract is not the only factor that may affect disability. The 
extent of fibres' decussation in eNS tracts is believed to be crucial in lessening the 
clinical manifestations of lesions in the eNS. In rare cases there is complete 
decussation, while in others, there is no anterior eST [339]. Therefore, the same 
lesion may produce a variable degree of disability in different subjects depending on 
the degree of pyramidal decussation (Figure 6.1) [340]. For a randomly selected 
sample (irrespective of degree of decussation as in our sample), greater difference in 
axonal loss may be needed to produce a noticeable difference in disability between 
two groups, ie the calculated difference in axonal loss between PPMS and SPMS in 
our study may not be enough to produce a recordable difference in disability. 
The ratio of Ols to axons was calculated as the percentage of Ol number to axon 
number in each field. It is important to state that this ratio does not represent the 
actual ratio of Ols to axons. One axon can be myelinated by too many Ols along its 
course. Ratio calculated in this study reflects number of Ols and axons in cross 
sections and not in the three dimensional space. However, the calculated ratio may 
reflect the degree of Ols compared to axonal loss. The ratio suggests that axonal 
loss and Ol loss happen equally in the NAWM, while in the demyelinated areas, 
there is significantly less destruction ofaxons compared to Ols. 
In this study selection of fields was governed by unbiased sampling process, 
regardless of the myelin status, as the NE14 stain does not show areas of 
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demyelination clearly. The automatic counting ofaxons added more to the objectivity 
of the study. However, automatic counting may be affected by the obliquity of the 
section 
To validate our results and to exclude effects of shrinkage and atrophy in MS cases, 
we have calculated the total number ofaxons in the CST and the PCP. Total number 
ofaxons may reflect degree of disability better than density of axons. For example, 
the total number ofaxons on one side of the CST in the upper cervical cord of 
controls was 0.7 million and in MS was 0.1 million (85% reduction). In comparison, 
the mean axonal density in the CST in the lower cervical cord of controls was = 0.4 
million and in MS was = 0.2 Million (57% reduction). Total number ofaxons in MS 
was calculated by multiplying the mean density ofaxons with the eSA of the tract. It 
is therefore affected by the calculated eSA. It is possible that degree of atrophy in 
the CST is due to loss of other elements, such as glial cells and neuropil, and not 
only due to axons. 
6.6 Conclusion 
This study has shown variation in the amount of axonal loss between ascending and 
descending tracts in the NAWM of MS spinal cords. There was no difference 
between the two tracts in the DMWM. This may indicate the there is difference in the 
extent and timing of neuronal degeneration between ascending and descending 
tracts. This may imply that axonal survival in the NAWM is dependent mainly on 
degeneration and not due to local effects of the plaque. 
In spite of the significant demyelination of the PCP, there was no significant atrophy 
of the tract compared to the CST. This may represent evidence that atrophy is largely 
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affected by loss ofaxons in the NAWM, especially because loss of axons in the 
NAWM of the PCP was found to be limited. 
We also demonstrated that SPMS has a greater degree of axonal loss in the NAWM. 
This may be related to the observation in the previous chapter, when we found that 
there was also greater loss of OLs in the NAWM. Although there is an agreement 
between axonal loss and OLs in the NAWM (OLs: axons ratio in MS does not differ 
from controls when there was significant loss of both elements), it is not well known 
which one preceded the other. Possibly examination of the NAWM in acute MS for 
OLs' loss may answer this question. 
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Figure 6.1: Normal anatomical variation in degree of the CST decussation [340]. 
Original image 
Adjusting threshold 
convert to 8 bit image 
Separating particles by watershed 
feature then automatic counting 
Figure 6.2: Stages of automatic counting: the original image (1); coloured images are then converted to grey images 
(8 bit images) (2); Threshold of the image is then adjusted (3). Separation of particle is done automatically by the 
software (4). All particles in image 4 are then counted automatically. 
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NE14 
Figure 6.3: Human spinal cord cross section. Images were taken from the same subject and same level. Note that 
demyelinated regions are not easily identified on NE14 stained sections 
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Figure 6.5: Bar charts showing the differences between PPMS and SPMS in axonal density in NAWM. PMWM, and 
DMWM. The bars represent the mean axonal density in the NAWM, PMWM, and DMWM ± SEM. The significant 
difference between SPMS and PPMS is indicated by asterisks *, the significant difference between controls and 
SPMS are indicated by the number sign #, while the difference between controls and PPMS is indicated by". For 
each of the comparisons the Significant differences of p value < 0.05 are indicated by one sign , while the p values < 
0.01 are indicated by two signs. 
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Figure 6.6: Comparison between PPMS and SPMS in three differently myelinated areas regardless of the cord level. 
The bars represent the mean axonal density in the NAWM, PMWM, and DMWM ± SEM. The significant difference 
between NAWM and PMWM is indicated by asterisks *, between NAWM and DMWM is indicated by the number sign 
#, and between PMWM and DMWM is indicated by". For each of the comparisons, the p values < 0.05 are indicated 
by one sign , while the p values < 0.01 are indicated by two signs 
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Chapter 7: Pathology of neurons in the spinal cords of PPMS 
and SPMS 
7.1 Introduction 
Neurons are the fundamental units of the eNS, and their preservation is essential to 
maintain function in view of their inability to regenerate in most eNS locations. MS 
lesions can affect various GM regions of the eNS, including the cerebral cortex, 
thalamus, basal ganglia, hippocampus, and the spinal cord GM [106, 350, 351]. MS 
lesions in the GM lead to loss of myelin, which may in turn induce neuronal loss, 
neuronal shrinkage [106], and dendritic damage [311]. Neuronal pathology and the 
subsequent loss of function are possibly responsible for some of the disability in MS. 
In the brain, cerebral cortex pathology is believed to be responsible for decline in the 
cognitive functions in MS patients [352, 353). 
Researchers usually assess neuronal loss by directly visualizing neurons using 
histopathologic studies or neuronal culture studies (in vitro), or indirectly by 
measuring degree of NAA expression by means of MRS (in vivo) [131]. Various types 
of study have reported neuronal loss that is related to MS, including MRS studies 
[354-357] and histopathological studies [95, 351, 358). Additionally neuronal culture 
studies [354, 359] and experimental models of MS [360, 361] have shown neuronal 
loss that is related to MS pathology. Neuronal loss can be an early process as shown 
by the concentration of NAA, which was reduced in the NAGM of the cortex in short 
duration RRMS [357]. 
With respect to neuronal pathology, the spinal cord has again received less attention 
compared to neuronal pathology in the brain. Only one study examined quantitatively 
neuronal pathology in the spinal cord. The study was carried out in our lab using a 
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relatively big sample size, but there was no differentiation between PPMS and SPMS 
in neuronal counts [106]. In this study we have the opportunity to examine the two 
subtypes of progressive MS in a very well clinically characterised sample. 
7.1.1 Causes of neuronal loss 
Demyelination 
A number of studies have found correlation between demyelination and loss of 
neurons. The most recent spinal cord study was conducted by Gilmore et al 2009. 
The study quantified numbers and sizes of motoneurons and interneurons in 38 
cases of MS and 22 controls. Neuronal loss was mainly associated with 
demyelination of the GM. Atrophy of interneurons was also found to be significant 
and affected all cord segments in both demyelinated and normal appearing GM 
[106]. 
A recent study was carried out in 2009 by Papadopoulos and colleagues. 
Papadopoulos et al examined quantitatively hippocampus autopsy material from 45 
cases of progressive MS (mean disease duration was 27.8 years) and 7 controls. 
The study reported 30% demyelination and 23% atrophy of the archaeocortex (3 
layers cortex), which is the area responsible for memory. There was 27-29% 
reduction in number of neurons compared to controls. In addition, size of surviving 
neurons was reduced by 17%. Interestingly there was significant correlation between 
loss of neurons and degree of atrophy [362]. 
Similar to Papadopoulos study, Wegner et al studied quantitatively autopsy material 
from the neocortex (6 layers cortex) in 22 cases of MS and 17 controls [358]. There 
was 10% decline in the thickness of MS neocortex compared to controls. This was 
associated with 10% reduction in the neuronal number and 47% reduction in the 
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synaptophysin expression (a marker of synapses). Loss of neurons was associated 
with demyelinated areas while the normal-appearing regions of the neocortex were 
not associated with significant pathology of neurons. 
Another study has also quantified demyelination, neuronal and synaptic losses in MS 
cerebral cortex. There was 33% neuronal loss in the cerebral cortex lesions 
compared to the adjacent normally appearing cortex [351]. 
Degeneration 
Neuronal cell bodies may undergo degenerative changes when their axons are 
severed in the process of retrograde degeneration. This can affect demyelinated 
areas and normally appearing areas. Anterograde degeneration (Wallerian 
degeneration) may result in degeneration of the postsynaptic neuron. It is believed 
that neurons that do not receive action potentials may degenerate due to de-
afferentation [76]. Both retrograde and anterograde degeneration may continue to 
affect more than one order neuron. Retrograde degeneration has been directly 
demonstrated in different human CNS regions [97, 363], such as the cochlear 
system [363], the olivocerebellar pathway [364], and the CST [365] 
The effect of retrograde and transynaptic degeneration on neuronal survival in MS 
has been suggested in a number of studies. A correlation between loss ofaxons and 
neuronal changes within the same pathway has been reported by Evangelou et al 
2001 [95]. Evangelou quantified numbers and sizes ofaxons in the anterior optic 
pathway and compared it with degree of neuronal shrinkage and loss within the 
geniculate nucleus in 8 MS patients and 8 controls. There was strong correlation 
between loss of small diameter axons and shrinkage of small neurons. This further 
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confirms the effect of distant axonal loss on the GM and the subsequent neuronal 
loss. 
Cifelli et al demonstrated atrophy and loss of neurons in the thalamus in both MRS 
and histopathologic post-mortem analysis (two different samples). There was 30% 
reduction in the effective neuronal density measured by MRS study compared to 
22% reduction in the neuronal density measured by histopathology study [131]. 
Peterson et al investigated pathology of MS in the cerebral cortex including axonal, 
neuronal and inflammatory changes. Peterson and his colleagues quantified 
transected neurites and apoptotic neurons in the cerebral cortex of MS autopsy 
material. Neuronal apoptosis was found to be significant not only in the acute active 
lesions, but also in the chronic inactive lesions. Such findings suggest that neuronal 
apoptosis continues in chronic lesions in the absence of acute immune attack [311]. 
Moreover, Peterson and colleagues demonstrated changes in microglia morphology. 
Microglia were seen abutting neuronal cell bodies and possibly causing de-
afferentation of these neurons. This may provide initial protection to degenerating 
neurons from further injury. This is because excitatory impulses can cause further 
damage to the already injured neuron. A negative effect of glutamate on neuronal 
survival has been reported previously [77]. But with prolonged de-afferentation, these 
neurons may degenerate and even be phagocytosed by the microglia. 
Other causes 
A number of potential causes have been suggested to contribute in neuronal damage 
in MS. These may include glutamate excitotoxicity, nitric oxide neurotoxicity, or 
chemokines/cytokines cytotoxicity. 
183 
Pathology of the spinal cord in progressive multiple sclerosis (primary progressive vs secondary progressive) 
Vericello in 2007 studied effects of excitotoxicity on survival of neurons in the 
cerebral cortex of MS tissue. Vericello and colleagues evaluated excitatory amino 
acid transporter expression in lesions of cerebral cortex of 10 autopsy material. The 
examined protein prevents excitotoxicity by reducing level of extracellular glutamate 
(increases glutamate uptake). Vericello reported a correlation between activated 
microglia and loss of excitatory amino acid transporter expression. Activated 
microglia also correlated with an increase in c-Jun N-terminal kinase expression (a 
marker of neuronal excitotoxicity). The main conclusion from the study was the 
possible significant role of excitotoxicity in causing neuronal and synaptic losses. 
Diffusion of harmful proteins from the plaque to the CSF may induce distant neuronal 
loss. Within MS plaques, macrophages produce proteases which cause tissue 
destruction. These soluble factors may include antibodies against neurons. In fact, a 
number of antibodies against neurons were reported in the sera of MS patients [366-
368]. In addition to antibodies, soluble cytokines and chemokines may induce 
neuronal injury in cultures such as TNF-alpha [369-371]. 
This has been reported in another study in 1998 by Alcazar et al. Neuronal culture 
was treated with CSF from three groups of patients; worsening PPMS, stable PPMS 
and non-inflammatory neurological diseases. Apoptosis was only demonstrated in 
cultures treated with CSF from worsening PPMS [372]. 
A more recent study by Cid et al (2002) investigated the relation between MS 
relapses and the degree of apoptosis of cultured neurons. A sample of 24 patients 
with relapsing disease was studied. The CSF was taken during relapses and added 
to the cultured neurons. Increased apoptosis was induced by the CSF that had been 
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taken during the relapses that were associated with poor recovery from the attack. In 
addition the CSF, which was taken from relapses that were associated with MRI 
findings, induced the greatest degree of neuronal apoptosis [354]. 
Xiao et al (1996) compared CSF effects on inducing nitric oxide release from glial 
cultures between patients with MS and patients with other CNS diseases. 34% of MS 
cases stimulated glial cell culture to produce nitric oxide compared to less than 10% 
from other diseases [373]. In relation to nitric oxide neurotoxicity, three mechanisms 
have been postulated; direct toxicity, peroxynitrate formation from superoxide anion, 
and via elevation of intracellular cGMP and induction of programmed cell death [374]. 
7.2 Aims and Hypothesis 
Neuronal loss has been reported in a number of studies, but most of these studies 
were conducted at the level of the brain GM. Considering differences between the 
two progressive subtypes in demyelination, atrophy. Ols' quantification and axonal 
loss, this study will investigate if there is any difference between PPMS and SPMS in 
neuronal pathology. Neuronal survival may be affected by inflammation, 
demyelination and Ols' loss, which occur in PPMS and SPMS in varying degree. 
This has been achieved by examining human spinal cord sample. Numbers and 
sizes of neurons were estimated in the VH of DMGM and NAGM. Effect of 
demyelination on neuronal number and sizes were studied. Comparison was made 
between PPMS and SPMS in various levels of the cord. 
7.3 Material and methods 
Human autopsy material was analyzed including MS and controls. MS tissue 
includes material from one source which is the MS Society tissue bank (PPMS n =13, 
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SPMS n = 14), while controls were collected from three sources; MS Society tissue 
bank (n = 5), Oxford Radcliffe (n = 6), and Netherlands brain bank (n = 2). Summary 
of the included sample is in Table 7.1. For this study, we used the NE14-stained 
slides to quantify neurons. These slides have been used previously to quantify axons 
within the WM. As we have mentioned, we have examined one slide of 5 IJm 
thickness from each paraffin-embedded block. The NE 14 stain traces the 
neurofilaments in the axons and neuronal cell body. The myelin status of the VHs 
has been assessed using MBP stain in the previous chapter. 
Table 7.1: Summary of the sample used for quantifICation neurons 
Post-
Type of the Gender Age (years Duration of the mortem disease disease (years) delay 
J h o u ~ ~
Minimum 33 22 
male Maximum 88 26 
Normal control Mean 60 24 Minimum 41 9 
female Maximum 93 33 
Mean 67 17 
Minimum 54 16 5 
male Maximum 92 54 20 
PPMS Mean 74 35 10 Minimum 45 5 6 
female Maximum 77 37 87 
Mean 61 20 24 
Minimum 40 9 8 
male Maximum 73 47 23 
SPMS Mean 57 25 14 Minimum 39 15 7 
female Maximum 78 50 27 
Mean 57 23 14 
7.3.1 Quantification of neurons 
The digital slides of the NE14 stain were used to perform quantification 
measurements. On each slide and at low power. the surface area of the VHs was 
estimated. The VH area includes the area anterior to a horizontal line from the 
anterior border of the GM commissure [106]. The dorsal part of the VH between the 
GM commissure and the central canal has been excluded because it contains 
numerous small neurons that can be difficult to differentiate from glia [106]. 
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At magnification of 40X, the area was scanned manually for the presence of neurons. 
The considered neurons were identified by having a large cell body, Nissl bodies, 
and presence of nucleolus. Only neurons with visible nucleolus were considered in 
the analysis. This is because the nucleolus is the smallest visible part of the neuron. 
For each neuron, the boundary was identified manually and the software 
automatically calculates the eSA of the neuron. The axon and the dendrites were not 
included in calculation of the neuron eSA. The maximum and the minimum 
diameters of the neuron were measured. The minimum and the maximum diameters 
of the neurons pass through the nucleolus. 
7.3.2 Classification of neurons 
According to the maximum and the minimum diameters, neurons were classified into 
motoneurons and interneurons. Similar to the previously used criteria [106, 375], 
motoneurons include all neurons with the maximum diameter of 30 ~ m m and above 
and with a minimum diameter of 13.5 ~ m m and above, whilst the rest of neurons were 
considered interneurons. 
7.3.3 Determination of myelin status 
Using the MBP stain, the myelin status of the VH was assessed. To increase the 
sample of the examined VHs, partially myelinated VHs were considered either 
demyelinated or normally appearing VHs according to the proportion of 
demyelination. The VH was considered demyelinated if the demyelinated area 
occupied more than 50% of the CSA of the VH; otherwise, it was considered 
normally appearing VHs. Consequently, VHs were classified into three groups; 
healthy VHs from controls, normally appearing VHs, and demyelinated VHs. 
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7.3.4 Correction of neuronal numbers 
The resultant neuronal numbers were obtained from counting neurons in cross 
section areas, ie in two dimensional space. These numbers do not usually reflect the 
actual number of neurons in the real three dimensional space, especially because 
the neuronal cell bodies are relatively large and can be counted in serial sections. 
For accurate estimation of neuronal numbers, stereology that examines serial section 
is the ideal method. 
Since our analysis depends on cross sections and applying stereology is not 
possible, the smallest visible particle of the neuron, which is the nucleolus, was used 
to identify the countable neurons. However, size of nucleoli may vary and can be 
higher than the section thickness. Therefore, the resulted number of countable 
neurons was corrected using Abercrombie method, which considers section 
thickness and the particle height [376], which is the nucleolus. 
Assuming that the nucleolus is rounded in shape, the height has been estimated by 
measuring the diameter of all nucleoli in each VH. The mean diameter of all nucleoli 
in each VH was used to correct the number in that VH. Figure 7.1 shows the 
distribution of the diameter of the nucleoli. The normal distribution of the nucleolus 
diameter in Figure 7.1 suggests that there is no significant difference between the 
diameter of the nucleolus in motoneurons and intemeurons. 
The used Abercrombie formula for correcting neuronal number: 
N = ~ ~
t+H 
Where: N = actual number; n = number of counted particles; t = section thickness; H 
= particle height. 
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7.3.5 Statistics 
Unpaired t-test was used to compare neuronal counts between MS and controls and 
between PPMS and SPMS. Multiple linear regression was used to study effects of 
age. gender. demyelination. disease duration and disease subtype on neuronal 
numbers and sizes. 
Comparison between MS and controls was carried out on all five segments. while 
comparing PPMS and SPMS was restricted to the upper 4 segments. because there 
were not enough cases to accomplish reliable comparison in the lower lumbar 
segment. 
7.4 Results 
7.4.1 The ventral horn surface area 
The surface area of the VHs was reduced in MS spinal cords compared to MS. The 
reduction in the surface area was significant in the upper cervical (p = < 0.001). lower 
cervical (p = 0.016). and upper lumbar segments (p =0.006). There was no difference 
at the thoracic (p = 0.934) and lower lumbar segments (p = 0.164). 
7.4.2 Quantification of neurons (Control vs. multiple sclerosis) 
In controls and MS. the highest number of neurons was found in the VH of the lower 
lumbar segment. The lowest number of neurons was found in the VH of the thoracic 
cord. MS showed reduced total numbers of neurons compared to healthy controls. 
This reduction was more obvious in the higher cord levels. There was a tendency 
toward significant reduction in the upper cervical (p = 0.059). and Significant 
reduction in the lower cervical (p = 0.024) and upper lumbar (p = 0.05). There was no 
difference in the thoracic (p = 0.785) and the lower lumbar segments (p = 0.685). 
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By considering neuronal types, there was greater loss in interneurons compared to 
motoneurons, especially in the higher cord levels. For example, in the upper cervical 
segment, MS cases demonstrated considerable, although not significant, loss in 
interneurons (p = 0.059) with no significant loss in motoneurons (p = 0.577). In the 
lower cervical segment, there was similarly greater reduction in interneurons (p = 
0.045) compared to motoneurons (p = 0.094). Interneurons and motoneurons were 
both significantly reduced only in the upper lumbar segment (interneurons p = 0.007; 
motoneurons p = 0.01). There was no difference between MS and controls in the 
thoracic (interneurons p = 0.805; motoneurons p = 0.878) and lower lumbar 
segments (interneuron p = 0.371; motoneurons p value 0.945) (Figure 7.2). The 
absolute numbers of neuronal counts are mentioned in Table 7.2. 
7.4.1 Effect of demyelination on neurons 
A reduction was observed in the total number of neurons in the demyelinated VHs 
compared to controls. All levels showed a tendency toward significance, however, 
the difference was only significant in the thoracic cord. Compared to controls the p 
values were as the following; upper cervical (p value 0.073), lower cervical (p = 
0.089), thoracic (p = 0.001), upper lumbar (p = 0.083) and lower lumbar (p = 0.069). 
When the type of neurons was considered, the calculated reduction in number of 
interneurons in the demyelinated VHs had a trend towards significance in the upper 
cervical cord (p = 0.056). There was no difference in the rest of the cord levels; lower 
cervical (p = 0.103), thoracic (p = 0.111), upper lumbar (p = 0.546) and lower lumbar 
(p = 0.169). Motoneurons number was not affected in the demyelinated areas 
compared to normal controls in the upper cervical (p = 0.972), lower cervical (p = 
0.242), thoracic (p = 0.128), upper lumbar (p = 0.066). However, motoneurons were 
notably reduced in the lower lumbar (p = 0.047) (Table 7.3). 
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Table 7.2. Companson between MS and controls In neurona counts of the ventral hom 
Spinal cord 
segment 
category 
Upper 
Cervical 
Lower 
Cervical 
Thoracic 
Upper 
Lumbar 
Lower 
Lumbar 
Sample type and Total neurons Std. 
number number Dev 
P 
value 
Moto-
neurons 
number 
P 
value 
Inter-
neurons 
number 
P 
value 
3.50 1.22 Control n = 6 5.79 4.56 
I - - - - - + - - - - + - - - - - ~ ~ ~ 0.059 1-----1 0.577 1-----1 0.059 
MS n = 14 3.92 3.14 1.04 2.13 
Control n = 14 8.06 5.09 3.97 4.09 
I - - - - - + - - - - + - - - - - + _ ~ ~ 0.030 1-----1 0.094 1-----1 0.046 
MS n = 8 4.07 2.57 2.58 1.95 
Control n = 2 2.35 0.62 1.0 1.36 
I - - - - - + - - - - + - - - - - ~ _ _ _ _ l l 0.785 1-----10.878 1-----10.805 
MS n = 10 2.53 2.16 0.89 1.10 
Control n = 9 6.50 2.78 3.35 3.15 
I - - - - - + - - - - + - - - - - + _ ~ ~ 0.005 1------1 0.021 1------1 0.007 
1.42 MS n = 12 2.65 1.06 1.49 
5.07 5.31 4.32 I----+----+-----t-----I 0.685 1-----1 0.945 1-----1 0.371 Control n = 10 9.63 
MS n = 12 8.66 5.84 5.42 3.24 
Density of neurons was calculated in the demyelinated VHs of MS and was 
compared with the density from normal appearing VHs and healthy VHs. The mean 
density of neurons in the demyelinated VHs was 2.45/mm2 and in the normally 
appearing VHs was 3.68/mm2 (p = 0.003). Compared to the density of neurons in the 
healthy VHs, which was 3/mm2, there was no Significant difference from 
demyelinated areas (p = 0.200). 
Similar results were obtained when the type of neuron was considered in the analysis 
of density. Intemeurons' density was significantly reduced in the demyelinated VHs 
compared to normally appearing VHs (p = 0.021) but insignificantly reduced 
compared to normal controls (p = 0.188). Similarly, motoneurons' density was 
Significantly reduced compared to normally appearing VHs (p = 0.024) and 
inSignificantly reduced compared to health VHs (p = 0.663) (Table 7.4). 
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7.4.2 Quantification of neurons in the normal appearing ventral horns 
Total number of neurons was compared between normal appearing areas and 
normal controls. Apart from the upper lumbar segment, results did not show a 
difference between demyelinated and controls VHs at any of the cord levels (upper 
cervical p = 0.126; lower cervical p = 0.095, thoracic p = 0.865; upper lumbar p = 
0.004; lower lumbar p = 0.882). This applies to interneurons (upper cervical p = 
0.144; lower cervical p = 0.189; thoracic p = 0.948; upper lumbar p = 0.06; lower 
lumbar p = 0.618). Motoneurons' number did not show a difference between normal 
appearing and normal controls at any level, except in the upper lumbar segment 
(upper cervical p = 0.454; lower cervical p = 0.171; thoracic p = 0.828; upper lumbar 
p = 0.027; lower lumbar p = 0.540) (Figure 7.3). 
Table 7.3: Total number of neurons in the demyelinated and normall appearing VHs (The Abercrombie correction 
Corrected Corrected 
Spinal cord segment Myelin status number Total intemeur Corrected 
category neurons ons motoneurons 
number number 
Upper Cervical Demyelinated VHs n=7 2.74 1.50 1.24 
Normally appearing VHS n =16 3.36 2.41 0.95 
Lower Cervical Demyelinated VHs n =9 4.74 1.95 2.79 
Normally appearing VHs n =6 4.21 1.94 2.27 
Thoracic Demyelinated VHs n =6 0.78 0.44 0.34 
NormallyappearingVHs n =12 2.60 1.43 1.16 
Upper Lumbar Demyelinated VHs n=3 3.05 2.18 0.87 
Normally appearing VHs n =19 2.89 1.30 1.59 
Lower Lumbar Demyelinated VHs n=2 2.04 1.01 1.03 
NormalwappearingVHs n =10 9.99 3.69 6.29 
Table 7.4: Density of neurons in demyelinated, normally appearing and healthy VHs 
Myelin status Neurons density Motoneurons clensity Intemeurons density 
Demyelinated 2.451mm 2 1. 17lmm2 1.28/m,,? 
Normally appearing 3.681mm 2 1.691mm2 1.99lmm2 
Normal control 3.OOImm 2 1.26Imm2 1.741mm2 
7.4.3 Quantification of neurons in PPMS and SPMS 
Comparing the total number of neurons between the two disease subtypes did not 
reveal a significant difference at any of the cord levels. These results were similar 
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with interneurons and with motoneurons. There was no difference in the total number 
of neurons in the demyelinated VHs between PPMS and SPMS (upper cervical p = 
0.479; lower cervical p = 0.225; thoracic p = 0.990; upper lumbar p = 0.262). This 
was also found with interneurons (upper cervical p = 0.570; lower cervical p = 0.115; 
thoracic p = 0.507; upper lumbar 0.074) and with motoneurons (upper cervical p = 
0.509; lower cervical p = 0.462; thoracic p = 0.578; upper lumbar p = 0.498) (Tables 
7.5 and 7.6). 
Table 7.5: Comparison between PPM and In neurona counts regardless of myelin status S SPMS' 
Spinal Type of the Total neurons Motoneurons Intemeurons 
cord 
segment disease 
category value 
P • p •• value P • p •• value 
Upper PPMS n=14 3.92 0.254 0.102 1.13 0.810 0.435 2.79 Cervical SPMS n=9 2.00 0.045 0.89 0.452 1.11 
Lower PPMS n=8 4.07 0.024 0.469 2.61 0.135 0.928 1.45 Cervical SPMS n=7 5.05 0.086 2.54 0.155 2.51 
Thoracic PPMS n=10 2.53 0.912 0.157 1.03 0.963 0.509 1.51 SPMS n=8 1.32 0.184 0.72 0.644 0.60 
Upper PPMS n=12 2.65 0.001 0.232 1.30 0.014 0.261 1.35 Lumbar SPMS n=10 3.22 0.008 1.72 0.041 1.50 
Lower PPMS n=12 8.66 0.685 - 5.42 0.942 3.24 Lumbar -
p. companson of the means between the subtype and the correspondIng segment from controls 
P" comparison of the mean between the two subtypes. 
P • 
0.261 
0.052 
0.021 
0.223 
0.896 
0.542 
0.034 
0.090 
0.371 
P •• 
0.121 
0.264 
0.163 
0.682 
-
Including all the cord levels, the average density of neurons in the demyelinated VHs 
of PPMS was 2.5/mm2 and in SPMS was 2.4/mm2 (p = 0.882). The density of 
motoneurons was 1.21mm2 in PPMS and 1.2/mm2 in SPMS (p = 0.959), while the 
density of interneurons was 1.3/mm2 in PPMS and 1.21mm2 in SPMS (p = 0.726). 
Table 7.6: Companson be tween an In num r PPMS d SPMS' the be of neurons In e ~ y e l l n a a. th clem r ted VHa 
Total number of intemeurons 
Spinal cord segment Type of the disease neurons motoneuron. 
category 
number P number p number p 
Upper Cervical PPMS n=4 3.63 0.479 1.86 0.570 1.39 0.509 SPMS n=3 3.50 1.04 1.04 
Lower Cervical PPMS n=6 
1.81 0.225 1.37 0.115 2.52 0.462 SPMS n=3 2.15 3.10 3.32 
Thoracic 
PPMS n=4 1.60 0.990 0.52 0.507 0.27 0.578 
SPMS n=2 1.60 0.28 0.50 
Upper Lumbar PPMS n=2 4.85 0.262 2.94 0.074 1.31 0.498 SPMS n"'1 1.04 0.65 0.00 
Lower Lumbar PPMS n=2 1.75 
-
1.01 
-
1.03 
-
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7.4.4 Sizes of neurons (MS vs. controls) 
The eSA of interneurons did not show difference between MS and controls in all 
levels (upper cervical p = 0.630; lower cervical p = 0.732; thoracic p = 0.830; upper 
lumbar p = 0.544; lower lumbar p = 0.995). Similarly, motoneurons eSA was not 
different in MS from healthy controls (upper cervical p = 0.853; lower cervical 0.091, 
thoracic p = 0.569, upper lumbar p = 0.788; lower lumbar p = 0.681). 
7.4.5 Effect of demyelination on neuronal sizes 
Within MS cases, there was no significant difference between demyelinated areas 
and NAGM in interneurons eSA (upper thoracic p value 0.134; lower cervical p value 
0.274; thoracic p value 0.238; upper lumbar p value 0.587, lower lumbar p value 
0.098). There was also no difference between Motoneurons' sizes in demyelinated 
and normal appearing areas (upper cervical p value 0.124, lower cervical 0.323, 
thoracic p value 0.317, upper lumbar p value 0.333; lower lumbar p value 0.298) 
(Figure 7.3) 
7.4.6 Sizes of neurons (PPMS vs. SPMS) 
Regardless of myelin status, the size of intemeurons was compared between the two 
disease subtypes in the 4 cord segments. The obtained data did not demonstrate any 
significant difference between the two forms of the disease (upper cervical p value 
0.601; lower cervical p value 0.099; thoracic p value 0.427, upper lumbar 0.056). The 
only significant difference in motoneurons' sizes was at the lower cervical level 
(upper cervical p value 0.129; lower cervical p value 0.001; thoracic p value 0.909; 
upper lumbar p value 0.732). 
In the demyelinated areas, there was no significant difference between PPMS and 
SPMS in eSA of intemeurons (upper cervical p value 0.240; lower cervical p value 
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0.420; thoracic p value 0.216; upper lumbar p value 0.117) and motoneurons (upper 
cervical p value 0.452; Lower cervical p value 0.026; Thoracic p value 0.376). In 
normally appearing areas, there was no significant difference between the two forms 
in sizes of interneurons (upper cervical p value 0.789; lower cervical p value 0.059; 
thoracic p value 0.962; upper lumbar p value 0.083) and motoneurons (upper cervical 
p value 0.196; lower cervical 0.145; thoracic p value 0.504; upper lumbar p value 
0.955) (Figure 7.3 and Table 7.7). 
Table 7.7: Neuronal sizes in the de r ed mye Inat II , normally appeanng, an ea 1Y sin e lsease orms d h Ith VH . th two d· 
Mean cross sectional Mean cross sectional area of Spinal cord area of interneurons 
segment category Myelin status 2 motoneurons in IJm 2 inlJm 
Demyelinated 189 633 
Upper Cervical Normally appearing 242 762 
Normal control 249 721 
Demyelinated 283 1156 
Lower Cervical Normally appearing 243 992 
Normal control 290 799 
Demyelinated 202 724 
Thoracic Normally appearing 257 864 
Normal control 245 912 
Demyelinated 290 1040 
Upper Lumbar Normally appearing 241 961 
Normal control 238 969 
Demyelinated 414 956 
Lower Lumbar Normally appearing 269 1456 
Normal control 254 1188 
7.4.7 Effects of age, gender and disease duration on quantification of 
neurons 
In controls, the total number of neurons is significantly affected by age (p = 0.005) 
and the cord segment (p = 0.02) contrOlling for gender, cord segment, and post-
mortem delay. Total neurons were reduced by age and were higher in the lower cord 
segments. When the type of neuron was considered, it was only the motoneurons 
that were reduced by age (Correlation -0.805, p = 0.001) and were also affected by 
cord level (p = 0.014) and not interneurons (Table 7.8). 
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Examining effects of independent factors in MS illustrated that the cord level (p value 
0.005) is the only factor that has a significant effect on total neuronal number 
controlling for age, gender, myelin status, duration of the disease, and post-mortem 
delay. However, controlling for the same factors, spinal cord level has only significant 
effects on motoneurons' numbers (p value < 0.001) and not on interneurons (p value 
0.646). There is also significant effect of gender on number of motoneurons (p = 
0.04) and not on interneurons (p 0.524), where motoneurons numbers was greater in 
males. 
Table 7.8: correlation between age and numbers of neurons in controls 
Correded Correded Correded 
Control Variables intemeurons motoneurons total number 
number number of neurons 
Gender & Spinal cord segment I Correlation -.359 -.805 -.730 
category & Post-mortem delay I Significance (2-tailed) .228 .001 .005 
7.4.8 Summary of results 
In controls, there seem to be a reduction in the motoneurons with age progression. 
There is also an increase in the number of motoneurons in the lumbar cord 
compared to the cervical cord. 
Compared to controls, total neurons count appeared to be reduced in MS and 
showed tendency toward significance for this reduction in most of the cord levels. 
This affected both motoneurons and intemeurons. However, it seems that 
interneurons suffered from greater loss. There was no significant difference between 
PPMS and SPMS in numbers of interneurons and motoneurons. Demyelination 
possibly has negative effects on numbers of neurons. There was a reduction in total 
neurons in the demyelinated areas compared to normal controls, which again 
affected mainly interneurons. Density of neurons was Significantly reduced in the 
demyelinated VHs compared to normal appearing VHs. There was no Significant 
difference between PPMS and SPMS in numbers of interneurons or number of 
motoneurons and this applied to demyelinated and normally appearing areas. Our 
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data did not demonstrate considerable effects of demyelination or NAGM on 
neuronal sizes. There was no difference between PPMS and SPMS in this respect. 
Numbers and morphology of neurons probably varies among different spinal cord 
levels especially motoneurons, while interneurons do not show great variation. 
7.5 Discussion 
This study might be the first histopathological study that has quantified neurons in 
PPMS and SPMS in the spinal cord. The results obtained from the study provide 
additional evidence that there is loss of neurons in the spinal cord GM due to MS with 
no variation between the two disease subtypes. There was a trend toward 
significance regarding neuronal loss that mainly affected the upper segments and 
demyelinated areas with no difference between the two disease subtypes. 
7.5.1 Source of errors in neuronal counts 
In contrast to a number of previous studies, our study has examined a relatively big 
sample size [131, 351, 358], but fewer than Gilmore's et al study (MS n = 37; controls 
n = 22). loss of neurons in our sample was less extensive than in Gilmore's et al 
study. This could be due to difference in sample size, section thickness, the stain 
used, and the method used for calculations (video camera vs electronic images). 
More importantly, due to lack of enough completely demyelinated VHs in our sample, 
we considered the VHs that have demyelination of 50% and above as demyelinated. 
In contrast, Gilmore only considered the completely demyelinated VHs in the 
analysis. 
The study by Gilmore et al quantified neurons within the VH of human spinal cords in 
multiple cord levels; upper cervical, upper thoracic, and lumbar. Gilmore used Cresyl 
violet stain on 15 ~ m m thick sections. In comparison, we have used 
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immunohistochemistry against NE14 to trace neurons on 5 IJm thick sections. It is 
expected that thick sections would include a greater number of nucleoli compared to 
thinner sections (the split cell error) [377]. 
Accurate neuronal count has been under debate for a long time. It is estimated that 
the most precise methods have ± 10% error [377]. In addition, Abercrombie has 
stated that his correction formula may have up to 10% of overestimation. Another 
error that may have arisen from using the Abercrombie method is that shape and 
orientation of cells are not taken into account. In addition, the way that Abercrombie 
has identified the particle height is not always accurate, because the method 
assumes that the level of cut is on right angle through the particle (nucleolus in our 
study) [377]. Furthermore, due to the difference in nature of particles, William et al 
1988 has indicated that some cells may be pushed aside during cut (like cutting a 
mixture of gelatine and hazel nuts with a knife) [377]. 
Another issue is that the Abercrombie correction formula is sensitive to tissue 
thickness. This problem may not only apply on different studies, but may affect the 
same study. For example, it was reported that there is a 50% variation in thicknesses 
of adjacent paraffin sections [378]. This has been attributed to unstable tissue blocks 
or knives, or due to temperature changes [377]. Another potential source of error is 
that the Abercrombie correction formula is biased when the particle height is more 
than one third of the section thickness, as in our study. 
An important concern with neuronal numbers is the presence of significant normal 
individual variation [379]. There is also normal variation in motoneurons' numbers 
between different spinal cord segments which has been reported in this study. Table 
7.9 demonstrates the variation in neuronal numbers among healthy controls. 
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Table 7.9: Nonnal variation in neuronal numbers (numbers were corrected in each ventral hom using the 
Abercrombie correction fonnula) 
Spinal cord Minimum Maximum Mean SO Coefficient of 
segment (corrected total (corrected total variation 
category number) number) (SOlMean)% 
Upper Cervical 1.13 10.32 5.79 3.50 60 
Lower Cervical 2.54 17.57 8.06 5.09 63 
Thoracic 1.91 2.79 2.35 0.62 26 
Upper Lumbar 2.92 11.73 6.50 2.79 43 
Lower Lumbar 2.79 16.96 9.63 5.07 53 
7.5.2 Neuronal counts 
With respect to neuronal pathology in the spinal cord, two important findings have 
been further confirmed in this study; there is a greater degree of neuronal loss in the 
DMGM of the spinal cord compared to controls and normally appearing VHs. This 
loss seems to affect intemeurons more than motoneurons. It is possible that 
intemeurons are more sensitive to demyelination, and thus more prone to injury, 
compared to motoneurons [106]. This can be also due to possible size selective 
neuronal injury which can be due to retrograde degeneration caused by the size 
selective axonal loss [95]. 
Similar to other elements, such as OLs and axons, it seems that there is also 
predilection for upper cord segments with respect to neuronal injury. Greater loss of 
neurons in the upper segments has been reported by Gilmore et ai, and was 
attributed to a high proportion of demyelination in upper segment compared to lower 
segments. The relationship between demyelination and loss of neurons has also 
been reported in other sites of the eNS. There was 30% loss of neurons in the 
demyelinated regions of the hippocampus [362] and 10% loss in the demyelinated 
regions of the cerebral cortex [358]. 
Demyelination may result in loss of neurons by depriving neurons of trophic support. 
Trophic support of neurons may come from neuroglia or from myelin [380-385]. 
Within the GM, neurons have an intimate relationship with peri neuronal Ols. A 
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previous electron microscopic study demonstrated the presence of a sheath of 
myelin-like substance surrounding some neuronal bodies in the human cerebral 
cortex [169]. Therefore, one of the presumed functions of perineuronal cells is 
supporting neurons. There is evidence that perineuronal OLs may protect neurons 
from undergoing apoptosis [386]. In previous chapters, we demonstrated excessive 
loss of OLs in the spinal cord DMGM. Loss of these OLs may promote neuronal 
apoptosis. 
In this study there was no reduction in neurons in the normally appearing VHs. While 
loss of neurons in NAGM has been reported in the thalamus [131] and the lateral 
geniculate nucleus [95], other studies reported normal neuronal counts in the NAGM 
of the cerebral cortex [351, 358] and the spinal cord [351]. It seems that neuronal 
pathology is not similar between different regions of the GM in the eNS. Recent 
studies reported variation in GM pathology according to the region involved [129, 
387, 388]. 
A possible explanation is that inflammation seems to be different between various 
GM regions. There is little inflammation in the cerebral cortex lesions compared to 
the WM lesions [389]. In comparison, deep GM nuclei inflammation score was 
intermediate between degree of inflammation in the WM and that of the cortical GM 
[388]. In comparison, the spinal cord GM did not show a difference in inflammation 
from the nearby WM [124]. 
Another explanation is that the degree and nature of GM demyelination is different 
between GM regions. In the cerebral cortex, it has been suggested that MS starts as 
focal disease in the WM and that cortical demyelination is part of chronic progression 
[390]. On the other hand, deep GM nuclei pathology appears to be different from 
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cortical GM pathologies. Vercellino et al 2009 studied deep GM pathology in 14 
cases of MS. Demyelination affected mainly the thalamus and caudate, which are the 
areas of excessive connections. The spinal cord GM demyelination seems to be 
different from the cerebral cortex and the deep GM nuclei. This is because spinal 
cord lesions are commonly mixed GM and WM lesions [124]. 
Another possible reason is that the cerebral cortex, deep GM nuclei, and the spinal 
cord GM have different connections with various parts of the eNS. It is expected that 
areas with more extensive connections may undergo degenerative neuronal loss in 
the NAGM more than other parts. It is important to differentiate between two types of 
connections in the eNS; distant connections with various parts of the eNS via long 
axons, and local connections via intemeurons. It is possible that areas with multiple 
distant connections are more vulnerable to retrograde degeneration than areas with 
local connections only. For example, the thalamus is connected to many regions of 
the eNS with long axons [212]. Tao et al 2009 conducted a MRI study on the deep 
GM nuclei. The thalamus and caudate showed the highest degree of atrophy. 
Interestingly, deep GM nuclei atrophy correlated significantly with WM lesions. Such 
a finding further supports the assumption that pathology of deep GM nuclei (unlike 
pathology of the cortical and spinal GM which seems to be independent of WM 
lesions) depends considerably on WM lesions [129]. 
A number of studies support the effects of long term Wallerian and transynaptic 
degenerations on GM by pathology study [95] and MRI study [94]. Pathologically, 
Evangelou demonstrated loss of small neurons in the NAGM of the geniculate 
nucleus secondary to loss ofaxons in the optic tract. Radiologically, Sepulcre et al 
2009 studied the contribution of different WM lesions in causing lateral geniculate 
nucleus atrophy in 61 MS patients. Using MRI, lateral geniculate nucleus atrophy 
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was measured and mapping the WM was carried out. Lateral geniculate atrophy 
correlated with lesions of the optic tract and not with any other lesions [391] 
Our study did not reveal changes in neuronal numbers in the NAGM. This may 
indicate that the role of retrograde degeneration is limited in causing neuronal injury 
of the normal GM of the spinal cord. In the VH neurons are involved in a complex 
network of local interneurons that maintains circuits of action potentials, and this may 
prevent or delay degeneration of neurons with severed axons. 
7.5.3 Correlation between loss of neurons and atrophy of the GM 
In normal controls, the relationship between the volume of the GM and the number of 
neurons is already established in the spinal cord. Normally, there is greater amount 
of GM in the thickened spinal cord segments. The VHs of the lower cervical and 
lower lumbar have greater volume because they have high numbers of neurons to 
supply the upper limbs and the lower limbs. 
To our knowledge, one previous study has demonstrated significant correlation 
between neuronal loss and atrophy and this was in the archaecortex [362]. The main 
constituent of cortical GM atrophy is demyelination ofaxons and to a lesser extent 
neuro-axonal loss, especially in the frontal cortex [216]. In this study, we reported 
atrophy of the VHs which affected mainly the higher cord segments. There was also 
significant correlation between number of neurons and surface area of the VH. 
Therefore, it is possible that one of the main constituents of spinal cord GM atrophy 
is neuronal loss. 
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7.5.4 Interpretation of results from neuronal sizes and source of error 
We used size criteria to differentiate between motoneurons and interneurons. Using 
fixed size criteria may produce variable results because of different shrinkage factors 
among different types of tissues. In addition, neurons themselves may interact 
differently to fixation process, ie neurons may shrink more than the nearby neuropil. 
This is suggested from the common profile in Figure 7.4. It has been also suggested 
that shrinkage is not uniform throughout the section, because shrinkage near the 
section centre may be greater than shrinkage at the section edge [392]. 
However, we should acknowledge that classification of neurons, depending on 
maximum and minimum diameters, may affect interpretation of results obtained from 
neuronal sizes. Although measurement of neuronal sizes was independent of the 
minimum and the maximum diameters, classification of neurons into interneurons 
that are less than 13.5 IJm minimum width or less than 30 IJm maximum diameters 
may reflect neuronal sizes. Moreover, assuming there is considerable neuronal 
shrinkage in MS; motoneurons may shrink to be within interneurons determined 
range. Additionally, it is not accurate to apply the same range of diameters 
classification of neurons on MS and controls when there is a possibility of neuronal 
atrophy in MS. 
Nevertheless, the NE14 stain does not differentiate between motoneurons and 
interneurons; therefore, we had to use size criteria to differentiate between the two 
subtypes. Size criteria has been used in previous studies [375, 393-396]. But in those 
studies, discrimination was sometimes associated with morphological observation to 
differentiate between motoneurons and intemeurons. Only the study by Gilmore 
employed size criteria without considering morphological variation [106]. 
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Because of the irregular shape of neurons and the fact that we count them on cross 
sections that can pass any level of the neuronal cell body, morphological 
discrimination between motoneurons and interneurons is highly subjective. 
Therefore, considering maximum and minimum diameter of the neuron may be a 
good indicator of the type of neuron, especially with the minimum diameter, as the 
minimum diameter of an object does not change with the level of cut. This fact is 
based on the assumption that level of cut is through the centre of the cell body, which 
is the nucleolus in our example. In addition, neurons are very irregular in shape and 
effects of maximum and minimum diameters on neuronal size are possibly minimal. 
In the present study, there was no Significant difference between neuronal sizes in 
controls and MS cases and between PPMS and SPMS. Gilmore et al demonstrated 
significant reduction in sizes of interneurons which affected demyelinated and normal 
appearing areas. Neuronal shrinkage has been reported also in the hippocampus 
[362). Gilmore et al reported increase in sizes of motoneurons which has been 
attributed to size selective neuronal loss, miSinterpretation of shrunken small 
motoneurons as interneurons, or pathological swelling of motoneurons. In 
comparison, in our study there was no significant difference between sizes of 
motoneurons in MS and controls. 
7.5.5 Quantification of neurons PPMS vs. SPMS 
The relationship between neuronal loss and clinical course of the disease in PPMS 
and SPMS seems to be a complex issue, owing to complexity of neuronal circuits 
and variation between ascending and descending tracts in nature and speed of 
neuronal degeneration. 
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While correlation between spinal cord GM pathology and disability has not yet been 
established, correlation between brain GM (cortical and deep GM nuclei) and 
disability has been reported. A study has investigated the correlation between deep 
GM nuclei pathology and clinical progression of the disease in 97 patients. It was 
stated that there is strong association between deep GM lesions and worsening of 
symptoms [128]. 
The correlation between axonal loss and disability has been reported several times 
[397-399], but the clinical significance of neuronal loss specifically has not been 
demonstrated yet For example, despite having a greater degree of demyelination and 
neuronal loss in the cervical segment of the spinal cord, upper limbs' paralysis is not 
a recognized feature of MS compared to other motoneurons diseases. Additionally, in 
previous chapters, we demonstrated differences in demyelination, atrophy, Ols and 
axonal loss between PPMS and SPMS. In this study, SPMS showed a tendency 
toward fewer numbers of neurons compared to PPMS, but the difference was not 
statistically significant. 
This is possibly because number of neurons is significantly less than number of Ols 
and axons in a cross section. Therefore, a potential difference between PPMS and 
SPMS in the amount of neuronal loss may be minimal and thus a greater sample size 
is needed to reveal such a difference. It is also possible that surviving neurons are 
not always functioning and this affects results obtained from correlation with 
disability. 
7.6 Conclusion 
In summary, the study has further confirmed the presence of neuronal loss in the 
demyelinated GM of the spinal cord with no remarkable loss in the NAGM [106, 400, 
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401]. Demyelination seems to have significant effect on neuronal loss possibly by 
causing loss of trophic support from neuroglia and/or neurotoxicity from molecules 
released within the plaque. Despite the presence of OLs in GM lesions of PPMS and 
SPMS, numbers and function of these OLs may be insufficient to protect neurons 
[236,238,239]. In addition, neuronal loss was found to be an early processes [357]. 
Neuronal loss was found to be greater in the upper cord segments [106]. This can be 
associated with demyelination that affects mainly the upper segments. Unlike 
neuronal loss in the thalamus or geniculate nucleus, neuronal loss in the spinal cord 
GM is probably due to local lesion factors and independent of distant lesions. This is 
evident from the observation that neurons are spared in the NAGM. More 
importantly, despite differences between PPMS and SPMS in degree of 
demyelination, atrophy, OLs loss and axonal loss, there was no significant difference 
in numbers of neurons. 
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Figure 7.1 : Distribution of the diameter of the nucleoli in the neurons of the ventral horn. The normal distribution may 
indicate that there is no significant difference between the diameter of the nucleoli of the motoneurons and the 
intemeurons. A significant difference would probably produce bipolar distribution 
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Figure 7.2: The Left bars illustrate the total number of neurons, number of interneuron, and number of motoneurons 
in the 5 cord segments of MS and controls. Note that there is a greater reduction of neurons in the upper cord 
segments and this affects intemeurons more extensively. The right bar chart illustrates the total number of neurons, 
interneuron, and motoneurons in the 5 cord segments in PPMS, SPMS and in controls. SPMS and PPMS have no 
Significant difference between each others in neuronal numbers. The Data represent the mean corrected number of 
all neurons, interneurons, and motoneurons ± SEM. The significant difference between MS and controls are indicated 
by asterisks, the significant difference between controls and SPMS are indicated by the number sign # , while the 
significant difference between PPMS and control are indicated by". The p values < 0.05 are indicated by one sign, 
while the p values < 0.01 are indicated by two signs. 
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Figure 7.3: A bar chart showing number of neurons, interneurons, and motoneurons in the five cord segments in 
normal controls, normally appearing VHs, and demyelinated VHs. The bars represent the mean number of neurons, 
internerons, and motoneurons in the VHs ± SEM. The significant difference between normally appearing VHs and 
demyelinated VHs are indicated by an asterisk . , the difference between normally appearing VHs and controls are 
indicated by the number sign # , while the significant difference between normal controls and demyelinated VHs is 
indicated by A. The significant differences of p values < 0.05 are indicated by one sign, while the p values < 0.01 are 
indicated by two signs. 
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Figure 7.4: A bar chart shows the mean cross sectional areas of interneurons and motoneurons in the demyelinated, 
normally appearing and healthy GM and in the two disease subtypes. Data represent the mean CSA of neurons and 
motoneurons ± SEM. There was no significant difference between PPMS, SPMS and controls in the CSA of neurons. 
Figure 7.5: A neuron in a human VH (a common profile in our study). Note the space between neuropil and the 
boundary of the neuron. This can be due to variation in post-mortem changes, during fixation and tissue processing 
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Chapter 8: Summary and conclusion 
The two subtypes of progressive MS have different clinical course at the early stages 
of the disease. SPMS begins with relapsing remitting stage that may continue for 
many years, while PPMS is progressive from the beginning. Many believe that with 
better understanding of the disease pathology, more effective treatment can be 
achieved in the future. 
In this study, the two examined groups of tissue (SPMS and PPMS) derived from 
patients that had similar degree of disability prior to their death. The study has 
focussed on quantifying the major five pathological changes associated with PPMS 
and SPMS. These changes include the lesions load, tissue atrophy, Ol, axons and 
neuronal pathology. 
We have chosen the spinal cord for this comparison for a number of reasons. The 
spinal cord anatomy allows for comparing similar anatomical regions in the two 
examined groups. The spinal cord has both ascending and descending tracts that 
may be affected by the same lesion. Demyelination of the spinal cord commonly 
affects the GM and the WM within the same lesions. Furthermore, the spinal cord 
lesions are frequently associated with clinical symptoms and thus may explain the 
clinical variation between the two subtypes [127). 
One of the characteristic features of MS is the presence of demyelination 
preferentially affecting different regions of the eNS. The study has addressed the 
topographic distribution of demyelination throughout the spinal cord in the two 
subtypes. The demyelination was found to be greater in the upper cord levels in both 
forms of the disease. However, it appeared that SPMS spinal cords were affected by 
a higher degree of demyelination compared to PPMS especially in the upper cord 
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levels. Another important feature of progressive MS is tissue atrophy. There is 
obvious atrophy in SPMS and PPMS spinal cords. This has again affected mainly the 
upper levels of the spinal cords. When the volumes of the spinal cords were 
compared between the two groups, SPMS showed more atrophy especially in the 
upper levels. It is possible that due to the presumed higher lesion load and frequency 
of occurrence of new lesions, SPMS may cause atrophy faster than PPMS 
There seems to be correlation between lesion load and atrophy of the spinal cord; 
demyelination and atrophy affected mainly the upper cord levels and both were 
greater in SPMS. We found significant correlation between demyelination and 
atrophy in SPMS but not in PPMS. Therefore, it is possible that lesion load plays a 
more important role in atrophy of tissue in SPMS compared to PPMS. 
Quantification of OLs in the GM and the WM has been carried out in this thesis. 
Number of OLs was found to be low in the demyelinated areas of the WM and the 
GM. Although SPMS demonstrated higher number of OLs in the demyelinated areas 
compared to PPMS, the presence of these OLs was not associated with myelin in the 
two disease forms. This is possibly because their number is very low in the two 
subtypes compared to the normal controls or to the nearby normally appearing areas. 
In addition to low numbers of OLs in chronic lesions, it is possible that these OLs are 
immature and unable to myelinate. 
Outside the lesion, there was a surprising increase in OLs numbers in the NAGM 
compared to normal controls and the NAWM. This was observed particularly in 
SPMS. This could be due to presence of extra sources of OLs in the GM or the 
abundance of inhibitory factors on OLs proliferation in the WM, such as myelin and 
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dystrophic axons. In addition, SPMS may maintain higher inflammation and thus 
induce more proliferation of cells including Ols. 
Axons are also damaged in MS. Axonal loss affected the DMWM with no difference 
between the two subtypes in the density ofaxons. There was also no difference in 
the density ofaxons in the lesions of the CST and the PCP. This may indicate that 
the local effect of demyelination on axons does not depend on the disease subtype 
or the affected tract. The difference in axons' density between the two tracts and the 
two subtypes was apparent in the NAWM. There was considerable loss ofaxons in 
the NAWM of the descending tracts compared to the ascending tracts. There was 
also greater loss ofaxons in the NAWM of SPMS compared to PPMS. It is possible 
that the mechanism of axonal loss in the NAWM is a different from that in the 
DMWM. Loss ofaxons in the NAWM can be due to the effect of Wallerian 
degeneration, while loss ofaxons in the demyelinated areas is possibly due to both 
demyelination and degeneration. Wallerian degeneration of the NAWM of the 
descending tracts is expected to come from higher lesions in the brain where the 
SPMS consistently showed a greater degree of demyelination, while Wallerian 
degeneration of the ascending tract is expected to come from caudal levels in the 
spinal cord where lesions are rare. Consequently, we observed limited loss ofaxons 
in the NAWM of the ascending tracts. Another important observation that suggests 
different mechanism of axonal loss between the DMWM and the NAWM is that there 
was a very low OLs to axons ratio in the DMWM compared to normal controls while 
there was normal ratio in the NAWM. This suggests that the oligodendrocytes may 
playa lesser role in the loss ofaxons in the NAWM. 
The total number of neurons was reduced in MS and showed a tendency toward 
Significance in most of the cord levels. There was greater loss of intemeurons 
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compared to motoneurons. This reduction affected the demyelinated GM but not the 
NAGM. There was no significant difference between PPMS and SPMS in numbers of 
interneurons or number of motoneurons and this applies to demyelinated and 
normally appearing areas. Motoneurons possibly tolerate demyelination better than 
interneurons. Preservation of neurons in the NAGM is possibly due to the limited 
effect of retrograde degeneration on the neuron cell body. Neurons of the NAGM of 
the spinal cord may not be liable to the effects of retrograde degeneration as the 
case of neurons in other parts of the eNS (for example the thalamus) because of 
differences in connectivity. 
8.1 Conclusion 
There are differences between the two disease subtypes in the degree of 
demyelination, atrophy, Ols density, and axonal density. There was no significant 
difference in the degree of neuronal loss or axonal loss within the WM lesion itself. 
Spinal cord axonal pathology is probably responsible for much of the disability in MS, 
while neuronal loss may have a limited role in causing disability. This is suggested by 
three main observations; neuronal loss is restricted only to the demyelinated areas, 
degree of neuronal loss is less than axonal loss, and flaccid paralysis is not a 
common clinical feature of MS. 
The question whether PPMS and SPMS are two different disease entities or not is 
still debated. Developing RRMS or PPMS from the beginning may be affected by the 
nature of the disease itself, age of patient at disease onset (PPMS patients are older 
and thus may have less nervous tissue plasticity), anatomy of the affected tract and 
degree of decussation (less decussation means more severe symptoms), strategic 
location and size of the first lesion (initial lesions of PPMS commonly involve 
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strategic areas such as the brain stem), and probably other genetic or environmental 
factors [110]. 
In SPMS, a possible explanation of progression after a period of RRMS is failure of 
the CNS compensatory mechanisms [402, 403]. This is supported by the fact that 
high disease activity and frequency of relapses shortens the duration after which 
RRMS becomes SPMS. It was reported that patients with MS demonstrate a variable 
duration of time to reach an EDSS of 4. while progression from 4 to 7 takes a similar 
duration in all patients [41]. 
8.2 Future work 
Many scientists believe that with suitable intervention MS lesions can undergo repair. 
Such repair can be in the form of remyelination, neuronal preservation or 
regeneration, and restoring axonal conduction [404]. Inducing repair of spinal cord 
lesions may be more beneficial than that of brain lesions as these lesions were more 
associated with clinical symptoms. Spinal cord lesions are also more accessible than 
brain lesions for introducing molecules or transplanting Ols. 
It is important initially to identify the most potent and most appropriate mitogen that is 
responsible for OLs proliferation. In vivo molecular imaging of the microglia in MS 
has been carried out, which carries promising results to provide imaging of other 
cells, especially OLs [405]. Comparing the degree of expression of OL mitogens 
between PPMS and SPMS and between the GM and the WM may identify the most 
potent factor that can induce remyelination in MS. This may also explain two 
important issues; why SPMS demonstrated greater numbers of Ols in the GM areas 
compared to the corresponding areas in PPMS; and why the NAGM showed greater 
numbers of Ols compared to the NAWM. 
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Oligodendrocytes in the NAGM and the DMGM have not been studied in details yet. 
CA II positivity in Ols is not enough to reveal their level of maturity as CA II is 
expressed in most developmental stages of Ols. Identifying Ols around GM lesions 
using double labelling and staining NG2 positive cells may answer the question about 
origin and function of these cells. Future studies may double stain CA II positive cell 
with other markers, such as MOG for mature Ols, NG2 for Ols progenitors, PDGFR-
a for migratory Ols progenitors, or nestin for multipotent neural stem cells. 
It is also important to explore more the relation between lesion load in the brain and 
the degree of axonal loss in the spinal cord, especially the NAWM of descending 
tracts. This may explore the mechanism of axonal loss in the spinal cord. 
Future studies may include RRMS cases to compare with PPMS and SPMS. The 
poSitron imaging tomography for molecular imaging can be used in vivo to compare 
these subtypes. This will overcome the lack of post-mortem RRMS samples and 
differentiate between RRMS, SPMS, and PPMS. Including RRMS may explain why, 
when and how RRMS enters the stage of SPMS. Answering these questions may 
hopefully lead to treatment that delays relapses or reduces their severity. Such 
treatment may include introducing agents (systemic or intrathecal) that induce 
migration and proliferation of Ols to the site of lesions, and transplanting cells in the 
site of lesions that may have similar characteristics to Ols progenitors [244}. 
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Appendix A 
Station reagent time 
1 10% formalin 1 
2 50% alcohol 3 
3 70% alcohol 4 
4 95% alcohol 4 
5 100% alcohol 4 
6 100% alcohol 4 
7 100% alcohol 4 
8 100% alcohol/100% chloroform (50 I 50 mix) 6 
9 100% chloroform 18 
10 100% chloroform 6 
11 wax 2 
12 wax 2 
13 wax 6 
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Appendix B 
Immuno Protocol 
Slides were put in a beaker of 10mM EDTA (3.7g EDTA in lltr distilled 
water, pHed to 8 with NaOH) 
The EDTA was heated in the microwave at power 8 for 25mins 
The slides were transferred to cold running water for 15mins 
They were incubated in Buffer 1 for 2 x 5mins 
They were incubated in 2% normal goat serum for 30mins 
They were incubated in 0.5% aqueous hydrogen peroxide for 10mins 
Primary antibody was added at 1:8000 made up in DAKO diluent, for 1 
hour 
They were washed with Buffer 1 
They were incubated in Buffer 1 for 2 x 5mins 
Secondary antibody was added for 30mins 
They were washed with Buffer 1 
They were incubated with Buffer 1 for 2 x 5mins 
DAB was added for 5 mins 
They were was with distilled water 
They were counterstalned with Haematoxylin 
They were dehydrated and mounted with DPX 
Buffer 1 
11tr PBS 
109 Bovine Serum Albumin 
2ml Tween 20 
primary Antibody - Rbt pAb to Carbonic Anhydrase II (Abeam ab6621-5) 
Secondary Antibody - part of Envision DAKO K5007 DAB kit 
QA6 - Provided by Des Powe 
257 
